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End stage liver disease represents a common end point for a number of disease processes,
the only current treatment for which is liver transplantation, but the demand for donor
organs exceeds the supply. This has led to the use of more marginal donors with an
increase in the rates of complications. Mesenchymal stem/stromal cells (MSC) are a
multipotent cell capable of modulating the immune system through a number of different
processes and represent a potential therapy in post transplantation liver injury.
In this study I describe the prospective isolation and culture expansion of murine
MSC. In in vitro assays MSC suppressed T lymphocytes and following stimulus with
inflammatory cytokines MSC secreted a number of cytokines including Il-10. In the
MDR2-/- model intravenous MSC therapy led to a reduction in liver injury with an increase
in restorative macrophages. Subcutaneous administration of MSC showed no beneficial
effect. MSC were also tested in a hepatic ischaemia reperfusion injury model where no
effect was seen.
In summary MSC were able to suppress lymphocyte proliferation and secrete anti-
inflammatory cytokines in vitro, and in vivo they were able to reduce liver injury in the
MDR2-/- model but not the hepatic ischaemia reperfusion injury mode.
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Liver disease is an endemic problem found in both developing and developed countries and
whilst the aetiology may be different depending on a countries human development index
the progression to end stage liver disease yields the same outcome. Once this progression
reaches its end stage transplantation is the only option and there is an urgent need for
better therapies to improve outcomes in these patients.
In this thesis I focus on the isolation and characterisation of murine Mesenchymal
Stem/Stromal Cell (MSC), and their use as a therapy in models of post transplantation
liver injury with the aim of identifying novel ways to improve outcomes from marginal donor
liver transplantation. In this introduction some sections are taken from a commissioned
review in the field that I designed and wrote during my research time [1].
1.2 End-stage liver disease
End-stage liver disease represents a common end point for many chronic disease processes
of the liver. Repeated injury of liver parenchyma leads to scar formation and fibrosis. Due
to changes in liver architecture associated with fibrosis liver function can be impaired
[2]. There are a number of different causes of liver fibrosis (table 1.1) with histologically
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different patterns of scar formation, however functional impairment due to capilliarisation
of sinusoids, deposition of extra-cellular matrix and impairment of normal bile transport
are common in all pathologies [3]. Progression of fibrosis to cirrhosis is seen as a move
from potentially reversible to irreversible pathology, although there exists some debate as
to whether cirrhosis may be reversible [4]. There exists some differences in the description
of cirrhosis in the literature, however the formation of fibrotic nodules of regenerative
parenchyma surrounded by fibrotic septa coupled with disruption of the hepatic vascular
architecture is a commonly used pathological description of cirrhosis [5]. Key therapeutic
strategies for patients who develop fibrosis focus on treating the underlying cause in order
to prevent the progression from fibrosis to cirrhosis. The rate of progression from fibrosis
to cirrhosis is determined by a number of factors including the underlying pathology,
environment and genetics. Patients who develop cirrhosis are deemed to have end stage
liver disease, the only recognised treatment for which is liver transplantation. In the United
Kindgom (UK) two percent of all deaths are due to liver disease, and whilst all other
leading causes of death are decreasing, those from end stage liver disease have increased by
400% since 1970 [6]. Liver disease is the leading cause of premature death in the UK, and
given the relatively young age of patients developing end stage liver disease, is responsible
for the loss of a greater number of life years than other major causes of death in the UK.
There is a clear need for novel therapeutic options in order to reduce the global impact of
liver diseases.
Pathology
Alcohol related liver disease Non-alcoholic fatty liver disease Glycogen storage disease
Chronic hepatitis (B, C and D) Wilson’s disease Budd-Chiari syndrome
Primary biliary cirrhosis Haemochromatosis Glycogen storage disease
Primary sclerosing cholangitis Biliary obstruction Autoimmune hepatitis
Table 1.1 – List of causes of end stage liver disease.
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1.3 Anatomy and function of the human liver
The liver is the largest internal organ in the human body and the second largest overall
after the skin. It lies inferior to the diaphragm on the right hand side and on average weighs
approximately 1500 g which accounts for 2.5% of the total body weight [7]. The liver is an
organ found in vertebrates and is responsible for hundreds of metabolic functions including
absorption, digestion, steroid hormone metabolism, protein synthesis and detoxification
(figure 1.2). The liver also represents a major store of glycogen and is involved in glucose
metabolic pathways including glycogenolysis and gluconeogenesis. Another important
function of the liver is to regulate the immune system [8].
Function
Bile production Absorption of vitamin K Vitamin storage (A, D, E, K, B12)
Fat absorption Protein digestion Ferritin storage
Cholesterol absorption Bilirubin metabolism Copper homeostasis
Digestion of fats Carbohydrate metabolism Metabolism and excretion
Synthesis of clotting factors Protein synthesis Xenobiotic detoxification
Table 1.2 – A list of functions of the human liver.
1.3.1 Surfaces and functional anatomy of the liver
The liver has a diaphragmatic surface which is in opposition to the inferior surface of the
diaphragm and a visceral surface which is found on the inferior aspect separated from
the diaphragmatic surface by its inferior border. The liver is broadly separated into 4
anatomical lobes (left, right, caudate and quadrate) with a functionally independent right
and left side of roughly equal size which receives independent blood supply from the
hepatic vessels. The liver can also be divided into 8 segments based on its blood supply
(figure 1.1).
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Figure 1.1 – Diagram representing the functional anatomy of the liver. The liver
is split into 8 different segments determined by their blood supply from the hepatic artery
and hepatic portal vein. Figure taken from wikimedia [9].
1.3.2 Blood supply to the liver and biliary drainage
The liver has a dual blood supply with 70 % of it’s supply coming from the hepatic portal
vein and 30% from the hepatic artery [8]. The portal vein is formed by the superior
mesenteric vein and the splenic veins as they join and as it enters the liver it divides into
the right and left branches which subsequently ramify. Venous drainage from the liver is
via the right, middle and left hepatic veins which subsequently drain into the inferior vena
cava.
Bile is produced in the hepatocytes and flows along the bile canaliculus into the bile
duct. Small bile ducts join together eventually forming the right and left hepatic ducts
outside of the liver. The right and left hepatic ducts join to form the common hepatic
duct and this is joined by the cystic duct to form the common bile duct. The cystic duct
connects to the gallbladder where bile can be stored, and the common bile duct joins the
small intestine at the ampulla of Vater where bile can be secreted into the intestines [10].
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(a) (b)
Figure 1.2 – Graphics depicting the microarchitecture of the liver. (a) The liver
microarchitecture can be organised as an anatomic lobule with the hepatic vein at the centre
and the portal triad at the edges. (b) Other representations include the portal lobule with
the portal vein at the centre or the functional representation called the acinus. Figures taken
from easy card and Spirstein [11, 12].
1.3.3 Microscopic anatomy of the liver
The liver is composed of five main types of specialised cells which can be divided into
parenchymal and non-parenchymal with hepatocytes being the only parenchymal cell type,
and the non-parenchymal cells being made up of Kupffer cells, stellate cells, cholangiocytes
and sinusoidal endothelial cells. The two dimensional microarchitecture of the liver can
be viewed from three different perspectives; the classical lobule, the portal lobule or the
hepatic acinus, with the lobule being an anatomical representation of the microarchitecture
and the acinus being a functional representation (figure 1.2). The classical lobule is
hexagonal in shape and has the central vein at the centre and is a purely anatomical
representation, the portal lobule is a triangular shape with the portal vein at the centre
and the central veins making up each corner and follows the flow of bile through the liver
and the the acinus is a diamond shape and follows the flow of blood through the liver as a
purely functional representation.
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1.3.4 Comparison of mouse and human liver
Mouse liver anatomy is similar to human liver anatomy. Whilst mice tend to have a greater
number of anatomical lobes (usually 6) each lobe still retains it’s own blood supply as in
the human liver. The microscopic architecture of the mouse liver has a lobar structure
surrounding a central vein again showing remarkable similarity to the human liver. Recent
advances in micro computed tomography have allowed for accurate examination of the
anatomy of the murine liver, further demonstrating the similarities between human and
mouse livers [13].
1.4 Current therapeutic strategies in patients with end
stage liver disease
The development of cirrhosis currently marks a step down an irreversible pathway. In
the pre-cirrhotic stage the main therapeutic strategies are targeted at the underlying
pathology, however there are some novel therapies under investigation to attempt to slow
or reverse fibrosis development and progression. Due to the involvement of the Renin
Angiotensin Aldosterone System (RAAS) in hepatic stellate cells and their production of
reactive oxygen species Reactive Oxygen Species (ROS), modulating this pathway has
been shown in animal models to reduce the development of fibrosis [14]. In patients with
cirrhosis levels of Lipopolysaccharide (LPS) have been found to be elevated [15], and Toll
Like Receptor (TLR) signalling, particularly via TLR4 has been demonstrated to be
important in animal models suggesting that TLR4 inhibitors may have a roll in treating
liver fibrosis [16, 17].
1.4.1 Cell therapy for end stage liver disease
A number of cell types have the potential for use as therapy in fibrosis and end stage
liver disease. During liver injury hepatocytes are able to divide and replace injured areas,
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however this mechanism can be compromised in a cirrhotic liver. The liver also contains
liver progenitor cells which are able to divide and differentiate into new hepatocytes to
replace injured areas [18], however this mechanism may be impaired in alcohol related liver
disease [19]. Finally bone marrow derived and circulating non-hepatic stem cells are able
to enter the liver and differentiate into hepatocytes although how and when this occurs in
vivo is still not fully understood [20].
Hepatocyte transplantation in order to repopulate an injured liver has been studied in a
number of models and has been shown to improve survival in rats with decompensated liver
cirrhosis [21]. Whilst some success has been demonstrated using hepatocyte transplantation
as a therapy in patients with metabolic liver diseases [22], these patients have normal liver
architecture and as yet there has been no benefit shown using hepatocyte transplantation
in patients with liver cirrhosis. The use of Granulocyte colony stimulating factor (G-CSF)
in order to stimulate the proliferation of hepatic progenitor cells has been demonstrated
with success in patients suffering from alcohol related steatohepatitis [23], however this
therapy has yet to be translated into a treatment that improves outcome or reduces liver
injury. Trials of haematopoietic stem cells as a therapy in mouse models of liver fibrosis
showed promise with resolution of fibrosis seen following therapy [24], however a recent
clinical trial combining G-CSF and haematopoietic stem cell therapy showed no benefit
in patients with liver cirrhosis [25].
1.4.2 Liver transplantation
Liver transplantation currently represents the only curative strategy for patients with end-
stage liver disease. A liver transplant is a major surgical undertaking requiring accurate
risk stratification due to the limited pool of donor organs available. The decision to list a
patient for liver transplantation is complex with a multitude of factors contributing to the
final decision but the United Kingdom End Stage Liver Disease (UKELD) score (figure
1.3), a physiological scoring system, is a major component of this decision in the UK with
patients who have a predicted 5 year mortality of greater than 50% generally excluded
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from transplantation [26, 27].
(5.395× ln(INR)) + (1.485× ln(Creatinine)) + (3.13× ln(Bilirubin))− (81.565×
ln(Sodium)) + 435
Figure 1.3 – Equation to calculate the UKELD score.
Recent publications from the National Health Service Blood and Transplant Service
(NHSBT) show the impact of the paucity of donor organs which leads to long delays from
meeting the transplant criteria to receiving a liver transplantation. Between 2005 and
2015 almost 49,000 have waited for a transplant and over 6,000 patients have died before
a donor organ has become available. There are currently around 600 patients on the UK
organ transplant waiting list and 130 of these have been waiting over 1 year with the
average wait for an adult currently 137 days [28]. As a result of the limited donor organs
transplant centres have begun to use more marginal organs.
1.4.3 Marginal organ donation
Traditionally liver transplantation has been performed using Donation after Brainstem
Death (DBD) organs, the so called ’heart beating’ donors. With a shortage of donor
organs worldwide the use of more marginal organs has become widespread. Donor organs
from ’non-heart beating’ donors such as those from Maastricht class III and IV Donation
after Cardiac Death (DCD) has increased in recent years [29]. Whilst using more marginal
donor organs has led to controversy in the literature with some studies demonstrating
significantly worse outcomes and reduced long term survival [30], although these findings are
debated and centres who use careful donor selection criteria have been able to demonstrate
comparable outcomes between DBD and DCD organs [31]. The less favourable survival
figures seen in both graft and recipient in patients who receive a DCD liver transplant are a
reflection of the more profound ischaemic injury inflicted on the donor organ during donor
death. The initial generation of ROS coupled with early neutrophil migration and release
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of further ROS, further augmented by the slightly delayed adaptive immune response
leads to a characteristic injury pattern and loss of hepatocytes [32], compared with the
predominantly endothelial related injury which occurs during the ‘cold ischaemic’ phase
demonstrated in DBD donor organs. This injury pattern represents the early ischaemic
damage seen in liver transplantation.
1.4.4 Complications of liver transplantation
Liver transplantation is a major surgical undertaking in a patient population who are at
high surgical and anaesthetic risk due to the underlying disease process and its effects on
a multitude of organ systems. There are a number of potential complications which can
occur either during a liver transplant operation, in the immediate post operative period,
or over a longer time frame. The incidence of some of these complications can be different
depending on whether a DBD or DCD liver is used.
1.4.4.1 Perioperative complications
There are a number of complications commonly seen during liver transplantation sur-
gery. Almost all major perioperative complications occur following organ reperfusion and
whilst most complications seem to have a similar incidence the number of some of these
complications vary depending on the donor source [33].
Bleeding is a complication in almost all types of surgery, however major blood loss
can occur during a liver transplant operation due to the combination of surgery involving
major blood vessels and a patient population who usually have abnormal clotting function
and bone marrow suppression leading to low platelet numbers. This leads to a requirement
for blood products which itself brings a risk of infection, graft failure, multi-organ failure
and an increased mortality, therefore strategies are implemented in order to minimise
blood loss and therefore requirement of transfusion of blood products [34].
The use of vasopressors and inotropes is common in liver transplant surgery due to
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rapid shifts in fluid and changes in vascular tone and remaining on inotrope therapy in
the early postoperative period whilst seen as a complication is commonplace and similar
between DBD and DCD transplantation surgery [35, 33].
Post reperfusion syndrome is a state of cardiovascular collapse originally described by
Aggarwal 40 years ago [36] with further more specific definitions being postulated, the
most recent by Fukazawa [37]. Both post reperfusion syndrome and post reperfusion hyper-
kalaemia have been shown to occur more frequently following DCD liver transplantation
[33].
1.4.4.2 Acute and chronic rejection
Rejection post liver transplantation is an immunological phenomenon and can be cat-
egorised as acute or chronic. Acute cellular rejection occurs in up to 25% of transplants
however does not pose major problems as it can be readily treated with corticosteroids
[38]. Acute reaction is a consequence of transplanting Major histocompatibility complex
(MHC) incompatible organs and leads to a T cell mediated response which is characterised
by ductular injury and T cell infiltration [39]. Chronic rejection occurs in up to 17% of
liver transplants and is a major source of morbidity leading to graft loss [40]. In contrast
to acute rejection the pathophysiology is not well understood but probably involved a
mixture of antibody mediated damage and vascular occlusion [41].
1.4.4.3 Biliary complications
Biliary complications following a liver transplant occur in the medium term and DCD
liver transplants have a significantly greater incidence of these when compared with
DBD transplants [42]. The most common biliary complication seen following DCD liver
transplantation is ischaemic cholangiopathy, whereas common bile duct leak or strictures
tend to be the most common in DBD transplants [42]. The development of biliary
complications appears to be related to donor age with age greater than 40 being linked to
an increased risk of biliary complications. Ischaemic cholangiopathy seems to be increased
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when the cold ischaemic time is greater than 6.5 hours [42].
Ischaemic cholangiopathy is characterised by multiple intra-hepatic strictures in the
absence of hepatic artery insufficiency [43]. The underlying aetiology of ischaemic cholan-
giopathy is unclear but there is likely a combination of microvascular obstruction and
immune mediated injury [44]. Ischaemic cholangiopathy leads to significant morbidity
with an increased hospital stay, increased re-transplantation rate and reduced quality of
life in transplant recipients suffering from this complication [45]. Ischaemic cholangiopathy
is also a cause of non-anastomotic biliary strictures, however the commonest cause of this
complication is hepatic artery thrombosis.
Bile leak post liver transplant usually occurs at the anastomotic site and can be a
result of ischaemia, downstream obstruction or following T tube removal [46]. Biliary
strictures following liver transplant are commonly categorised as anastomotic; being related
to the biliary tract surgical anastomosis, and non-anastomotic; being at site not related to
the anastomosis [47]. Anastomotic stenosis occurs due to a combination of inadequate
mucosal surface contact coupled with ischaemia and can be related to surgical technique
[48]. Non-anastomotic biliary complications tend to be more extensive and the underlying
aetiology is less clear. There is an increased incidence as cold ischaemic time increases,
however an immune mediated injury is thought to be likely due to the higher incidence
when ABO mismatching occurs [47].
1.5 Hepatic ischaemia reperfusion injury
Ischaemia and reperfusion injury are important concepts with clinical relevance. The main
reason for graft dysfunction following liver transplantation is ischaemia reperfusion injury
[49]. Ischaemia (figure 1.4a) and reperfusion injury (figure 1.4b) can be thought of as two
separate but related processes.
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1.5.1 Ischaemic injury to the liver
Ischaemia is not a new concept and can be defined as:
’an inadequate blood supply to an organ’ [50]
The word originating from the Greek word iskhaimos meaning ’to stop blood’ as early
as the 19th century. It was not until the 1980’s however, that the concept of reperfusion
injury was postulated The first description of reperfusion injury which described an injury
occurring as a result of superoxide generation used a feline model of gastrointestinal tract
ischaemia and reperfusion [51]. Since this publication nearly 40 years ago there has been
a considerable amount of work done to illicit the causes of reperfusion injury. Ischaemic
injury to the liver usually occurs during both liver resection and liver transplantation,
either due to organ preservation and transport, major haemorrhage or deliberate vascular
inflow occlusion with an aim to reduce surgical blood loss [52, 53, 54, 55]. One of the first
descriptions of occluding the liver vasculature was by Pringle, who described a process of
retracting the liver to occlude its blood supply in patients with major haemorrhage [56],
the eponymous Pringle manoeuvrer, or a variation of the original description is still used
today in liver surgery. In the context of liver transplantation ischaemia can be categorised
as either warm or cold ischaemia. Cold ischaemia occurs during cold preservation of the
explanted liver and is defined as occurring from the beginning of cold preservation to the
removal from 4°C cold storage. Warm ischaemia can be further categorised into donor
warm ischaemic time, occurring between withdrawal of life support and the initiation
of cold storage, or graft warm ischaemic time which occurs between removal from cold
storage and establishment of reperfusion [57]. In a DBD transplant donor warm ischaemic
time should not exist as cold preservation occurs whilst blood flow is still maintained.
Whilst there are some organ specific differences in the response to ischaemia broadly
speaking the responses are the same. Ischaemic injury to an organ occurs following an
interruption of the supply of oxygen usually as a result of an interruption to the blood
supply. The extent of the cell dysfunction and death seen is thought to be related to
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the extent and the duration of the ischaemic period [58]. Usually ischaemia occurs in a
sterile environment, although the resultant inflammatory stimulus resembles that seen
following invasion by an external pathogen [59]. Humans rely on aerobic metabolism
utilising oxygen as an electron acceptor in order to generate Adenosine Triphosphate
(ATP) which is required for almost all metabolic processes. When the oxygen supply
is interrupted a process of glucose fermentation (often called anaerobic respiration) is
used to generate further ATP which involves the conversion of glucose to lactate without
the need for a terminal electron acceptor. This process is considerably less efficient than
aerobic respiration and leads to an increase in H+ ions and a reduction in cellular pH
as lactate is converted into lactic acid. There is activation of the Na+/H+ transporters
in an attempt to correct the raised intracellular H+ concentration and in the process of
pumping H+ ions out of the cell the intracellular Na+ concentration increases [60]. The
result of this increase in intracellular Na+ ions leads to an osmotic gradient favouring
water movement into the cell causing cellular swelling, oedema and subsequently cell death.
The lack of oxygen as a terminal electron carrier leads to the electron transport chain
becoming reduced with interruption of electron flow. This leads to reduction of pyridine
nucleotides and results in an increase in the ratio of NADH/NAD+ [49]. As ATP is
depleted there is also an increase in ATP breakdown products such as adenosine, xanthine
and hypoxanthine. There is also an increase in cellular cyclic Adenosine Monophosphate
(AMP), an important intracellular messenger responsible for signalling in carbohydrate
metabolism [61]. Other cellular ion pumps are effected by the lack of ATP, one important
pump being the ATP dependent Ca2+ pump which removes Ca2+ from the cytoplasm by
either expulsion from the cell or uptake into the endoplasmic reticulum. Once inactive
intracellular Ca2+ accumulates further distorting the osmotic gradient and also causing the
activation of Ca2+ dependent proteases which cause disruption of the cellular structure and
can lead to cell death [62]. Hypoxia also leads to priming of the Mitochondrial permeability
transition (MPT) pore which opens at reperfusion and leads to a change in electrical
gradient within the mitochondria causing further impairment of mitochondrial function
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and therefore reduced ATP production [63], although MPT pores can also be opened
due to cellular Ca2+ overload. Hepatocytes are particularly prone to warm ischaemia and
changes occur in hepatocytes at the mitochondrial level. The extent of ischaemia injury
has been shown to be in part related to the amount of blood supply/oxygen delivery lost
and the duration of the ischaemic period [64].
1.5.2 Hepatic reperfusion injury
Whilst restoration of blood flow and oxygen delivery as quickly as possible has been the
mainstay of treatment for ischaemia it was first noticed in the 1960s that this came with
it’s own problems when studying myocardial ischaemia in canine models [65]. ROS were
first discovered to be important in reperfusion injury in the early 1980’s when superoxide
generation was demonstrated to contribute to reperfusion injury in a feline model of
gastrointestinal tract ischaemia and reperfusion [51]. ROS or Oxygen Free Radicals (OFR)
include superoxide, Hydroxyl (OH) and Hydrogen Peroxide (H2O2) and are produced early
on following reperfusion. The primary sources of ROS in the early phase of reperfusion is
intracellular xanthine oxidase, Kupffer cells and infiltrating polymorphonuclear cells [66].
Kupffer cells become activated following exposure to damage associated molecular patterns
released from neighbouring hepatocytes [67]. Following activation Kupffer cells also release
pro-inflammatory cytokines including Tumour Necrosis Factor α (TNFα), Interferon γ
(IFN-γ) and Il-12 [68] which leads to further neutrophil recruitment and a cycle of ROS
release, inflammatory cytokine release and immune cell recruitment and activation [49].
Activated hepatic endothelial cells also express a number of surface adhesion molecules as
well as MHC which primes the endothelium for accumulation of immune cells as well as
platelet binding and aggregation which can lead to microvascular occlusion [69]. Damage
Associated Molecular Pattern (DAMP) are also able to bind to TLR4 and trigger an
inflammatory cascade via an MyD88 independent pathway [70]. Mice treated with a
TLR4 inhibitor have been shown to have lower levels of liver injury following ischaemia
reperfusion injury [71]. The extent to which the initial cellular injury contributes to
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the inflammatory response seen in ischaemia reperfusion injury is not fully understood,
however it has been shown that there is an important link between DAMPs released
during cell damage and the subsequent inflammatory response[70]. T cell mediated injury
is an important cause of reperfusion related liver injury and blocking T cell co-stimulation
or using T cell deficient mice shows a reduction in liver injury [72]. Following reperfusion
there appears to be an increase in CD4+ T cells but not in CD8+ T cells suggesting
a role for CD4+ cells in reperfusion injury [73]. T cells may have a role in neutrophil
recruitment to injured liver, but treatment of mice with Il-10 leads to a reduction in T
cell numbers and a dramatic reduction in liver injury following reperfusion which can
be reversed by transplanting further T cells into the injured mice [74]. When examining
subsets of CD4+ cells it appears that T cells contribute to neutrophil recruitment, Natural
Killer T Lymphocyte (NKT) cells are able to directly injure the liver, whereas Natural
Killer (NK) cells and Treg cell appear to have little effect in liver reperfusion injury [75],
and in models of stroke Tregs appear to have a protective effect [76]. It is not clear the
exact mechanism by which T cells become activated in hepatic ischaemia reperfusion injury,
although it is thought that this occurs without exposure to ’cognate’ antigens[77]. Platelet
aggregation and activation also plays an important role in reperfusion injury, both due to
occlusion of the microvasculature, but also through their ability to stimulate regeneration
through the release of serotonin [78]. The final result of these injury pathways is structural




Figure 1.4 – Diagram showing the main cellular ion changes in ischaemia and
reperfusion injury. (a) During an ischaemic insult cells deplete their oxygen reserves and
begin using anaerobic pathways which leads to an accumulation of H+ ions. This leads to
activation of Na+/H+ transporters to correct the electrochemical imbalance. Inactivation of
the Ca2+ transporters leads to accumulation of Ca2+. (b) Following reperfusion H+ ions are
rapidly washed out of the ischaemic tissue and the oxygen supply is restored. Figures taken
from Kalogeris [58].
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1.5.3 Strategies to limit ischaemia reperfusion injury
Ischaemia reperfusion injury has long been recognised as a major source of morbidity
following organ transplantation but is a necessary evil due to the nature of transplant
surgery and the need for cold preservation and transport of donor organs. As such
considerable research has been undertaken with an aim at reducing the injury sustained
during ischaemia and reperfusion [79].
1.5.3.1 Ischaemic preconditioning
Ischaemic preconditioning was originally proposed as a means to reduce infarct size in
ischaemic myocardium however it was subsequently suggested as a means of mitigating
injury from ischaemia reperfusion injury [80]. It involves subjecting an organ to a brief
ischaemic period in an attempt to reduce subsequent ischaemic injury. Small animal studies
have shown that ischaemic preconditioning of the liver can lead to a reduction in hepatocyte
and sinusoidal endothelial cell apoptosis by reducing caspase activity independent of Bcl-2
expression [81]. It seems that the protective effect of ischaemic preconditioning is due to
nitric oxide generation and adenosine supplementation of animals undergoing ischaemia
is able to mimic this effect due to its ability to stimulate nitric oxide release [82, 83].
Clinical studies have also shown a reduction in markers of liver injury when using ischaemic
preconditioning [84], however recent reviews of clinical trials have shown no proven benefit
in the use of ischaemic preconditioning in liver surgery [85] or liver transplant operations
[86], but both conclude that further research is required to confirm these findings.
1.5.3.2 Treatment with xanthine oxidase inhibitors
The generation of intracellular ROS has been shown to occur in animal models of ischaemia
reperfusion injury [87]. Due to this finding the xanthine oxidase inhibitor allopurinol
was tested successfully in small animal models of hepatic ischaemia reperfusion injury
[88]. Unfortunately this therapy has not been translated into clinical practice. There are
17
potentially a number of reasons for this. Firstly the doses used in animal experiments
required a number of high doses, considerably more than the single low dose of allopurinol
required to completely inhibit xanthine oxidase. This implies that the effects are off
target and not related to xanthine oxidase inhibition. Further work has demonstrated a
beneficial effect of allopurinol which appearers to inhibit mitochondrial injury although
the mechanism by which this happens has not been elucidated [89]. Secondly the clinical
importance of xanthine oxidase as a means of generating ROS has been challenged as the
enzyme requires xanthine and hypoxanthine to act as substrates. Whilst these substances
have been shown to accumulate in ischaemic tissue they are quickly metabolised and
unlikely to provide adequate substrate to xanthine oxidase the generate enough ROS to
cause significant damage [90].
1.5.3.3 Cyclophilin D inhibitors
Mitochondria present in hepatic parenchyma play an important role in warm ischaemia
reperfusion injury as they are able to trigger cellular necrosis by opening their membrane
permeability transition pores leading to a loss of the mitochondrial membrane potential
inhibiting the production of ATP. Mitochondria also release cytochrome C following
injury through mitochondrial outer-membrane permeabilisation which has pro apoptotic
effects [91]. Mitochondrial permeabilisation transition is regulated by cyclophilin D, and
inhibitors of cyclophilin D have been shown in rat models of liver ischaemia to reduce
injury [92]. So far this finding has not been translated.
1.6 Animal models of liver injury
A number of models of liver injury exist in the literature, however few truly recapitulate the
injury seen in DCD liver transplantation. There are no models described to demonstrate
the biliary complications seen following liver transplantation.
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1.6.1 Carbon tetrachloride
The Carbon Tetrachloride (CCL4) model is a model of liver fibrosis originally described
in the 1930’s [93]. First described as a chronic model the CCL4 model has been modified
to demonstrate acute injury. Administration of CCL4 to mice causes hepatocyte injury
and centrilobular necrosis followed by hepatic fibrosis. In the early stages of the CCL4
model ROS are generated which contribute to the damage seen [94], as such CCL4 can be
used as a model of oxidative stress.
1.6.2 MDR2-/-
The MDR2-/- Mouse model is a model of biliary injury which has been used to model
Primary Sclerosing Cholangitis (PSC) due to similarities in the phenotype seen [95, 96].
The MDR2-/- model has a targeted disruption of the multi-drug resistance gene 2 (Abcb4)
which leads to an absence of biliary phospholipids. This leads to bile acid leak and a
cytotoxic injury to the biliary tree. A pattern of onion skin fibrosis is seen in the peri-portal
regions in the first few weeks which continues to develop with widespread fibrosis being
seen at 4-5 months of age [95, 97, 98]. In female mice gallstone formation occurs and
seems to be more prevalent from 15 weeks of age [99]. Immune mediated injury occurs
early on in the model with higher levels of lymphocytes seen in the first few weeks of life
[98]. Microvascular injury and biliary fibrosis is seen, similar to that in post transplant
liver injury [100].
1.6.3 Hepatic ischaemia reperfusion injury
Ischaemia reperfusion injury has been studied for the last 4 decades with small animal
models being used widely. Whilst ischaemia reperfusion injury is relatively simple to induce
surgically there is a variety of heterogeneity in the literature making comparison between
studies difficult [101]. Clamping of the blood supply to the liver for a predetermined period
of time followed by release and a period of reperfusion leads to a warm ischaemic and
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reperfusion injury with generation of ROS and resultant immune cell infiltration [102].
Whilst a good model of warm ischaemia due to the fact that no vessels are divided it would
be challenging to model cold ischaemia in standard hepatic ischaemia reperfusion models.
1.6.4 Liver transplantation
A number of models of liver transplantation have been described in the literature, mainly
using rats due to their larger size than mice making surgery more straightforward [103, 104].
Whilst the surgical technique is similar to that in human liver transplantation it was
noticed that in mice failure to reconnect the hepatic artery did not lead to ischaemic
injury or complications [105]. This finding was also confirmed in rat models and due to the
technical challenge of reconnecting the hepatic artery models tended not to do this. Recent
studies however have found that whilst ischaemic damage does not seem to occur as a
result of leaving the artery tied off there is an effect on the immune system, in particular
graft function with greater levels of rejection in those animals who do not have the arterial
supply reconnected [106]. Whilst transplantation models recapitulate a lot of the clinical
environment and include both warm and cold ischaemia there are few published papers
which demonstrate a prolonged period of warm ischaemia such as that seen in DCD liver
transplantation.
1.7 Immune system
The immune system is a complex collection of cells, tissues and organs which perform a
number of vital function in man including prevention of infection from micro organisms and
suppression of tumour formation. The immune system develops in three main components
the macrophage, lymphatic and haematopoietic systems which originate independently
of each other. The macrophage system arises from the coelomic cavity as mesenchymal
amoeboid cells and has the ability to recognise self from foreign antigens. The lymphoid
system develops from the endoderm of the pharyngeal pouches. Lymphocytes that originate
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here retain the ability to divide and seed all lymphatic organs. The final component of the
immune system is the haematopoietic component which originates from the splanchnic
mesoderm of the yolk sac [107]. Early haematopoiesis occurs in the umbilical vesicle in
the foetus but quickly move to the liver. The spleen and bone marrow subsequently take
over production.
There are a number of classifications for the immune system including anatomical
and functional but a commonly used system is to separate into the innate and adaptive
components.
1.7.1 Innate immunity
The innate immune system is traditionally thought of as the first line of defence against
invading pathogens and consists of phagocytic cells such as macrophages and dendritic
cells [108]. The innate immune system is responsible for the presentation of antigen to the
adaptive immune system, the clearance of foreign substances by phagocytosis and activation
of the complement cascade. Whilst it was originally thought that the innate immune
system is non-specific this is not entirely true as it has the ability to differentiate between
self and non-self. The innate immune system uses a small number of Pattern Recognition
Receptors (PRR) in order to recognise non-self organisms. Pathogen Associated Molecular
Patterns (PAMP) are specific patterns that react with PRR. One extensively studied
group of PRR are the TLR which can be divided into several subfamilies related to the
PAMP that they are able to recognise. TLRs utilise the same signalling molecules as
those used for Il-1R [109]. Antigen presenting cells such as macrophages and dendritic
cells are the main source of TLR expression, however antigen presenting cells are also able
to activate the adaptive immune system and activated dendritic cells are able to control
differentiation of naive CD4+ T cells into T helper (Th), either Th1 or Th2 cells [108].
The complement system forms a distinct part of the innate immune system which
consists of circulating proteins and glycoproteins predominantly formed in the liver. The
complement system has a classical and alternative pathway of activation and its main
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functions are to bind to foreign pathogens and mark them for removal by phagocytic cells
and to attack bacterial cell membranes leading to cell wall rupture [110].
NK cells, whilst a type of lymphocyte, are a part of the innate immune system. They
have an ability to control the spread of infection and tumour preventing tissue damage.
They also have an immunomodulatory role by interacting with T cells, macrophages and
dendritic cells and are therefore able to both increase and decrease immune responses. NK
cells are able to recognise stress induced self ligands. They also possess TLRs and CD16,
an Fc receptor which enables them to recognise cells coated with antibody [111].
1.7.2 Adaptive immunity
Whilst the innate immune system provides an ability to rapidly sense and eliminate
pathogens, the adaptive immune system is able to provide a broader reaching system able
to deal with variability in pathogens and their ability to mutate in an attempt to evade
the body’s defences. Broadly speaking the adaptive immune system is composed of T
cells which mature in the thymus and B cells, which are able to produce antibody. Cells
of the adaptive immune system begin in the thymus and bone marrow and once mature
migrate to secondary lymphoid tissue such as the spleen and lymph nodes. Adaptive
immune responses are often triggered by innate immune responses due to circulating
antigen presentation cells. Trafficking of immune cells is then regulated by adhesion
molecules and chemokine receptors.
1.7.2.1 T lymphocytes
T cells, so called because they mature in the thymus, are distinct from other cells in
the adaptive immune system due to the presence of a T Cell Receptor (TCR) on their
cell surface. In humans the TCR consists of a number of subunits. The majority of
TCRs are composed of α and β chains, with a smaller proportion being composed of γ
and δ chains, the so called γδ T cells. The T cell receptor allows T cells to recognise
22
and bind to foreign antigens presented by cells in specialised glycoproteins. These MHC
antigen complexes are expressed on the cell surface and allow recognition of intra-cellular
pathogens or endocytosed antigen. TCRs are diverse and intricate structures made from
a combination of V, D and J gene segments and recombination of these variable segments
leads to a large number of potential combinations allowing for recognition of a broad range
of antigens [112].
During development the thymic microenvironment directs differentiation and positive
and negative selection leading to T cells which are restricted and self-tolerant. Originally
produced from haematopoietic stem cells in the bone marrow, lymphoid progenitor cells
travel to the thymus to complete a process of antigen independent maturation into
functional T cells. Cells entering the thymus are termed double (or sometimes triple)
negative cells due to the lack of CD3, CD4 and CD8 expression [113]. These cells can be
subdivided based on their expression of CD44 and CD25 and pass through a number of
stages leading to rearrangement of the TCR mediated by RAG1 and RAG2. Following
successful rearrangement the TCR β chain associates with a pre-TCR α chain and CD3
to form the pre-TCR complex [114, 115]. Double positive αβ T cells undergo positive
and negative selection in the thymus. Positive selection requires that the rearranged αβ
TCR be able to bind to cortical epithelial cells expressing either MHC class I or class II
along with self peptide. If binding occurs with enough affinity survival signals are sent
and apoptosis is prevented[116]. Development to either cytotoxic or Th cells is dependent
on which class of MHC is recognised and is in part mediated by Notch signalling[117]. T
cells which survive positive selection pass further into the thymus where they encounter
bone marrow derived antigen presenting cells with high expression of MHC-self peptide
complexes. T cells with a high affinity for this complex undergo negative selection and die
by apoptosis[116].
T cells are activated by binding of their receptor with antigen complexed with MHC.
In the case of CD8+ T cells this is MHC class I, expressed by all cells and in CD4+ T cells
this is MHC class II, expressed by antigen presenting cells. Once bound the TCR requires
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co-stimulation in order to trigger down stream effects. The best characterised pathway for
co-stimulation in T cells is CD28 which binds to CD86 and CD80 [118]. Activation of T
cells is supported by the T cell co-receptor CD3 and the TCR ζ chain accessory molecules
[119]. Whilst this signalling process leads to gene transcription within the T cell further
co-stimulation is required for activation as without this T cell anergy occurs, a way of
protecting against self recognition by T cells. Whilst a number of co-stimulatory molecules
have been discovered CD28 is one of the best known and studied [120].
CD4+ T cells have been shown to have a number of phenotypically different subsets
(figure 1.5) with differing roles in the immune system. T helper cells are CD4+ cell with
an αβ TCR. T helper cells are able to divide and produce two main subsets of T helper
cell, Th1 cells which are produced in response to IFN-γ, Il-12 and Il-18 and are able to
secrete Il-2 and IFN-γ, and Th2 cells which are produced in response to Il-4 and are able
to secrete a number of interleukins including Il-4, Il-5, Il-10 and Il-13 [121]. Regulation of
T cell responses is performed in part by the subset of CD4+ cells known as regulatory T
cells. These cells are known to express CD4, CD25 and FoxP3 [122].
A pro-inflammatory T cell subtype can be generated following stimulation with Trans-
forming Growth Factor β (TGFβ) and Il-6. Known as Th17 cells they have the ability to
secrete Il-17 and are thought to be important in autoimmunity. Exposing Th2 cells to a
combination of TGFβ and Il-4 can cause them to secrete Il-9. These so called Th9 cells
are thought to be important in helminth infection.
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Figure 1.5 – Diagram showing the subsets of CD4+ T lymphocytes. CD4+ cells
expressing the αβ TCR are able to divide and produce a variety of different effector cells.
Whilst initially it was thought that CD4+ cells secreted a broad range of cytokines it has
been since shown that the secretome of CD4+ cells is dependent on which subset of cells is
present. Image taken from Bonilla[121].
1.7.2.2 B lymphocytes
Production of B lymphocytes occurs in the bone marrow and it is during their development
that they acquire their antigen specificity. B cells leave the bone marrow in an immature
state and on maturity they become naive B cells expressing both IgD and IgM. B cell
development occurs without exposure to antigens. Following this antigen independent
phase B cells will become activated when they are exposed to antigen and this is termed
the antigen dependent phase. Following activation B cells can either acquire memory of
the antigen to which they were exposed and become memory B cells, or differentiate into
plasma cells and produce antibodies. B cell activation can occur in a T cell dependent
or T cell independent fashion, although the former accounts for the majority of B cell
activity. The interaction between B cells and T cells occurs via co-stimulatory molecules
such as CD40, CD80 and CD86 and following this interaction B cells can migrate to a
follicle and form a germinal centre which enables class switching from IgM and IgD to
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IgA, IgG or IgE. Mutations in immunoglobulin heavy chains in the germinal centre can
lead to higher affinity antibodies against a particular antigen [123].
1.7.2.3 Natural killer T cells
NKT are a subset of T lymphocytes which are restricted to recognise lipid antigens
presented by CD1d molecules. They have two functional subtypes determined by their
TCR. NKT cells have a TCR and express CD3, as well as CD44 and CD122. There exists
considerable heterogeneity within the NKT cell lineage but as their name suggests NKT
cells share functional and phenotypic properties with both NK cells and T cells. NKT
cells have been shown to have both pro and anti-inflammatory actions [124].
1.8 Mesenchymal stromal cells
The definitions of MSC have developed over time due to advances in isolation techniques
and a greater functional understanding of how MSC exert their effect. Whilst no clear
consensus exits as to exactly what MSC are the International Stem Cell Therapy Society
(ISCT) have developed a set of minimal criteria for describing MSC [125, 126]. It has been
argued more recently that these criteria are dated and require updating [127] with ongoing
debate as to whether the term ’stem cell’ should be used or whether MSC represent a
type of stomal cell [128]. It has even been suggested that MSC are a type of fibroblast
[129]. Criticism of the ISCT criteria focus on their inability to account for heterogeneous
populations of cells which commonly occur following traditional isolation techniques.
Whilst cells can be isolated from wide variety of tissues using different techniques and
culture methods, they are still able to meet the minimum criteria for an MSC as defined
by the ISCT [130]. Whilst debate will almost certainly continue as to what exactly
constitutes an MSC it is generally agreed that MSC are multipotent, self-renewing cells
originating in the mesoderm or the neural crest, their differentiation potential being limited
to chondrocytic, osteocytic and adipocytic lineages [131]. Until recently the ability of MSC
26
to self renew has been inferred from their behaviour in culture as techniques to isolate
purified populations of cells have been lacking and heterogeneous populations of cells were
cultured following plastic adherence [130]. MSC exist in a number of adult tissues, albeit
in low numbers [132], and whilst traditional isolation techniques have relied on their ability
to adhere to tissue culture plastic and proliferate [133], prospective isolation with cell
sorting based on specific cell surface markers is gaining popularity as the isolation method
of choice.
1.8.1 Evolution of a bone marrow stromal cell niche
Whilst modern day research into MSC dates back over 50 years one of the first hypotheses
regarding their existence can be dated back over 100 years. In 1908 a description of
the ability of bone marrow stroma to create an environment in which haematopoietic
precursors are able to differentiate was first suggested in 1908 by Maximov [134, 135]. The
osteogenic potential of bone marrow was demonstrated in experiments by Tavassoli in the
1960s. In these experiments Tavassoli showed that serial transplantation of bone marrow
fragments in rats, rabbits and dogs led to complete reconstitution of the bone marrow and
the eventual establishment of a micro-circulation and haematopoiesis. These experiments
were limited however as it was not possible to identify which cellular constituents within
the bone marrow were responsible for this reconstitution [136]. It took a further 2 years
before Friedenstein was able to demonstrate that a rare population of bone marrow cells
with fibroblastic properties were responsible and confirm Tavassoli’s hypothesis and the
term Colony Forming Unit Fibroblast (CFU-F) was used to describe them [137]. These
bone marrow cells have subsequently been shown to be multi-potent [138] and able to
differentiate into different mesenchymal cells at the colony forming level by modifying
the culture conditions, but their complex interplay with haematopoietic stem cells has
only recently been demonstrated [139]. The term MSC was first used in 1991 when it was
introduced by Caplan [140], and the idea of a stem cell niche within the bone marrow was
further developed by the discovery of a rare, self-renewing population of cells [132]. The
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MCAM/CD146 expressing cells found in the sub-endothelium of human bone marrow were
found to be capable of recapitulating the haematopoietic micro-environment following
transplantation to heterotopic sites, which began the currently ongoing debate regarding
the correct criteria with which to judge MSC. More recently cells who do not express
CD146, but do express CD271 have also been shown to be MSCs[141]. Due to their
mixture of stem and stromal like properties both stem and stromal cell have been suggested
as correct terms, although the ability to self-renew and tri-lineage differentiation potential
(osteogenic, chondrogenic, adipogenic) appear in most definitions [142, 126].
The descriptive criteria for human MSC are focused on their ability to adhere to tissue
culture plastic, their multi-potency and their expression of specific cell surface antigens
(table 1.3). The minimal criteria described by the ISCT in 2006 defined a population of
human MSC as needing to be greater than 95% positive for positive antigens and less than
2% positive for negative antigens [126]. In mice however, CD105, CD90 and VCAM-1 have
been described as important markers of MSC purity (table 1.3), although as discussed
next the successful isolation of MSC from murine bone marrow has been considerably
more challenging with robust and reproducible techniques only recently being discovered
[143]. These difficulties have led to a number of studies using markedly heterogeneous cell
populations with inconsistent results in pre-clinical studies making comparison between
them difficult. Prospective isolation of MSC using cell sorting techniques and specific
surface markers has been demonstrated. In humans and mice, MSC can also be isolated
based on their expression of Low-affinity Nerve Growth Factor (LNGFR) along with Thy1
and Vascular Cellular Adhesion Molecule (VCAM). Cells with an LNGFR+ (CD271),
THY-1+, VCAM-1hi expression profile have also been shown to meet the ISCT criteria for
an MSC due to their ability to undergo tri-lineage differentiation and self-renewal [144].
The intermediate filament protein nestin has also been shown to identify a population
of perivascular MSC which are able to support the haematopoietic niche and may also
be used as a marker for prospective isolation. Notably the overlap between PαS MSC
and nestin+ cells is not complete, with the majority of nestin+ cells not expressing Stem
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Cell Antigen (Sca-1), suggesting some phenotypic differences [139]. Cells expressing
nestin were also shown to form clonal mesenspheres and following serial transplantation
these mesenspheres were able to self renew and generate haematopoietic activity. More
recently Zhou et al.[145] have described the expression of the leptin receptor on murine
bone marrow derived MSC. It is clear from the description of various sub-populations of
CFU-Fs that early work demonstrated a heterogeneous population of cells and that MSC
only represent a small fraction of this.
Surface Antigens
Positive Negative
Human Mouse Human Mouse
CD105 CD105 CD86 CD45
CD90 (Thy1) CD90 CD80 Ter119
CD73 VCAM CD79α or CD19
CD73 PDGFRα CD45
CD71 Sca-1 CD40
CD44 Leptin receptor CD34
GD2 CD14 or CD11b
LNGFR (CD271) HLA-DR
PDGFRα
Table 1.3 – List of surface markers for human and mouse MSC.
1.8.2 Isolation techniques for MSC
The MSC literature has been hampered by an inability to isolate purified populations of
cells. Whilst there are hundreds of studies published assessing the effects of MSC in various
models of disease, the heterogeneity of cell types, isolation methods and culture techniques
makes comparison between studies challenging. Studies using MSC have focussed on
human cells, in part due the notion that findings should be readily translatable, but mainly
due to the difficulties in isolating murine MSC [131, 146]. There are obvious advantages
to the use of MSC isolated from mice including the avoidance of xenotransplantation and
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the ability to use genetic knockout models enabling finer study of the mechanism of action
of MSC which until recently has been lacking. Traditional techniques for MSC isolation
involve their ability to adhere to plastic. Following plastic adherence serial changes of
media enable the depletion of haematopoietic cells and allows the culture expansion of a
heterogeneous population of cells with colony forming potential [147]. Whilst this technique
has been successful for the isolation of human MSC, plastic adherence techniques in murine
MSC leads to a considerable number of contaminating cells [143, 148]. Techniques to
enrich the population of MSC have been demonstrated including immunodepletion and
positive selection. Immunodepletion using haematopoietic markers led to a population
of cells capable of tri-lineage differentiation, however cell growth was slowed due to a
down regulation of genes responsible for cell proliferation [149]. Recent techniques have
investigated the prospective isolation of MSC based on a variety of markers thought to
represent more purified populations of stem/stromal cells. Morikawa was one of the first
to develop a technique for prospective isolation of murine bone marrow MSC based on
prospective markers [150]. The markers used were PDGFRα and Sca-1 with negative
markers for the haematopoietic markers CD45 and Ter119. Study of these cells in vivo
demonstrated a perivascular location and in vitro studies of isolated cells demonstrated the
ability to form colonies and undergo tri-lineage differentiation. Using a genetic mouse model
combining the intracellular filament protein nestin with Green Fluorescent Protein (GFP)
Méndez-Ferrer demonstrated a population of cells able to undergo tri-lineage differentiation
which could be propagated as clonal mesenspheres. This study also demonstrated the
functional in vivo link between MSC and Haematopoietic Stem Cells (HSC) [139]. As
isolation of cells expressing nestin requires a transgenic mouse, Pinho demonstrated that
cells isolated using PDGFRα and CD51 and that did not express endothelial markers or
haematopoietic markers are highly positive for nestin, suggesting an alternative technique
to isolate these cells [151]. Whilst all of these techniques produce cells that demonstrate the
properties of MSC and meet the ISCT definition, overlap between these populations is not
complete suggesting that heterogeneity still exists, however whether a truly homogeneous
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population of MSC will ever be described remains to be seen. It is certainly possible that
these cells do represent the same population of cells but in a different state of differentiation.
MSC can be isolated from a variety of tissue including bone marrow, umbilical cord,
umbilical blood and adipose tissue. Whilst sometimes seen as comparable due to being
described as MSC and meeting all of the basic requirements to be refereed to as MSC,
cells isolated from different tissues show differences in proliferation capacity and their
ability to modulate the immune system [152].
1.8.3 MSC and immunomodulation
The evolution of the MSC field has been directed around their ability to undergo differen-
tiation into tissue in the mesodermal lineage and the potential uses for this in regenerative
medicine. The ability of MSC to secrete trophic factors coupled with the low level of
MHC expression makes them an ideal candidate for use as a cell therapy [153]. In recent
years however the ability of MSC to modulate the immune system has gained widespread
interest. MSC have broad reaching immunomodulatory properties and have been shown
to exert effects on both the adaptive and the innate immune systems mediated by a
combination of paracrine signalling and more remote effects the mechanism of which has
not yet been elicited [139, 154, 155]. A number of the mechanisms by which MSC have
been demonstrated to modulate the immune system in predominantly pre-clinical studies
are described below (figure 1.6).
MSC are able to inhibit T cell proliferation and activation and a number of mechanisms
have been proposed and demonstrated to explain this finding. Early cell cycle arrest of T
cells may have a role in their suppressive action, and MSC have been shown to inhibit
cyclin D2 and up regulate p27Kip1. The mechanism by which MSC achieve this is not
entirely clear although it has been shown to be independent of MHC expression [156].
The suppressive activity of MSC is not however limited to a specific subset of T cells,
and has also been shown to occur during CD40L and Il-4 stimulation of B cells, which
likely reflects the role of cyclin D2 in driving B cell proliferation [157, 158]. Notably,
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an inflammatory environment is required for MSC to exert their immune-suppressive
effect as otherwise MSC have been shown paradoxically to exert a pro-inflammatory
effect on T cells [159]. MSC have been shown to inhibit the maturation of dendritic cells
[160, 161, 162] and decrease their expression of MHC class 1, MHC class 2 and other
co-stimulatory molecules. This leads to a reduction in the ability of dendritic cells to
present antigen to other immune cells. In vitro assays have been able to demonstrate that
MSC can stimulate plasmacytoid dendritic cells to increase their production of Il-10 and
can also inhibit the release of TNFα from dendritic cells via a Prostaglandin E2 (PGE2)
dependent pathway [163]. This mechanism has been proposed for the success of MSC in
graft versus host disease [164, 165]. MSC are able to inhibit and promote the release of
soluble factors such as Indoleamine 2,3-dioxygenase (IDO), TGFβ, PGE2 and Il-10. This
inhibitory effect has been shown to prevent activation of NK cells by Il-2, however once
NK cells are activated the inhibitory effect of MSC is only partial. Reductions in IFN-γ
secretion by NK cells has been used to demonstrate the activity of MSC on activated NK
cells [166]. MSC can be induced to increase their production of MHC class 1 and 2 by
activation using IFN-γ, and inhibition of MHC production has been shown to protect
MSC from NK induced apoptosis [166]. It has recently been suggested that need MSC to
be induced to undergo perforin dependent apoptosis by host cytotoxic cells in order to
exert their immunosuppressive effects[167].
Whilst the phenotypic differences between human and mouse MSC are relatively well
described, and there is a clear difference in expression profiles and phenotype, differences
between strains of mice and rats with respect to their mode of immunomodulation have
also been demonstrated, with BALBc mice predominantly secreting inducible Nitric
Oxide (iNOS) as opposed to IDO being a proposed mechanism of immunosuppression
in other models [168, 169]. Parallels between some human and mouse cells have been
seen with human MSC also secreting IDO, a potential mechanism by which they exert
their immunosuppressive effect [170]. An understanding of the similarities and differences
between human and mouse MSC as well as the strain differences is critical when choosing
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mice for MSC isolation, particularly when carrying out studies with a translational
objective.
Figure 1.6 – Diagram showing the effects of MSC on the immune system. MSC
have been shown to have the ability to exert an effect on a range of cells involved in the
immune response. Direct effects can be exerted on CD4+, CD8+, γδT cells, FoxP3+ regulatory
T cells, neutrophils and monocytes. Indirect effects are also exerted on NK cells via their
action on dendritic cells. Picture taken from Owen [1].
1.9 MSC in liver disease
MSC have been investigated in both pre-clinical and more recently clinical trials of liver and
gastrointestinal disease. Mechanisms studied in this context range from paracrine trophic
signally, reduction of oxidative stress and modulation of immune responses including a
reduction in liver fibrosis. In the last decade whilst there has been a rapid increase in the
number of pre-clinical and clinical trials [146] in the MSC literature, few robust clinical
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trials have been undertaken in liver disease and there is clear need for well conducted
clinical trials in this area [1].
MSC therapy has been examined in a number of different liver pathologies with some
encouraging results.
1.9.1 Liver fibrosis and cirrhosis
Chronic liver disease is characterised by progression from injury to fibrosis and finally
cirrhosis. It is generally accepted that fibrosis represents a reversible phase and may be
amenable to therapies to prevent or reverse this stage [171]. Cirrhosis marks the final clinical
pattern in chronic liver disease and is generally accepted as a move towards irreversible liver
damage. During fibrosis stellate cell activation leads to deposition of Extracellular Matrix
(ECM) along with collagen and proteins [172]. When activated, stellate cells express P75,
a receptor which can trigger apoptosis in response to stimulation by Nerve Growth Factor
(NGF). MSC are able to release NGF and therefore stimulate stellate cell apoptosis.
Binding of NGF to P75 leads to induction of the NF-κB and c-Jun N-terminal kinase
(JNK) pathways [173]. Inflammation and fibrosis are not mutually exclusive and both
fibrosis and immune mediated injury can occur simultaneously, particularly in ongoing
injury. MSC have been used in models of fibrotic liver disease with an aim to reverse
fibrosis, however due to the nature of the models used ongoing immune injury is usually
present and so determining whether beneficial effects seen are due to reversal of the
fibrosis or immunomodulation is debated (figure 1.7). MSC are able to initiate stellate
cell apoptosis, and due to their role in ECM deposition and subsequent fibrosis this has
been suggested as a possible mechanism by which MSC could improve fibrotic liver disease
[174]. In rat models of liver cirrhosis human umbilical cord MSC have been shown to
decrease the expression of markers of fibrosis including α Smooth Muscle Actin (α-SMA)
[175]. MSC are also able to secrete the Matrix metalloproteinase (MMP) MMP9, a
protease which is able to breakdown the ECM and in mouse models of fibrosis MSC have
been shown to increase expression of MMP9 along fibrous septa leading to a reduction in
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fibrosis [176]. It as been suggested that MSC can differentiate into hepatocytes and are
able to repopulate fibrotic or cirrhotic liver, however this mechanism seems unlikely due to
the low numbers of MSC administered and the even lower number of cells which actually
arrive at the liver [177]. Clinical trials in liver fibrosis have shown conflicting results with
early observational studies demonstrating an increase in liver volume but later randomised
control trials demonstrating no beneficial effect of MSC therapy [178, 179].
Figure 1.7 – Diagram showing the effects of MSC in liver fibrosis. MSC are able
to secrete NGF which binds to p75 expressed on activated stellate cells. This causes stellate
cell apoptosis and therefore a reduction in ECM due to less stellate cell production. MSC
also secrete MMP9 which is a protease able to cleave collagen in the ECM. MSC may also
act via an as yet undiscovered mechanism to reduce the secretion of stellate cell α-SMA and
TGFβ1. Image taken from Owen [1].
1.9.2 Acute liver failure
Acute liver failure is relatively rare but has a high morbidity and mortality. There are a
number of causes of acute liver failure and the prevalence of these varies between developed
and developing countries with drug induced liver injury being the most common in the
developed world whereas hepatitis induced acute liver failure is the commonest aetiology
n developing countries [180]. Drug induced liver failure accounts for over 50% of cases
of acute liver failure in the United States of America (USA) and across Europe with
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the commonest drug being paracetamol [181, 182]. In both CCL4 and concanavalin A
induced liver failure MSC therapy has been shown reduce liver injury through a reduction
in pro-inflammatory cytokines such as TNFα and IFN-γ with a greater effect seen with
repeated dosing of MSC [183, 184, 185]. In the acute CCL4 model oxidative stress has
been demonstrated as discussed earlier. MSC have been shown to have the ability to act
as free radical scavengers in the CCL4 model and reduce liver injury by reducing oxidative
stress [186]. In mouse models of paracetamol induced liver failure MSC have been shown
to reduce liver injury by inhibition of JNK, a change that has been shown to persist along
with reduction in overall hepatic JNK and TNFα whilst levels of glutathione seem to be
preserved [187, 188].
1.9.3 Ischaemia reperfusion injury and transplantation
Ischaemia reperfusion injury occurs due to trauma, blood loss and during liver surgery [189].
The broad mechanisms of injury which occur in ischaemia reperfusion injury have been
described earlier with one important component of reperfusion injury being the infiltration
of CD4+ T cells and their subsets including NK cells and γδT cells [190]. A number of
potential roles for MSC therapy have been investigated (figure 1.8). A therapy that has
been studied in hepatic ischaemia reperfusion injury is hepatocyte transplantation and
using MSCs in this setting appears to increase the survival of transplanted hepatocytes as
well as maintain their function [191, 192]. MSC have also been shown to reduce the number
of TUNEL positive hepatocytes in a rat model of ischaemia reperfusion injury [193]. MSC
have been shown to inhibit neutrophil apoptosis via modulation of the Bcl-2:Bax pathway
in vitro [194], possibly through secretion of Il-6 leading to increased phosphorylation of
STAT3 [1], the relevance of this in ischaemia reperfusion injury needs consideration due to
the role of neutrophils in reperfusion injury.
MSC that have been transfected to enable them to overexpress Hepatocyte Growth
Factor (HGF) have been shown to improve survival in models of small for size liver
transplantation although it is not clear if this is an effect of HGF alone [195, 196]. In
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reduced size liver transplantation MSC have been shown to prolong graft survival, although
the mechanism by which they achieve this is not clear [197].
In models of liver transplantation MSC have been shown to induce tolerance by
suppressing cytotoxic T cell levels whilst increasing the levels of regulatory T cells [198, 154].
So far these results have not been translated into clinical practice, however results from
small studies in renal transplant have shown that MSC may improve graft survival
[199, 200].
Figure 1.8 – Diagram of the effects of MSC in ischaemia reperfusion injury. MSC
are able to inhibit CD4+, CD8+ and γδ T lymphocytes by secreting a number of anti-
inflammatory cytokines including LHA-G5, IDO, Haem Oxygenase 1 (HO1), TGFβ and
PGE2. MSC may also differentiate into hepatocytes, although this occurs in low numbers
and is unlikely to be a significant mechanism of action. Hepatocyte apoptosis is also inhibited
by MSC due to their ability to secrete HGF. MSC may also adhere to hepatocytes and
reduce TNFα and phospho-JNK. Image taken from Owen [1].
1.9.4 Acute hepatitis
In the developing world acute liver failure is commonly caused by viral infection with
hepatitis A and hepatitis E [201, 202, 203]. Whilst predominantly a cause of chronic
37
hepatitis viral infection with hepatitis B has also been shown to cause acute on chronic
liver failure [204]. In a case control study MSC therapy has been shown to reduce liver
volume, as well as improve liver function tests and albumin production in patients with
acute on chronic hepatitis B [205]. Due to the design of this study it is difficult to infer
causality and so further work is needed to ascertain if MSC are a viable therapy in acute
on chronic liver failure.
1.9.5 Chronic hepatitis
MSC may have a role in patients suffering from chronic hepatitis B and C infection. In
patients with hepatitis B related cirrhosis MSC have been shown to improve liver function
tests when compared with anti-viral therapy alone [206]. The mechanism proposed for the
beneficial effects of MSC in hepatitis B are an increase in regulatory T cells and a reduction
in Il-17 secreting T helper cells [207]. In hepatitis C small clinical trials have shown a
reduction in markers of fibrosis along with a decrease in pro-inflammatory cytokines and
and increase in anti-inflammatory cytokines in patients treated with a combination of
MSC and G-CSF [208]. Hepatitis B virus is able to infect MSC without any apparent
effect on their ability to modulate the immune system, the clinical significance of this
needs further study [209].
1.9.6 Concerns about tumour formation
There has always been a concern with stem and stromal cell therapy about the theoretical
risk of tumour formation. Indeed any immunosuppressive treatment can potentially lead
to and increased risk of tumour formation due to the complex role that the immune system
plays in prevention and removal of abnormal cells. MSC have also been demonstrated
to secrete pro-angiogenic factors including platelet derived growth factor and vascular
endothelial growth factor which could support tumour growth [210]. MSC have been
shown to inhibit tumour growth in hepatocellular carcinoma by stimulating the down
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regulation of factors associated with the Wnt signalling pathway, but in other models
MSC seem to promote tumour growth by secreting trophic factors [211].
Transformation of MSC has been shown to occur and is a possible explanation for the
heterogeneity seen in pre-clinical and clinical studies. It is seen more commonly in murine
MSC and more commonly when using plastic adherent isolation techniques [212].
There were two reports which described spontaneous transformation of human MSC
following transplantation which led to the suspension of a number of clinical trials [213, 214].
These reports were subsequently retracted after it was demonstrated that the MSC used
in these studies had been cross contaminated with the HT1080 human fibrosarcoma cell
line [215, 216].
Studies into murine MSC have been able to generate more robust data indicating a
potential problem with MSC therapy. Late passage MSC (passage 65) have been shown
to be able to bypass senescence and generate fibrosarcomas in multiple organs after being
injected into mice and early passage MSC have been shown to exhibit genetic instabilities
which can go on to form tumours [217]. Whilst the increased susceptibility of inbred murine
cells to malignant transformation is well documented, human cells appear to be relatively
resistant. Human fibroblasts have been shown to require mutations in 6 different signalling
pathways in order to undergo malignant transformation whereas mouse fibroblasts only
require mutations in 2 pathways [218]. Whilst some of these findings may raise concern it
is worth noting that so far no clinical trials have demonstrated malignant transformation
of human MSC when used as a cell therapy.
1.9.7 Route of administration and homing
Delivery of MSC into animals and humans has been achieved using a number of different
routes of administration. Conventional routes of administration such as Intravenous
(IV) have been tested extensively, however other routes of administration such as intra-
portal and Intraperitoneal (IP) are an attractive prospect as they enable bypassing of
the pulmonary circulation which is responsible for trapping the majority of systemically
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administered MSC [219]. Strategies to improve homing of MSC to target organs have
been trialled with some success. In CCL4 induced liver injury MSC use CD29 and
CD44 to mediate adhesion to the sinusoidal endothelium leading to increased engraftment
[220]. Human MSC are able to express a number of molecules involved in adhesion and
trafficking including the CXC Chemokine Receptor (CXCR)s CXCR4, CXCR5 and
CXCR6, however the in vivo relevance of this requires further study [221]. In standard
culture conditions MSC quickly lose expression of CXCR4, however culture in hypoxic
conditions CXCR4 expression is increased which may aid in homing to hypoxic tissues
expressing SDF-1α [222]. By converting surface CD44 on MSC into Hematopoietic Cell E-
/L-Selectin Ligand (HCELL) MSC can be modified using glycosyltransferase-programmed
stereosubstitution to adhere to endothelial tissue expressing E-Selectin aiding recruitment
to therapeutic targets[223]. MSC encapsulated in alginate have been shown to survive
longer in vivo and in models of graft versus host disease are able to reduce the injury
seen suggesting that paracrine signalling plays an important role in the effects of MSC in
systemic inflammatory conditions [155].
1.9.8 Cell therapy without administering cells
Due to the potential risks of administering live cells and the potential unpredictability
of the response in vivo work has been undertaken to find alternative ways to achieve the
same clinical outcomes without administering cells. MSC conditioned media is media
taken from cultured cells and along with MSC based extra corporeal membranes have been
show to have similar effects to administering cells. In a study using the d-galactosamine
model of acute liver failure extracorporeal membranes containing MSC showed the greatest
reduction in liver injury, followed by MSC conditioned media with systemic administration
of MSC alone showing the least improvement in liver function [224]. Studies in other
diseases have shown a benefit from the MSC secretome with models of Multiple sclerosis
(MS) showing an improvement [225]. Whilst encouraging, MSC derived conditioned media
contains a large number of cytokines and further work needs to be done to elicit which of
40
these are important in order to effectively reduce liver injury.
Extracellular vesicles were first described in the 1980’s and it was believed that they
were a means for cells to excrete waste products [226]. Recent studies have demonstrated
that cells are able to use extracellular vesicles to facilitate cell to cell communication by
transferring biomolecules [227]. MSC secrete extra cellular vesicles and administration of
MSC derived extra cellular vesicles has been shown to increase hepatocyte proliferation
and cell viability in an acute CCL4 model [228].
1.9.9 Tracking MSC in vivo
Due to the lack of clarity as to whether MSC need to be located in an area of inflammation
in order to exert immunomodulatory effects it is important to be able to accurately
track the location of systemically administered MSC in order to gain further insight into
their mechanism of action. Early techniques to allow for the tracking of MSC required
magnetoporation of MSC to enable labelling with super-magnetic iron oxide allowing
visualisation in a Magnetic Resonance Imaging (MRI) scanner [229]. Whist promising
initially it has subsequently been discovered that magnetoporation inhibits MSC migration
and differentiation making this tracking technique unusable [230]. An alternative technique
involves the use of manganese oxide nanoparticles and this technique has been used with
success in models of glioblastoma [231]. Quantum dots are a stable nanoparticle which
can be used to label cells for an extended period of time without significant deleterious
effects on cell function. Recent studies have successfully used quantum dots to track MSC
in rat lung injury models, however further work is required in order to demonstrate that
quantum dots are truly inert in murine MSC [232].
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1.10 Aims and Objectives
With the paucity of donor organs available for liver transplantation and the increasing
incidence of liver disease in the developed world there is an urgent need for novel therapies
in order to reduce the morbidity and mortality from liver disease and liver transplantation.
MSC have great potential as an immunomodulatory therapy which may be able to reduce
the immune mediated injury that occurs in liver transplantation operations and the
resulting medium term complications that occur as a result of ischaemia reperfusion
injury to the donor liver. The pre-clinical MSC literature demonstrates a huge amount
of heterogeneity in both the isolation techniques used for MSC and the type of cell used
with a mixture of the xenotransplantation of human MSC into mouse models and the
allotransplantation mouse MSC into mouse models.
In order to test the potential of MSC as a potential therapy for improving liver
transplantation outcomes I opted to use murine bone marrow derived MSCs prospectively
isolated based on their expression of PDGFRα and Sca-1 (PαS) and test them in models
of liver injury.
1.10.1 Hypotheses
In order to investigate the hypothesis that MSC represent a translatable therapy for
marginal donor liver transplantation I first considered a number of hypotheses. The
hypotheses for this study were:
1. PαS MSC are able to suppress lymphocyte proliferation in vitro
2. PαS MSC are able to reduce hepatobiliary injury in the MDR2-/- mouse model
3. PαS MSC are able to exert their immunomodulatory effects via a remote action




The specific aims for this study were to:
1. Isolate and characterise PαS MSC from murine bone marrow
2. Optimise an in vitro splenocyte reaction and test the in vitro efficacy of PαS MSC
3. Characterise the MDR2-/- model of biliary injury and test the in vivo efficacy of
PαS MSC in this model
4. Investigate the trafficking of PαS MSC following systemic administration and test
their ability to exert remote immunomodulatory effects
5. Develop a model of hepatic ischaemia reperfusion injury and test the in vivo efficacy




2.1 Preparation of buffers and culture media
All buffers and media were made and stored refrigerated at 4°C for a maximum of 2 weeks
unless otherwise stated.
2.1.1 P2 buffer
P2 buffer was prepared by combining sterile Phosphate Buffered Saline (PBS) with 2%
Foetal Bovine/Calf Serum (FBS/FCS) (Gibco®, UK).
2.1.2 FACS buffer
Fluorescence Activated Cell Sorting (FACS)buffer was prepared by combining sterile PBS
with 2% FBS/FCS
2.1.3 MACS buffer
Magnetic Activated Cell Sorting (MACS)buffer was prepared by combining sterile PBS




C10 medium was prepared by combining Rosewll Park Memorial Institue (RPMI) (Gibco,
UK) with 10% FBS/FCS, 1% Penicillin-Streptomycin-Glutamine (PSG) (Gibco®, UK)
and 50 mM β-mercaptoethanol (βME) (Sigma-Aldrich, UK).
2.1.5 HBSS+
A solution of Hank’s Balanced Salt Solution (HBSS) (Gibco®, UK) was prepared with the
addition of 2% FBS/FCS, 1% PSG and 10 mM of HEPES buffer (Sigma-Aldrich, UK).
2.1.6 α-MEM culture medium
α Modified Minimum Essential Medium (Eagle) (α-MEM) culture medium was prepared
by combing α-MEM (Gibco®, UK) with 10% FBS/FCS and 1% PSG.
2.2 Animal husbandry
All mice were maintained at the . Care was
undertaken using the standard established care protocols at our institution. Mice were
housed in cages of no greater than 5 animals. The environment was controlled, with
a 12 hour light/dark cycle and a temperature of 22°C. Any procedures carried out on
animals were done so in accordance with the Animals (Scientific Procedures) Act 1986,
UK and all procedures underwent ethical review prior to being performed. Procedures




Male C57BL/6 mice and male FVB mice were purchased from
and male BALB/c mice were purchased from
. Animals were purchased
at age 7 weeks and acclimatised for 1 week prior to use in experiments. Genotyping was
not required in our institution.
2.2.2 OT-1 mice
Male OT-1 mice were purchased from . A breeding colony was
established and maintained at OT-1 mice
were maintained on a C57BL/6 background as homozygotes. Genotyping was performed
by TransnetYX® as described.
2.2.3 MDR2-/- mice
The MDR2-/- mouse colony was already established on an FVB background in
As this is a genetic knockout model injury develops from birth and does not recover.
Whilst animals were regularly observed for signs of distress this is a mild non-fatal model
and distress was not expected or seen. Whilst genotyping of all mice were not required due
to this being a homozygous colony occasional genotyping of breeding pairs was undertaken
to ensure there was no genetic drift. Genotyping was performed by TransnetYX® as
described.
2.2.4 Genotyping
Genotyping was undertaken by TransnetYX® (TransnetYX®, US). Ear clippings were
removed from breeding pairs by animal handling staff at the
labelled and shipped to TransnetYX® for analysis. Zygosity testing using
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real time PCR was undertaken using the primers in table 2.1. One probe per allele was
run and results were uploaded online.
Mouse strain Forward primer Reverse primer
OT-1 5’ - CAG CAG GTG AGA CAA AGT - 3’ 5’ - GGC TTT ATA ATT AGC TTG GTC C - 3’
MDR2-/- 5’ - CTC GTT AAC ATG CAG ACA GCA G - 3’ 5’ - GAC CAG GGA GAA CAT GTT ACA C - 3’
Table 2.1 – List of primers used for genotyping mice.
2.3 Prospective isolation of murine PαS MSC by cell
sorting
The prospective isolation of murine PαS MSC was originally described by Morikawa et al
in 2009 [150]. The technique for isolation of PαS MSC was further optimised by our group
[233] to ensure consistency and reproducibility in our laboratory. Prospective isolation
using this technique yields a highly purified population of PαS MSC (>99% pure).
2.3.1 Long bone removal and preparation
Each isolation was performed using 10 male wild type mice aged between 8 and 12 weeks as
following earlier optimisation this number represented the most efficient and least wasteful
number of mice to ensure adequate cell yield. Following sacrifice mice were sprayed with
70% ethanol. A transverse incision was made in the abdomen through the skin layer and
extended to each hind limb. Forceps were used to grip the knee joint and the skin was
folded back over the foot and then the foot removed and discarded. The tibia was exposed
by blunt dissection using scissors and the fibula discarded. An incision was made through
the knee joint and the tibia removed and cleaned by gentle rolling between a piece of
tissue paper until all soft tissue had been removed. The tibia was then placed into a 50
ml FalconTM (Corning, US) conical centrifuge tube containing PBS and kept on ice. The
femur was then exposed by a combination of blunt dissection and careful incisions in the
soft tissue. A further incision was made through the hip joint aiming to preserve the
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femoral head. The femur was then cleaned in the same manner as the tibia and again
placed into PBS. This process was then repeated for the other hind limb. Each mouse
was sacrificed individually just prior to long bone removal.
Following removal of all long bones the bones were washed 3 times in PBS by gentle
agitation in a conical tube. The bones were then placed into a pestle and mortar and each
bone broken with a single break in the middle. A bony paste was then produced by cutting
the bones with dissection scissors until there was no resistance felt (approximately 5-10
minutes). The bony paste was then washed with 5 ml of PBS and the bones transferred into
a further 50 ml FalconTM tube containing 20 ml of Dulbecco’s Modified Eagle’s Medium
(DMEM) (Gibco®, UK) with 0.2% crude collagenase (Wako, Germany) and treated with
PSG, pre-warmed to 37°C. The mixture was then placed in a rocking incubator at 37°C
with an oscillatory frequency of 110 rpm for 60 minutes.
2.3.2 Preparation of cell suspension
On removal from the incubator the tube was immediately placed on ice to stop the
collagenase reaction. The bone fragments were filtered using a 70 µm sterile filter (Corning,
US) into a new conical tube and kept on ice. The remaining bone fragments/bone paste
are returned to the mortar. HBSS+ solution is added to the bone fragments. The bone
fragments were then gently crushed using the pestle with repeated light tapping for 100
taps. This was followed by the addition of a further 2.5 ml of the HBSS+ solution was
added using a pipette. The total of 5 ml of solution was pipetted up and down 3 times to
aid with cell release. Gentle swirling of the bone fragments and liquid was carried out using
the pestle for 30 seconds. Further mixing with the pipette was carried out with repeat up
and down transfer. The solution was then carefully drawn up into the pipette being sure
to leave the remaining bone fragments and the solution filtered through a 70 µm filter
into the conical tube containing the previous filtrate, remaining on ice at all times. This
process was repeated a further 5 times until a total of 50 ml of solution had been collected
in the conical tube. The solution was subsequently spun in a pre-chilled centrifuge at 4°C
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for 7 minutes at 280g (1350 rpm). Following centrifugation the supernatant was discarded
and the cell pellet resuspended as previously described but no medium added.
2.3.3 Red cell lysis
Red blood cell lysis was required in order to remove all of the red blood cells, which are
not being collected, and therefore improve the efficiency of the later sorting step. Whilst
the technique described is a non-standard technique it has been found through meticulous
optimisation to give the greatest yield of PαS MSC compared with other methods of
red cell lysis. The resuspended pellet present in a 50 ml conical tube had 1 ml of cold
(approximately 4°C) sterile water (Sigma-Aldrich, UK) added whilst continuous rotating
of the tube was carried out by hand. After 5 seconds of contact with the water 1 ml of
double strength PBS solution (with 4% FBS/FCS added) was added followed by 13 ml
of HBSS+ solution to make a total volume of 15 ml in order to quench the reaction. The
cell suspension was then filtered through a sterile 70 µm filter before further spinning
in a pre-chilled centrifuge at 4°C for 5 minutes at 280g (1350 rpm). Following this the
supernatant was again discarded and the cell pellet resuspended as described previously
in 1ml of the HBSS+ solution.
2.3.4 Labelling of MSC with fluorescent antibodies
The staining colours were determined after careful analysis of the requirements of the
MoFloTM XDP cell sorter (Beckman Coulter, US) at the university of Birmingham along
with the availability of stains for the relevant markers. The antibody panel used was as
described in the literature. All antibodies were purchased from eBioscience in the UK.
The antibodies used were as follows; CD45-PE (1 μl/mouse), Ter119-PE (1 μl/mouse),
Sca-1-FITC (1 μl/mouse) and PDGFRα-APC (1.5 μl/mouse). Propidium Iodide (PI)
(Sigma-Aldrich, UK) solution was also used as described later. Sterile FACS tubes
(Corning, US) were used for all samples and controls. Staining of the main sample was
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carried out in the conical tube and transferred to a cuvette as described later. All samples
were kept on ice during the staining process. Staining was carried out in a standard hood
with the light switched off and all antibodies were protected from light exposure. Control
tubes were as follows; negative control (cells only), positive control for PE (cells and PE
antibody), positive control for FITC (cells and FITC antibody), and positive control for
APC (cells and APC antibody). Each control tube (4 in total) had 100 µl of HBSS+
solution, 4 µl of the cell suspension and 1 µl of the relevant antibody. The main sample
tube staining was achieved with the addition of 1µl per mouse of each of the 4 antibodies
(CD45-PE, Ter119PE, Sca-1-FITC and PDGFRα-APC). All samples were then incubated
on ice in the dark for 30 minutes. Following incubation the control samples were washed
by the addition of a further 1ml of HBSS+ solution. The control samples were then spun
at 2000 rpm for 5 minutes. The supernatant was discarded and the resulting cell pellets
resuspended as described earlier. The main sample conical tube was spun in a pre-chilled
centrifuge at 4°C for 5 minutes at 280g (1350 rpm). Following this the supernatant was
discarded and the resulting cell pellet resuspended. A solution of PI stain and HBSS+
was made with a concentration of 2 µl of PI per ml of HBSS+. The control tubes each
had 500 µl of PI/HBSS+ solution added. The main sample had 1 ml PI/HBSS+ solution
per mouse added (10-15 ml). Each control tube was filtered into a new FACS cuvette
through a sterile 50 µm filter (Partec, DE). The main sample was filtered into multiple
FACS cuvette tubes through a sterile 50 µm filter aiming for 3-4 ml in each cuvette. All
samples were then stored on ice in the dark ready for cell sorting.
2.3.5 Cell sorting of fluorescently labelled MSC
A MoFloTM XDP cell sorter was used for cell sorting. The cell sorter was configured
to the manufacturer’s exact specifications and calibrated extensively prior to use and
the machine allowed to reach a stable working temperature. Whilst many lasers are
available on this particular machine only the 488 nm and 647 nm lasers are used in this
protocol. Voltage, fanning, laser alignment and drop delay were all calibrated as per
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manufacturer specifications. The negative control was run through to ensure detection of
events without any significant detection by the lasers. Following this each single antibody
control/compensation tube was run starting with PE, then FITC then APC. Each of these
channels was compensated against the others in order to prevent significant colour bleed
between the fluorescent antibodies. Once compensation was complete gating was carried
out. Gating on PI allowed for the live cells to be selected. Negative gates for PE and
Ter119 were created and positive gates for PDGFRα and Sca-1 in order to select the PαS
cells. Finally a gate was drawn in order to select the central population of PαS cells based
on previous optimisations and experience from the literature. The positively selected cells
PαS were collected in a small collecting tube containing α-MEM media with added PSG
and 10% FBS/FCS. The mixture was then transferred into a FACS cuvette following
completion of the sort and spun in a centrifuge at 2000 rpm for 5 minutes. The resulting
pellet was resuspended and the appropriate amount of culture medium added for seeding
onto 6 well plates (Corning, US).
2.4 PαS MSC culture
Following cell sorting isolated purified PαS MSC were cultured in α-MEM. Media was
changed every 3 days and cells were assessed under light microscopy daily. Cells were
cultured in a humidified incubator at 37°C in 5% carbon dioxide. When cells reached 90%
confluency they were passaged and separated into larger containers. A minimum seeding
density of 5x103 cells per cm2 was used.
2.5 PαS MSC passage
Cell passage was performed when signs of confluence were detected. All media was removed
and the cells were washed 3 times with PBS whilst still adherent to the container or plate
they were housed in. A combination of trypsin and EDTA (TrypLE Express; Gibco®,
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UK) was added to the container and left covered in an incubator at 37°C for 3 minutes.
Loss of adherence was encouraged by gentle tapping and confirmed by microscopy. The
trypsin mixture was neutralised by the addition of an equal volume of α-MEM. The cell
suspension was transferred by pipette into either a 15 ml or 50 ml FalconTM Conical
Centrifuge tube depending on the volume of suspension being separated. Cells were
spun by centrifuge at 2000 rpm for 5 minutes. The supernatant was discarded and the
cells were then resuspended by vigorous tapping of the conical tube until a homogeneous
cell suspension remained. An appropriate volume of medium was then added and the
suspension agitated to achieve a homogeneous mixture. The cells were then seeded onto
larger plates to allow for continued growth.
2.6 In vitro naive lymphocyte immunosuppression as-
say
The in vitro immunosuppression assay used isolated naive CD4+ cells stimulated with
CD3e with co-stimulation provided by CD19+ B lymphocytes. Graded numbers of PαS
MSC isolated from C57BL/6 mice were added and cultured for 72 hours. Analysis was by
flow cytometry.
2.6.1 Isolation of CD4+CD25- T lymphocytes using MACS Mi-
croBeads
Isolation of CD4+CD25- T cells was undertaken using a CD4+CD25- T cell isolation kit
(Miltenyi Biotec, DE). Lymph nodes were removed from 8-12 week old C57BL/6 mice
following cervical dislocation. Lymph nodes were immediately placed into P2 buffer and
stored on ice. Lymph nodes were dissociated by passing through a 70 μm filter into 1 ml
of P2 buffer. and an aliquot taking for counting. Cells were washed in excess P2 buffer
and centrifuged at 1400 rpm for 7 minutes in a refrigerated centrifuge at 40C. The cell
pellet was resuspended in 40 μl of P2 buffer per 107 total cells. 10 μl of Biotin-Antibody
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Cocktail per 107 cells was added and the sample incubated for 5 minutes at 40C. Following
incubation 20 μl of P2 buffer, 20 μl of Anti-Biotin MicroBeads and 10 μl of CD25-PE
MicroBeads per 107 cells were added and the sample mixed well and incubated for 10
minutes at 40C. The samples were then quenched in excess P2 buffer and centrifuged at
1400 rpm for 7 minutes in a refrigerated centrifuge at 40C. Cell pellets were resuspended
in 500 μl of MACS buffer.
The first pass magnetic separation was then carried out using LD columns (Miltenyi
Biotec, DE). Columns were placed onto a stand containing a magnetic field and washed
with 2 ml of MACS buffer. 500 μl of the cell suspension was then placed onto the column
followed by 2 1 ml washes with MACS buffer and the flow through collected. The flow
through was washed in excess P2 buffer and centrifuged at 1400 rpm for 7 minutes in a
refrigerated centrifuge at 40C. The cell pellet was resuspended in 90 μl MACS buffer and
10 μl of anti-PE MicroBeads per 107 cells was added and the sample incubated at 40C for
15 minutes. Following incubation the sample was quenched with excess MACS buffer and
centrifuged at 1400 rpm for 7 minutes in a refrigerated centrifuge at 40C. The cell pellet
was resuspended in 500 μl of MACS buffer.
The second pass magnetic separation was carried out using MS columns (Miltenyi
Biotec, DE). Columns were placed onto a stand containing a magnetic field and washed
with 500 μl of MACS buffer. 500 μl of cell suspension followed by three 500 μl washes of
MACS buffered were passed over the columns and the flow through collected containing the
CD4+Cd25- naive T lymphocytes. Cells were washed in MACS buffer and centrifuged at
1400 rpm for 7 minutes in a refrigerated centrifuge at 40C. The cell pellet was resuspended
in C10 media and the resulting suspension kept on ice until required.
2.6.2 Isolation of CD19+ B lyphocytes using MACS MicroBeads
Isolation of CD19+ B lymphocytes was undertaken using MACS MicroBeads (Miltenyi
Biotec, DE). Spleens were removed from 8-12 week old C57BL/6 mice following cervical
dislocation. Spleens were immediately placed into P2 buffer and stored on ice. Spleens
53
were dissociated by passing through a 70 μm filter into red cell lysis buffer (Sigma-Aldrich,
UK). Cell filtrate was pipetted up and down to ensure adequate mixing with lysis buffer
and then quenched in excess P2 buffer. Samples were centrifuged at 1400 rpm for 7 minutes
in a refrigerated centrifuge at 40C.
An aliquot was removed for counting and then the cell pellet was resuspended in P2
buffer at a concentration of 90 μl buffer per 107 cells. 10 μl of CD19 MicroBeads were
added per 107 total cells and mixed well. Samples were incubated for 15 minutes at 40C.
Cells were washed in 2 ml of P2 buffer per 107 cells and centrifuged at 1400 rpm for 7
minutes in a refrigerated centrifuge at 40C. The cell pellet was resuspended in 500 μl of
P2 buffer.
Magnetic separation was then carried out using LS columns (Miltenyi Biotec, DE).
Columns were placed onto a stand containing a magnetic field and washed with 3 ml of
P2 buffer. 500 μl of the cell suspension was then placed onto the column. The column
wash then washed three times each with 3 ml of P2 buffer to wash out the unlabelled cells.
The column was then removed from the magnetic field and placed onto a collecting tube.
5 ml of P2 buffer was flushed through the column with a plunger to wash out the labelled
cells. The cell suspension was then washed in excess P2 and centrifuged at 1400 rpm for 7
minutes in a refrigerated centrifuge at 40C. Cells were then resuspended in C10 media and
stored on ice until required.
2.6.3 Proliferation and flow cytometric analysis
Isolated CD4+Cd25- naive T lymphocytes were cultured in 96 well round bottomed plates
(Starstedt, DE) at a seeding density of 2.5x104 cells per well. CD19+ B lymphocytes
selected by magnetic columns were added at a ratio of 2:1 (5x104 B cells). T lymphocytes
were stimulated by the addition of 0.8 μg/ml anti-CD3e antibody (BD Bioscience, US).
Culture was carried out in C10 medium. PαS MSC were added to some of the wells in
varying ratios and culture carried out for 72 hours in a standard humidified incubator at
370C with 5% CO2.
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Following incubation samples in each group were created by merging 3 wells. Media
from each well was pipetted up and down to wash off the non-adherent cells and collected
in FACS tubes leaving behind the MSC which are plastic adherent. Non-adherent cells
were washed in FACS buffer and centrifuged at 2000 rpm for 5 minutes. The cell pellet
was resuspended in 100 μl of FACS buffer for staining. Fluorescent antibodies to CD4
(PerCP, BD Bioscience) and CD19 (APC, BD Bioscience) were added to the samples
and appropriate controls and incubated for 30 minutes in the dark at 40C. Following
incubation excess FACS buffer was added and centrifuged at 2000 rpm for 5 minutes in a
refrigerated centrifuge at 40C. Cell pellets were resuspended in 400 μl of FACS buffer and
Flow Cytometry was undertaken on a Cyan ADP (Beckman Coulter, US).
2.7 In vitro splenoocyte reaction
Due to difficulties found when using a naive lymphocyte reaction I developed a splenocyte
reaction in order to allow for MSC to use intermediary cells in order to exert their effects.
By utilising immune cells extracted from the spleens of transgenic OT-1 mice [234] I was
able to use OVA peptide to stimulate T cell proliferation.
2.7.1 Isolation of bulk splenocytes
Spleens were removed from male OT-1 transgenic mice aged 8-10 weeks. On average one
spleen would yield 7-9x107 splenocytes, requiring 1-2 OT-1 mice per experiment. Spleens
were placed in C10 medium at 4°C. Spleens were pushed through a 70 μm with a syringe
plunger into a 6 well plate containing 1 ml of red cell lysis buffer (Sigma-Aldrich, UK).
The resulting mixture was pipetted up and down in order to encourage mixing and then
transferred to a 15 ml FalconTM conical tube and filled up to 15 ml with C10 media,
inverting gently to encourage mixing. The cell suspension was centrifuged at 1400 rpm in
a refrigerated centrifuge at 4°C for 7 minutes. The resulting cell pellet was resuspended in
5 ml of C10 media. The resulting cell suspension was filter through a 50 μm filter and
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cells counted using a haemocytometer. An aliquot of 2-3 million cells were removed to
be used as unstained and single colour controls. The cell suspension was centrifuged at
1400 rpm for 7 minutes at 4°C. The resulting cell pellet was resuspended in PBS at a
concentration of 1x106 cells per ml. Staining for proliferation analysis was undertaken
using a CellTraceTM Violet Proliferation Kit (Molecular Probes, US). CellTraceTM Violet
was reconstituted as per the kit instructions and in Dimethylsulfoxide (DMSO) and added
to the sample at a concentration of 1 μM per ml. The cell suspension was covered in foil
and incubated in the dark at 37°C on a rocking incubator with an oscillatory frequency of
50 rpm for 30 minutes. Following incubation 5x the staining volume of C10 media was
added to the suspension and a further 5 minutes of incubation undertaken. The suspension
was then centrifuged at 1400 rpm at 4°C for 7 minutes. The resultant cell pellet was
resuspended in C10 media.
2.7.2 Stimulation of CD8+ lymphocytes with OVA257-264 peptide
Bulk splenocytes were cultured in 96 well round bottomed plates (Starstedt, DE). Either
1x105 or 2x105 bulk splenocytes were cultured in a total working volume of 200 μl per
well. In order to stimulate cell proliferation OVA257-264 peptide (AnaSpec, US) was added.
Different doses were tested based on the broad ranges found in the literature [235]. Low
and high doses of OVA257-264 peptide were used (2 μg/ml and 10 μg/ml) and supplemental
Il-2 was added at a concentration of 50 units/ml. Cells were cultured in a humidified
incubator at 37°C in 5% carbon dioxide. After 24 hours in culture variable numbers of
PαS MSC were added to the stimulated lymphocytes and then cultured for a further 72
hours. Cells were then stained and analysed by flow cytometry.
2.7.3 Flow cytometric analysis
After 96 hours in culture cells were stained for surface antigens and analysed by flow
cytometry. Wells were pooled to enable more accurate analysis so that 3 wells represent
56
one data point. Wells were pipetted up and down to free the non-adherent lymphocytes
leaving PαS MSC attached to the plate and then placed into FACS tubes. Cells were
washed in PBS and centrifuged at 1400 rpm in a refrigerated centrifuge at 4°C for 7
minutes. The resultant cell pellet was resuspended in 500 μl of PBS and viability staining
was undertaken using a live/dead marker. Cells were incubated at 4°C for 30 mins in the
dark. The reaction was quenched with the addition of 2 ml of FACS buffer per tube and
then two washing steps performed with FACS buffer. Cells were centrifuged at 2000 rpm
at 4°C for 5 minutes. Following washing the resultant cell pellet was resuspended in 100
μl of FACS buffer and surface staining undertaken. Antibodies were added and tubes
were incubated at 4°C for 30 minutes in the dark. The reaction was quenched with the
addition of 2 ml of FACS buffer per tube and then a washing step performed with FACS
buffer. Cells were centrifuged at 2000 rpm at 4°C for 5 minutes. Following washing the
resultant cell pellet was resuspended in 400 μl of FACS buffer and samples were filtered
through a 50 μm filter and analysed using a Cyan ADP flow cytometer. Compensation
beads (BD Biosciences, US) were run at the same time as the samples and compensation
and analysis was performed offline using FlowJo version X.0.7 (TreeStar, US). A complete
list of antibodies and dilutions is provided in table 2.4.
2.8 MDR2-/- knockout model of liver injury
The MDR2-/- Mouse model is a model characterised by Fickert et al [96] to demonstrate
sclerosing cholangitis. With targeted disruption of the multi-drug resistance gene 2 (Abcb4),
an absence of biliary phospholipids is seen leading to the leaking of bile acids and cytotoxic
injury to the biliary tree. The MDR2-/- mouse colony was maintained as homozygotes
on an FVB background. Genotyping to confirm breeding pair genotypes was carried out
by TransnetYX® as previously described. All animals were cared for in the
using standard care protocols as previously described.
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2.8.1 Treatment of MDR2-/- mice with PαS MSC
Male MDR2-/- mice aged 6-8 weeks old were injected with either PBS or PαS MSC at
passage 4. To prepare PαS MSC flasks were washed with sterile PBS and then incubated
with enough TrypLE Express (Gibco®, UK) to cover the bottom of the flask until cells
were no longer adherent (approximately 5 minutes). The reaction was quenched with the
same volume of α-MEM and then cells transferred to a FalconTM tube and centrifuged at
2000 rpm for 5 minutes. The resultant cell pellet was resuspended in PBS and following
counting and dilution aliquoted into Eppendorf’s and kept on ice. Either 1x105 or 2x105
PαS MSC were used and diluted into a volume of 100 µl for intravenous injection and 200
µl of subcutaneous injection. Prior to injection PαS MSC were pipetted up and down in
order to reduce clumping of cells. A 29 gauge insulin needle (Terumo, US) was used for IV
injections and a 25 gauge needle (Terumo, US) was used for Subcutaneous (SC) injections.
Animals had free access to food and water and were monitored for 2 weeks for any signs
of distress. On day 14 all animals were sacrificed and analysed as described below.
2.9 Murine model of hepatic ischaemia reperfusion in-
jury
In order to model the initial warm ischaemic injury seen in DCD liver transplantation I
developed a surgical model of hepatic ischaemia reperfusion injury based on previously
published literature and experience in our facility with this type of mouse model.
2.9.1 Surgical technique
The surgical model used male C57BL/6 mice aged between 8 and 10 weeks. Mice were
weighed and given a single dose of buprenorphine (Temgesic) 1 hour prior to surgery
in order to provide post operative analgesia. Timing of analgesia was important as
adequate analgesia needed to be onboard due to the extent of the surgery to ensure a
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quick recovery after surgery, however giving analgesia too close to induction of analgesia
led to unpredictable anaesthesia and a risk of intraoperative apnoea. Mice were then
placed into a warmer at 37°C as pre-operative temperature optimisation led to more stable
intraoperative temperature. Mice were anaesthetised with isoflurane anaesthesia with
pure oxygen as a carrier gas. An initial concentration of 5% was used for induction and
maintenance achieved with a concentration between 0.5% and 1.5% titrated to loss of
pedal reflex. After shaving and sanitising with chlorhexidine a 1.5-2cm incision was made
inferior to the epigastrium. Following insertion of a retractor the bowel was deflected
distally with the use of wet cotton wool buds. A 1-2 mm atraumatic micro-arterial clamp
(Harvard Apparatus, US) capable of an occlusion pressure of 15-29g was applied to the
portal vein and hepatic artery proximal to the inferior lobes allowing for the occlusion
of 70% of the hepatic blood flow. Occlusion was confirmed by observing lobar colour
change. A moist piece of gauze was placed over the abdominal incision to reduce fluid loss
and an infra red heating lamp used to maintain core temperature at 36.5-37°C. A rectal
thermometer was used for continuous core temperature monitoring. Five minutes prior
to clamp removal 500 µl of warm 0.9% saline was administered into the peritoneal cavity.
After 30-60 minutes of warm ischaemia the clamp was removed and a two layer closure
performed with surgical sutures for the deep layer and staples for the superficial layer.
Mice were recovered and given free access to food and water. Following surgery mice were
individually housed in a warmed recovery area at 25°C. Mice were given a second dose
of buprenorphine at 4 hours following surgery or sooner if required. No further doses of
analgesia were required after this. Reperfusion was allowed for up to 24 hours and mice
culled as described below. Regular monitoring for signs of distress was undertaken.
2.10 Collection of murine blood and tissue
At the appropriate predetermined time point for the completion of the experiment animals
underwent general anaesthesia with isoflurane. Induction of anaesthesia was undertaken
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with 4% isoflurane using pure oxygen as a carrier gas. Maintenance of anaesthesia was
carried out with 2% isoflurane with oxygen. Confirmation of anaesthesia was carried out
by pedal reflex testing. Cardiac puncture was undertaken with a 25 gauge needle under
terminal anaesthesia. Blood samples were placed in a 1.5 ml Eppendorf and left to stand
at room temperature for 2 hours to allow clot formation. Samples were then spun twice at
15,000 rpm in a micro-centrifuge for 10 minutes. Serum was taken and sent for analysis at
the Birmingham Women’s Hospital Laboratory. Excess serum was stored at -80°C.
2.11 Analysis of serum liver enzymes
Mouse serum was extracted and analysis for Alanine Transaminase (ALT), Alkaline
Phosphatase (ALP) and bile acids carried out. Analysis was performed by the biochemistry
department at the Birmingham Women’s Hospital Laboratory. Analysis was performed
using a clinical grade automated analyser.
2.12 Western blotting
Western blotting was carried out to quantify levels of Cytokeratin 19 (CK19), a marker of
biliary injury/proliferation. Protein lysates were made as described below and diluted and
then western blotting carried out as described below.
2.12.1 Liver tissue lysis
At the end of the 2 week MDR2-/- experiment small pieces of the caudate and right lateral
lobes were flash frozen in liquid nitrogen for later use. A small piece of frozen liver was
weighed and trimmed to a target weight of 70-90mg and then placed into a gentleMACS
M-tubes (Miltenyi Biotec, DE). A lysis buffer containing CelLyticTM MT lysis reagent
(Sigma-Aldrich, UK), 1% v/v phosphatase inhibitor cocktail 3 (Sigma-Aldrich, UK), 1%
v/v protease inhibitor cocktail (Sigma-Aldrich, UK) and 5U/ml DNase 1 (Sigma-Aldrich,
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UK) was added in the amount of 20 µl per mg of liver tissue. The samples were kept on
ice at all times. Following addition of the lysis buffer the tissue was homogenised on a
gentleMACS (Miltenyi Biotec, DE) using the programme Protein.01. Tubes were then
spun on a centrifuge at 1000g for 2 minutes. Following centrifugation tissue samples were
placed into eppendorfs and left on a vibrating platform, on ice for 1 hour. Eppendorfs
were then spun in a micro-centrifuge at 15000 rpm for 10 minutes. The supernatant was
then transferred into a clean eppendorf and protein concentration determined using the
biuret assay.
2.12.2 Determination of protein concentration using the biuret
assay
A working solution was prepared combining 50 parts Bicinchoninic Acid (BCA) solution
(Sigma-Aldrich, UK) to 1 part Copper (II) Sulphate pentahydrate 4% (Sigma-Aldrich,
UK). 200 µl of working solution was added to 25 µl of protein solution and then placed
in the corresponding well on a 96 well flat bottomed plate. A protein standard of know
concentration (Sigma-Aldrich, UK) was used for comparison. The plate was placed briefly
on a plate shaker for 5 minutes and then incubated at 37°C for 30 minutes. The plate was
immediately read on a plate reader (Synergy HT; BioTek, UK) at 562nm. The protein
concentration curve was calculated and the protein concentration determined for each
of the samples. Samples were then diluted with CelLyticTM MT buffer to a working
concentration of 1 µg per µl.
2.12.3 Western blotting for CK19
Gel tanks for western blotting (Bio-Rad, UK) were assembled as per manufactures instruc-
tions. A 1.5mm 12% resolving gel was formed using a mixture of 30% Degassed Acrylamide
(ProtoGel; National Diagnostics, US), Resolving gel buffer (National Diagnostics, US), 10%
w/v Sodium Dodecyl Sulphate (SDS) (Sigma-Aldrich, UK), and double deionised water.
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The gel was set by the addition of a 10% Ammonium Persulphate (APS) (Sigma-Aldrich,
UK) and N,N,N’,N’-Tetramethylethylenediamine (TEMED) (Sigma-Aldrich, UK). Once
set a 4% stacking gel (National Diagnostics, US) was added on top using a stacking buffer
(National Diagnostics, US) and made in the same way as the resolving buffer with 30%
Degassed Acrylamide, 10% w/v APS, and double deionised water. The gel was again
set with TEMED and APS with the addition of a comb in order to form suitable wells.
Once set the comb was removed and the gel transferred to a gel electrophoresis tank
(Bio-Rad, UK) and assembled as per the manufacturer’s instructions. A running buffer
(National Diagnostics, US) was added to the tank fill line. 20 µl of protein sample was
added to 5 µl of loading buffer (Promega, UK) and incubated at 100°C for 2 minutes.
Samples were then loaded into individual wells in the gel and a molecular weight marker
(Amersham™ ECL™ Rainbow™ Marker; Sigma-Aldrich, UK) used as a reference. Samples
were run at 200 volts for 30 minutes. The gel was then removed and carefully placed onto
a nitrocellulose membrane and assembled between filter paper and scotch pads into the
transfer apparatus. The transfer apparatus was placed into a clean tank with transfer
buffer (National Diagnostics, US) and an ice block with a magnetic stirrer and run at 100
volts for 1 hour. Following this transfer was confirmed by the addition of Ponceau red
solution (Sigma-Aldrich, UK) to the membrane.
Blocking of non-specific binding was achieved by incubating the membrane in 20ml of
a 5% milk solution (Premiere International Foods, UK) diluted in PBS containing 0.02%
TWEEN 20 (Sigma-Aldrich, UK) for 1 hour at room temperature. Primary antibody
for CK-19 (Cell Signalling Technologies, US) was added to 10 ml of Milk/PBS/TWEEN
solution and incubated overnight at 4°C. Three 5 minute washing steps were then performed
using PBS with 0.02% TWEEN 20. A secondary Horseradish Peroxidase conjugated
antibody (Cell Signalling Technologies, US) was then added at varying concentrations
to 10ml of the Milk/PBS/TWEEN solution and incubated at room temperature for 1
hour. Following this two 5 minute and one 30 minute wash steps were performed. The
membrane was then developed using Pierce ECL 2 developer solution (Thermo Fisher
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Scientific, US) as per the manufacturer instructions. Immediately following development
the membrane was imaged using X-Ray imaging and then scanned as an image file for
further analysis. Analysis was undertaken using Image StudioTM Lite software package
(LI-COR Biotechnology, US).
2.12.3.1 Loading controls
In order to generate protein loading controls membranes were stripped and re-probed.
Immediately following X-Ray imaging two 5 minute and one 30 minute wash steps were
performed. Following washing membranes were soaked in RestoreTM Western Blot Stripping
Buffer (Thermo Fisher Scientific, US) for 15 minutes. Stripping buffer was removed and
two 5 minute and one 30 minute wash steps were performed. The blotting process described
above was repeated beginning with blocking of non-specific binding. Primary antibody
against α-actinin (Cell Signalling Technologies, US) was used and incubation carried out
for 1 hour. Secondary antibody use and developing proceeded as previously described.
2.13 Liver immune cell isolation
Routine protocols in our laboratory to isolate murine lymphocytes involved density gradient
centrifugation using Lympholyte® (Cedarlane, US) which has demonstrated good results
in the OVA-Bil and CCL4 mouse models of liver injury. Unfortunately when using this
technique with MDR2-/- mice the number of lymphocytes isolated was very low. This
warranted a change of technique and the use of OptiprepTM (Sigma-Aldrich, UK) as well
as a reduction in the number of spin steps. Both techniques are described below. First a
cell suspension was generated as described prior to either the Lympholyte® or OptiprepTM
technique.
Following sacrifice, 10 ml of sterile 0.9% sodium chloride was injected through the
portal vein in order to wash out any remaining blood within the liver tissue. The liver
was then removed and two thirds of the median lobe was removed and weighed. The liver
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segment was then placed into a bijou containing RPMI media and placed on ice. Liver
segments were transferred into gentleMACS C-tubes (Miltenyi Biotec, DE) with 3 ml of
RPMI and then dissociated using the “Mouse spleen 1.01” programme. Samples were then
passed through a 70 µm sieve and collected in a 50 ml conical centrifuge tube.
2.13.1 Isolation of liver immune cells using Lympholyte®
Following collection in a 50 ml centrifuge tube the contents were made up to 50 ml
with RPMI and then a slow ’hepatocyte’ spin was undertaken to remove hepatocytes.
Samples were centrifuged at 54g for 5 minutes with the brake set to 3 for a slow stop.
The supernatant was collected in a new 50 ml conical centrifuge tube and made up to a
volume of 50 ml with RPMI. Samples were then centrifuged at 2000 rpm for 5 minutes and
the resultant cell pellet resuspended in 50 ml of RPMI. A further wash was undertaken
at the same centrifuge settings in order to remove fatty cells. The resultant cell pellet
was resuspended in 7 ml of RPMI and filtered through a 50 µm filter. A fresh 15 ml
conical centrifuge tube was placed on a rack in a dark tissue culture cabinet and 5 ml of
Lympholyte® was added ensuring the Lympholyte® was at room temperature prior to use.
The 7 ml of sample was carefully layered on top of the Lympholyte®. The samples were
then centrifuged at 2000 rpm for 30 minutes with a brake of 0. Following centrifugation
two thirds of the media at the interphase was removed and placed into a fresh 15 ml conical
centrifuge tube. The volume of the sample was made up to 15 ml with RPMI and the
sample centrifuged at 2000 rpm for 5 minutes. The resultant cell pellet was resuspended
in 500 µl of PBS and placed on ice ready for staining.
2.13.2 Isolation of liver immune cells using OptiprepTM
Following collection in a 50 ml centrifuge tube the contents were made up to 30 ml with
RPMI. The filtrate was transferred into two 15 ml conical centrifuge tubes and spun
in a centrifuge at 2000 rpm for 5 minutes. The supernatant was then discarded and
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the resultant pellet resuspended in 10 ml of RPMI. For each sample two 15 ml conical
centrifuge tubes were prepared containing 7 ml of OptiprepTM at a concentration of 1.09
g/ml at room temperature. A 5 ml layer of cell suspension was then carefully layered on
top and the tubes spun at 1000g for 25 minutes with no brake. This allowed the formation
of an immune cell layer at the interface. Following centrifugation two thirds of the media
at the interphase was removed and placed into a fresh 15 ml conical centrifuge tube. The
volume of the sample was made up to 15 ml with RPMI and the sample centrifuged at
2000 rpm for 5 minutes. The resultant cell pellet was resuspended in 500 µl of PBS and
placed on ice ready for staining.
2.13.3 Isolation of immune cells from whole blood
Animals underwent general anaesthesia with isoflurane. Induction of anaesthesia was
undertaken with 4% isoflurane using pure oxygen as a carrier gas. Maintenance of
anaesthesia was carried out with 2% isoflurane with oxygen. Confirmation of anaesthesia
was carried out by pedal reflex testing. Cardiac puncture was undertaken with a 25 gauge
needle under terminal anaesthesia. Blood samples were placed in a clinical grade collecting
tube containing EDTA. Red cell lysis was undertaken by adding 500 µl of red cell lysis
buffer (Sigma-Aldrich, UK) to 500 µl of whole blood in a 1.5 ml Eppendorf and left to
stand at room temperature for 5 minutes. Samples were then spun at 15,000 rpm in a
micro-centrifuge for 10 minutes. This process was repeated and the resultant cell pellet
was resuspended in PBS.
2.13.4 Viability and surface antibody staining of isolated circu-
lating or liver immune cells for flow cytometry
Throughout the staining process samples were kept on ice when possible and the procedure
carried out in a cell culture cabinet with the light turned off. Live/dead staining was carried
out using an intracellular live/dead marker for 30 minutes at 4°C. Following incubation
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excess MACS buffer containing FBS/FCS was added at 5x the staining volume and
samples centrifuged at 2000 rpm for 5 minutes. The resultant cell pellet was resuspended
in 100 µl of MACS buffer for cell surface staining. Fluorescent antibodies against multiple
cell surface antigens were used including CD3, CD4 and CD8 were used. A complete list
of antibodies and dilutions used is included in table 2.4. Isotype control samples were also
used by pooling aliquots of all samples in an experiment. Samples were incubated for 30
minutes at 4°C. Following incubation 5x the staining volume of MACS buffer was added
and samples centrifuged at 2000 rpm for 5 minutes. The resultant pellet was resuspended
in 400 µl of MACS buffer and filtered using a 50 µm filter prior to flow cytometric analysis
on a Cyan ADP analyser. Analysis of flow cytometric data was carried out using FlowJo
vX.0.7 software.
2.13.5 Intracellular staining for FoxP3
In a subset of experiments intracellular staining was undertaken to examine regulatory
T-Cells. Following cell surface staining fixation and permeabilization was undertaken.
Fixation and permeabilization working solution was prepared by adding 1 part of Fixa-
tion/Permeabilization Concentrate (ebioscience, UK) to 3 parts of Fixation/Permeabilization
Diluent (ebioscience, UK). Samples were prepared in FACS tubes and following centri-
fugation pellets were resuspended in 100 µl of workings solution and incubated in the
dark for 30 minutes at 4°C. Following incubation 1 ml of permeabilization buffer, made
from diluting Permeabilization Buffer 10X (ebioscience, UK) with deionised water, was
added and the samples centrifuged at 2000 rpm for 5 minutes. The resulting pellet was
resuspended in 100 µl of dilute permeabilization buffer containing intracellular antibodies
and incubated for 30 minutes in the dark at 4°C. The reaction was quenched with dilute
permeabilization buffer and centrifuged at 2000 rpm for 5 minutes. The resulting cell
pellet was resuspended in 400 µl of MACS buffer ready for flow cytometric analysis.
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2.14 MSC surface markers
Following prospective isolation using cell sorting and culture in α-MEM as previously de-
scribed PαS MSC were removed from their culture environment by the addition of TrypLE
as described for cell passaging. Following quenching of the reaction and centrifugation at
2000 rpm for 5 minutes cells were washed in PBS with a further centrifugation step. Cells
were then resuspended in 500 µl of PBS and placed on ice ready for staining.
Throughout the staining process samples were kept on ice when possible and the
procedure carried out in a cell culture cabinet with the light turned off. Live/dead staining
was carried out using an intracellular live/dead marker for 30 minutes at 4°C. Following
incubation excess MACS buffer containing FBS/FCS was added at 5x the staining
volume and samples centrifuged at 2000 rpm for 5 minutes. The resultant cell pellet was
resuspended in 100 µl of MACS buffer for cell surface staining. Fluorescent antibodies
against multiple cell surface antigens were used. A complete list of antibodies and dilutions
used is included in table 2.4. Isotype control samples were also used by pooling aliquots of
all samples in an experiment. Samples were incubated for 30 minutes at 4°C. Following
incubation 5x the staining volume of MACS buffer was added and samples centrifuged at
2000 rpm for 5 minutes. The resultant pellet was resuspended in 400 µl of MACS buffer
and filtered using a 50 µm filter prior to flow cytometric analysis on a Cyan ADP analyser.
Analysis of flow cytometric data was carried out using FlowJo vX.0.7 software.
2.15 Protein array
Protein profiling was undertaken on cell supernatant using a Proteome ProfilerTM (R&D
Systems, US). PαS MSC cultured to passage 5 and some flasks stimulated with 20 ng/ml
of murine IFN-γ (PeproTech, UK) and 20 ng/ml murine TNFα (PeproTech, UK). After
24 hours supernatant was collected and centrifuged at 2000 rpm for 5 minutes to remove
any debris. Protein profiling was carried out on 1 ml of each sample using a Proteome
ProfilerTM following the manufacturers instructions. Blots were processed using X Ray
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imaging and images were scanned and analysed with ImageJ. Pixel density was recorded
and background intensity subtracted from negative control spots. Mean pixel density was
calculated between replicates.
2.16 QDot605 experiments
In order to examine the bio-distribution of systemically administered PαS MSC I decided
to use the novel CryoVizTM system. As such intracellular labelling of PαS MSC was
required.
2.16.1 Labelling PαS MSC with QDot605
PαS MSC were cultured as previously described. Cells were removed from flasks by
incubation with TrypLE Express and washed. Labelling was carried out using QtrackerTM
605 Cell Labelling Kit (Thermo Fisher Scientific, US). Labelling solution was prepared
as per the manufacturers instructions. For every 1x106 PαS MSC 1.5 ml of labelling
solution and 0.2 ml of standard medium were combined. Cells were incubated at 37°C for
60 minutes in a standard culture incubator in the dark. Following incubation cells were
washed twice with standard medium at 2000 rpm. Cells were either resuspended in PBS
for staining and FACS or injection in to mice or were resuspended in standard medium
and placed in flasks for further culture. In a subset of experiments Live/dead staining was
performed prior to cell labelling as previously described.
2.16.2 Cryoimaging
Cryoimaging was undertaken on whole mice and individual organs. Organs were carefully
removed from sacrificed mice and injected ex vivo with QDot605 labelled PαS MSC. Organs
were then placed in foil baths and immersed in optimal cutting temperature compound
(OCT; Sakura FineTek, US). Organs were then frozen on dry ice and stored at -80°C prior
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to shipping to BioInVision (BioInVision, US) for analysis. MDR2-/- mice were injected
with QDot605 labelled PαS MSC and culled at different time points using a CO2 chamber.
Following confirmation of death whole mice were placed in foil baths and completely
submerged in OCT. Mice were then frozen on dry ice and stored at -80°C prior to shipping
to BioInVision. Samples were sectioned and imaged on the CryoVizTM instrument and
quantification and image generation undertaken by the technical staff at BioInVision.
2.17 Immunohistochemistry
Following confirmation of death the whole liver was divided and dissected. The distal one
third of the median lobe was placed in formalin solution for fixation and half of the left
lateral lobe snap frozen with liquid nitrogen.
2.17.1 Processing of paraffin samples
Formalin fixed samples were embedded in paraffin in accordance with local protocols.
Tissue blocks were then sectioned into 5 µm sections and fixed onto glass microscope
slides (X-tra adhesive; Leica, UK). De-waxing and rehydration for staining was achieved
by passing through three sequential Xylene (PFM medical, UK) baths for 2 minutes each,
followed by two Industrial Methylated Spirits (IMS) (PFM medical, UK) baths for 2
minutes each and finally one water bath for 2 minutes. Dehydration of slides following
staining was achieved by reversing the rehydration steps described earlier. Mounting of
cover slips was carried out using DPX (Leica, UK) and left to dry before imaging by
conventional light microscopy.
2.17.2 Processing of frozen samples
Snap frozen tissue was embedded in Optimal Cutting Temperature (OCT). Frozen blocks
were cut into 7 µm sections and mounted on coated glass slides (Thermo Fisher Scientific,
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US). Following mounting sections were fixed by submersion in acetone for 10 minutes.
Excess acetone was then removed by washing in Tris Buffered Saline (TBS) containing
0.05% TWEEN® 20 for two 5 minute washes. Slides were kept wrapped in foil at -20°C
until required.
2.17.3 Haematoxylin and eosin staining
Haematoxylin and Eosin (H & E) staining of paraffin sections was carried out on all
samples using local staining protocols. De-waxing and rehydration was carried out first as
previously described and immediately following on slides were moved sequentially though
baths of reagents as follows: Harris Haematoxylin (Leica, UK) for 4 minutes; water for 2
minutes; Acid Alcohol (Leica, UK) for 30 seconds; water for 2 minutes; Scott’s Tap Water
Substitute (Leica, UK) for 30 seconds; Eosin (Leica, UK) for 1 minute; and 2 water baths
for 2 minutes each. Dehydration and mounting was undertaken as previously described.
2.17.4 Periodic acid-Schiff staining
De-waxing and rehydration was carried out first as previously described. Wax rings were
drawn around slides and the staining steps carried out in a humidified container. Periodic
Acid Solution (Sigma-Aldrich, UK) was added at room temperature and the container
covered and placed on a rocker for 5 minutes. Slides were rinsed in a distilled water
bath for three 5 minute washes with changes of water between each wash. Slides were
then placed back into a humidified container and wax rings redrawn if required. Schiff’s
Reagent was added and the container covered and placed on a rocker for 15 minutes at
room temperature. Slides were rinsed in a tap water bath for three 5 minute washes
with changes of water between each wash. Slides were then placed back into a humidified
container and wax rings redrawn if required. Counter staining was undertaken with
Mayer’s Haematoxylin (Leica, UK) for 90 seconds. Slides were rinsed in a tap water bath
for two 5 minute washes one with warm water and one with cold water. Dehydration and
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mounting was undertaken as previously described.
2.17.5 Chromogenic immunohistochemistry
De-waxing and rehydration was carried out first as previously described. Wax rings were
drawn around slides and the staining steps carried out in a humidified container. Blocking
of endogenous peroxidases was carried out by adding 200 µl of Peroxidase-Blocking Solution
(Dako, DK) to each slide and the humidified container covered and placed on a rocker for
40 minutes. Slides were then washed in a water bath containing TBS with 0.1% TWEEN®
20 for three 5 minute washes with changes of wash fluid between each wash. Antigen
retrieval was then performed. Antigen unmasking solution (Vector Laboratories, US) was
diluted from 10x stock with TBS and a volume of 1 litre added to a plastic bucket. The
unmasking solution was then heated in a microwave on full power for 5 minutes. Slides
were transferred to a plastic holder and placed in the warm unmasking solution and the
buck loosely covered and heated on full power for 15 minutes. The slides were allowed to
passively cool for 10 minutes and then cool water slowly added until the solution reached
room temperature. Slides were then washed in a water bath containing TBS with 0.1%
TWEEN® 20 for three 5 minute washes with changes of wash fluid between each wash.
Wax rings were redrawn on the slides if required and the slides transferred into a humidified
container. Blocking of non-specific staining was carried out by adding 150 µl of 10x Casein
(Vector Laboratories, US) diluted to a 1x solution with TBS. The humidified container was
covered and placed on a rocker for 60 minutes. Following blocking 150 µl of the primary
antibody was added with out washing. Antibodies were diluted in TBS, a full list of
antibodies and dilutions is included in table 2.4. The humidified container was covered and
placed on a rocker for 60 minutes. Slides were then washed in a water bath containing TBS
with 0.1% TWEEN® 20 for three 5 minute washes with changes of wash fluid between
each wash. One drop of secondary antibody (Vector Laboratories, US) was added and
the humidified container was covered and placed on a rocker for 60 minutes. Slides were
then washed in a water bath containing TBS with 0.1% TWEEN® 20 for three 5 minute
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washes with changes of wash fluid between each wash. 3,3’-Diaminobenzidine (DAB)
substrate (AbD Serotec, UK) was prepared following the manufacturers instructions and
150 µl added to each slide. Incubation for up to 2.5 minutes was undertaken observing
for a colour change in the slides or the Isotype Matched Control (IMC). Slides were then
washed for 5 minutes in tap water. Counter staining was undertaken with filtered Mayer’s
Haematoxylin which was added to the slides for 30 seconds. Following counter staining
slides were washed for 2.5 minutes in cold tap water followed by a further wash for 2.5
minutes in warm tap water. Dehydration and mounting was undertaken as previously
described.
2.17.6 Structural fluoresence staining
Frozen slides were thawed on the bench for 15 minutes. Slides were then fixed in acetone
for 5 minutes. Wax rings were drawn around the slides and slides were then washed in
a water bath containing TBS with 0.1% TWEEN® 20 for three 5 minute washes with
changes of wash fluid between each wash. Cytoskeletal staining was undertaken by adding
Phalloidin (Thermo Fisher Scientific, US). Slides were place in a humidified container with
a lid and covered in foil. The container was then placed on a rocker for 20 minutes. Slides
were then washed in a water bath containing TBS with 0.1% TWEEN® 20 for three 5
minute washes with changes of wash fluid between each wash. Slides were then stained
with 4’,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, UK) at a concentration of
0.5μg/ml in water. Slides were place in a humidified container with a lid and covered in
foil. The container was then placed on a rocker for 2 minutes. Slides were then washed in
a water bath containing TBS with 0.1% TWEEN® 20 for three 5 minute washes with
changes of wash fluid between each wash. Mounting of cover slips was then performed
using fluorescence mounting medium (Dako, DK).
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2.17.7 Slide scanning and analysis
After mounting slides were left and adequate amount of time to dry. Slides were scanned
with a Zeiss Axio Scan Z.1 (Zeiss, DE) onto a PC running Carl Zeiss Microscopy Zen 2
software (Zeiss, DE). Whole slides were scanned using the 20x lens and images stitched
by the software. Representative images were taken from whole slide images using Carl
Zeiss Microscopy Zen 2 software. Multiple images were taken for analysis and converted
to portable network graphic format for analysis using GNU Image Manipulation Project
Software (GNU Image Manipulation Project Software, US). Quantification of staining was
undertaken using ImageJ Software (NIH, US).
2.18 Statistical analysis
Statistical analysis was carried out using Prism 6.0 (Graphpad Software). Normally
distributed data were analysed using an unpaired Student’s t-test when comparing two
groups. For multiple group comparison one-way analysis of variance (ANOVA) testing
was used. A p-value of ≤ 0.05 (* - p<0.05, ** - p<0.01, *** - p<0.001, **** - p<0.0001)




All mouse strains, consumables, reagents and antibodies used in this study are described
in the following tables.
Table 2.2 – Table of mouse strains used in this study.
Type Background Supplier Catalogue Number
C57BL/6 - Charles River Laboratories, UK 027
FVB - Charles River Laboratories, UK 207
BALB/c - The Jackson Laboratory, US 000651
OT-1 C57BL/6 The Jackson Laboratory, US 003831
MDR2-/- FVB N/A N/A
Table 2.3 – Table of software used in this study.
Name Version Supplier Location
FlowJo X.0.7 TreeStar US
Image StudioTM Lite 5.2 LI-COR Biotechnology US
ImageJ 1.51j NIH.gov US
Carl Zeiss Zen 2 software 2 Zeiss DE
GNU Image Manipulation Project 2.8.18 GIMP US
Summit 4.3 Beckman-Coulter US
LyX 2.2.2 LyX Team US
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Table 2.4 – Table of antibodies and dilution factors used in this study.
Antibody Fluorophore Concentration Use Supplier Location Catalogue
number
CD105 FITC 5 μg/ml FC eBioscience UK 12-1051
CD11b PE 1.25 μg/ml FC eBioscience UK 12-0112
CD11b FITC 0.025 μg/ml FC eBioscience UK 11-0112
CD11c PE 0.05 μg/ml FC eBioscience UK 12-0114
CD19 APC 1:100 FC BD Biosciences US 561738
CD19 PE 0.0125 μg/ml FC eBioscience UK 12-0193
CD25 PE 1.25 μg/ml FC eBioscience UK 12-0251
CD25 APC 1.25 μg/ml FC eBioscience UK 17-0251
CD29 PE 10 μg/ml FC eBioscience UK 12-0291
CD3 PE 5 μg/ml FC eBioscience UK 12-0031
CD3 APC 2.5 μg/ml FC eBioscience UK 17-0031
CD3 PE-Cy7 10 μg/ml FC eBioscience UK 25-0031
CD3 BV500 5 μl/test FC Biolegend UK 100233
CD34 FITC 10 μg/ml FC eBioscience UK 11-0341
CD3e V500 4 μg/ml FC BD Biosciences US 560771
CD4 BV450 5 μl/test FC Biolegend UK 100544
CD4 FITC 2.5 μg/ml FC eBioscience UK 11-0042
CD4 PerCP 1:100 FC BD Biosciences US 561090
CD4 V450 4 μg/ml FC BD Biosciences US 560468
CD41 APC 0.025 μg/ml FC eBioscience UK 17-0411
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CD44 FITC 5 μg/ml FC eBioscience UK 11-0441
CD45 PerCP-Cy5.5 0.0125 μg/ml FC eBioscience UK 45-0451
CD49e PE 5 μg/ml FC eBioscience UK 12-0493
CD62L APC 0.6 μg/ml FC eBioscience UK 17-0621
CD69 FITC 5 μg/ml FC eBioscience UK 11-0691
CD69 Pacific Blue 2.5 μg/ml FC Invitrogen UK HM4028
CD8a PE-Cy7 5 μg/ml FC eBioscience UK 25-0081
CD8a APC 1.25 μg/ml FC eBioscience UK 17-0081
CD8a APC-Cy7 1:100 FC BD Biosciences US 561967
CD8a FITC 0.05 μg/ml FC eBioscience UK 11-0081




450 nm 1 µm/ml FC Molecular Probes US C34557
F4/80 FITC 5 μg/ml FC eBioscience UK 11-4801
F4/80 APC 0.2 μg/ml FC eBioscience UK 17-4801
FoxP3 PE 10 μg/ml FC eBioscience UK 12-5773
Gr-1 APC 0.05 μg/ml FC eBioscience UK 17-9668
Live/Dead
Marker
eFluor®780 1 μl/ml FC eBioscience UK 65-0865
NK1.1 APC 0.0125 μg/ml FC eBioscience UK 17-5941
Qtracker™
605
605 nm N/A FC Thermo Fisher US Q25001MP
Ly6G V510 5 μg/ml FC Biolegend UK 127633
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Ly6C V421 5 μg/ml FC Biolegend UK 128032
CD45 PE 1 μl/mouse FACS eBioscience UK 12-0451
PDGFRα APC 1 μl/mouse FACS eBioscience UK 17-1401
Sca-1 FITC 1 μl/mouse FACS eBioscience UK 11-5981




















APC Variable FC eBioscience UK 17-4724
Rat IgG Κ
isotype




APC Variable FC eBioscience UK 17-4301
Rat IgG2b
Κ isotype
PE Variable FC eBioscience UK 12-4031
Rat IgG1
isotype
V421 Variable FC Biolegend UK 401911
Rat IgG1
isotype
V510 Variable FC Biolegend UK 400435
Rat IgG2a
λ isotype
V450 Variable FC BD Biosciences US 560723
Rat IgG2a
κ isotype
V500 Variable FC BD Biosciences US 560786
F4/80 Purified 1:100 IHC ABD Serotec UK MCA497R
CK19 Purified 1:500 IHC Origene US TA300867














N/A Pre-diluted IHC Vector Labs US MP-7444
Keratin
17/19
N/A 1:500 WB CST US 12434
α-Actinin
Antibody





N/A 1:2000 WB Dako DK P0448
CD3e Purified 0.8 μg/ml Functional BD Biosciences US 553057
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Table 2.5 – Table of reagents used in this study.
Item Supplier Country Catalogue
Number




Absolute ethanol Sigma-Aldrich UK 459844




Ammonium persulfate Sigma-Aldrich UK A3678
Antigen Unmasking Solution,
Tris-Based
Vector Laboratories US H-3301
Anti-rat/hamster
compensation beads
BD Bioscience US 552845
Bicinchoninic Acid solution Sigma-Aldrich UK B9643-1L
Blue/Orange Loading Dye, 6X Promega UK G1881
CD3/CD28 Dynabeads® Gibco UK 11452
CD4+CD25- T cell isolation
kit
Miltenyi Biotec DE 130-091-
041










DMEM Gibco UK 41965-039
DNase I Sigma-Aldrich UK AMPD1
DPX Mounting Medium Leica UK 08600E
EDTA Sigma-Aldrich UK E6758
Eosin Leica UK 3801602E







Harris Haematoxylin Leica UK 3801562E
HBSS Gibco UK 14170-088
HEPES Sigma-Aldrich UK H0887
Industrial Methylated Spirit PFM Medical UK PRC/R/101
Lympholyte® Mouse Cedarlane US CL5035







Murine recombinant IFN-γ PeproTech UK 315-05








OVA (257-264) peptide AnaSpec US 60193-5
Penicillin/Streptomycin/Glutamine Gibco UK 10378-016
Periodic acid Sigma-Aldrich UK 210064




Ponceau S solution Sigma-Aldrich UK P7170
Propidium Iodide Sigma-Aldrich UK P4170
Protease Inhibitor Cocktail Sigma-Aldrich UK P8340
Protein Standard Sigma-Aldrich UK P0914
Proteome ProfilerTM Mouse
XL
R&D Systems US ARY028
ProtoGel (30%) National Diagnostics US EC-890
ProtoGel Resolving Buffer
(4X)
National Diagnostics US EC-892
ProtoGel Stacking Buffer National Diagnostics US EC-893







Thermo Fisher Scientific US 21059
RNase-Free DNase Set Qiagen US 79254
RNase-Free DNase Set (50) Qiagen US 69506
RNeasy® Mini Kit Qiagen US 74104
RPMI Gibco UK 31870-025
Schiff Reagent Sigma-Aldrich UK 2818-71
Scott’s Tap Water Substitute Leica UK 3802901E
Sodium dodecyl sulfate Sigma-Aldrich UK 436143
ECL 2 Western Blotting
Substrate
Thermo Fisher Scientific US PI80196
Tissue-Tek® O.C.T.
Compound
Sakura FineTek US 4583
Tris-Glycine SDS PAGE
Buffer (10X)
National Diagnostics US EC-870
Tris-Glycine Electroblotting
Buffer (10X)
National Diagnostics US EC-880
TrypLE Express Gibco UK 12605010
TWEEN 20 Sigma-Aldrich UK P2287
Water Sigma-Aldrich UK W3500
Xylene PFM Medical UK PRC/R/201
α-MEM Gibco UK 32561-029
β-mercaptoethanol Sigma-Aldrich UK M6250
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Table 2.6 – Table of consumables used in this study.
Item Supplier LocationCatalogue Number
70 μm cell strainer Corning US 352350
1 ml Insulin Syringe & Needle
25g
Terumo US 01H2516
1 ml Insulin Syringe & Needle
29g
Terumo US 05M2913
15 ml polypropylene FalconTM
tubes
Corning US 430791
50 ml polypropylene FalconTM
tubes
Corning US 430829
50 μm cell strainer Partec DE 04-004-2327
6 well plate Corning US 3516
96 well flat bottom plate Corning US 353072
96 well U-bottom plate Sarstedt DE 83.18357.500
FACS tubes BD Biosciences US 352002
gentleMACSTM C tubes Miltenyi Biotec DE 130-096-334
gentleMACSTM M tubes Miltenyi Biotec DE 130-096-335
LD Columns Miltenyi Biotec DE 130-042-901
LS Columns Miltenyi Biotec DE 130-042-401
MACS Separators Miltenyi Biotec DE 130-042-302
Micro Vascular Clip for 1-2
mm diameter vessels
Harvard Apparatus US 610196
MS Columns Miltenyi Biotec DE 130-042-201
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RNeasy Mini Kit Qiagen US 74104
Sterile FACS tubes BD Biosciences US 352063
T175 Culture flask Corning US 353112
T25 Culture flask Corning US 430639
T75 Culture flask Corning US 430641
X-tra Adhesive Slides Leica US 38002032
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CHAPTER 3
IN VITRO PHENOTYPE AND PROPERTIES OF
PαS MESENCHYMAL STROMAL CELLS
3.1 Introduction and aims
MSCs were first postulated over 100 years ago, however their ability to regulate immune
cell function is a more recent discovery. Whilst traditional techniques for isolating MSCs
have focussed on exploiting their plastic adherence this leads to a heterogeneous population
of cells. In 2005 the ISCT defined minimal criteria for characterising MSC [125, 126],
although recently it has been proposed that these be further refined[127]. Developments
in isolation techniques to include prospective isolation using cell surface markers have
allowed for more defined populations of cells to be isolated. A number of prospective
isolation techniques for murine MSC have been described in the literature focussing on
different combinations of surface markers, however the uptake of these as techniques for
the generation of cells to be studied in in vivo experiments still seems low. This is likely
due to the complexity of the techniques, requirement for high speed cell sorting and the
relatively low yield of cells requiring extensive culture expansion. Originally described
by Morikawa [150], MSC isolated using the markers PDGFRα and Sca-1 (PαS MSC)
demonstrate all of the properties required by the ISCT including tri-lineage differentiation,
self renewal and plastic adherence. Since the description of PαS MSC in the literature
there has been little further research done on these cells likely due to the reasons described
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above. Whilst descriptions of murine MSC have shown overlap between PαS MSC and
other populations such as nestin+ cells [139], almost no work has been carried out to assess
the function of these cells, or their ability to act as immunomodulatory cells in the context
of cell therapy. Whilst work has already been undertaken in our institution to isolate [233],
characterise [236] and test the efficacy of PαS MSC [237], these cells were mostly isolated
from BALB/c mice. When attempting to assess the ability of PαS MSC isolated from
C57BL/6 mice to suppress lymphocyte proliferation no suppression could be demonstrated.
The propensity of BALB/c mice to adopt a Th2 response to inflammation could mean
that PαS MSC isolated from these mice have a different mechanism of immunosuppression
and indeed, work in our lab has demonstrated that these cells have a different mechanism
of action when compared with human MSC. The benefit of using PαS MSC isolated
from C57BL/6 mice may mean a closer analogue of human MSC aiding in subsequent
translation from pre-clinical to clinical research. So far robust in vitro testing of MSC
isolated from C57BL/6 mice has not been undertaken.
The MSC literature has demonstrated that MSC exposed to an inflammatory envir-
onment are able to modulate inflammation [238], as well as release chemokines including
the Chemokine (C-C motif) Ligand (CCL) CCL2, CCL3 and CCL12 [239]. There are a
number of conflicting reports relating to MSC and Il-10 with some studies demonstrating
that MSC secrete Il-10 [240, 241], whilst others disagree with this [242, 243]. it has been
suggested that MSC can polarise macrophages down a M2 route leading to the secretion
of Il-10 by M2 macrophages rather than MSC themselves [244, 128]. No studies so far
have demonstrated the secretome of PαS MSC and understanding the response of this
type of MSC may aid with an understanding of their immunomodulatory abilities and
potential as a cell therapy.
In order to address these needs I set out to prospectively isolate murine PαS MSC
by cell sorting and use these cells to study MSC biology and trafficking in the context
of post transplant liver injury. In particular I wished to study the use of exogenous PαS
MSC as a cell therapy models of liver injury that recreate features found after DCD liver
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transplantation. In the first instance I aimed to develop a robust technique to assess the
ability of these cells to suppress lymphocyte proliferation in vitro.
3.1.1 Specific chapter aims
Having described a novel and underutilised population of murine MSC I began this study
by assessing the function and phenotype of PαS MSC. The specific aims of this chapter
were:
1. To optimise the methodology to prospectively isolate and culture murine PαS MSC
2. To optimise the methodology of an in vitro assay for assessing MSC immunosup-
pressive efficacy
3. To demonstrate the in vitro immunosuppressive efficacy of PαS MSC
4. To assess the secretome of PαS MSC following exposure to an inflammatory stimulus
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3.2 Results
3.2.1 Prospective isolation of murine PαS MSC
I first sought to isolate and culture expand murine PαS MSC using a technique previously
described by Morikawa [150], and optimised in our laboratory [233, 245]. Long bones
were removed from C57BL/6 mice and following crushing were digested with collagenase.
Antibody staining for positive (PDGFRα and Sca-1) and negative markers (CD45 and
Ter119) was carried out and the cells were sorted by flow cytometry with the exclusion of
dead cells. The gating strategy, represented in figure 3.1, started by excluding all dead
cells, resulting in a viability of 60-80% of the total number of events. The haematopoietic
fraction was then removed by selecting cells negative for PE which was used to highlight
CD45 and Ter119, approximately 0.7-1% of the live cells. Finally the cells positive for
FITC and APC (Sca-1 and PDGFRα) were selected by cell sorting and represented
10-15% of the live non-haematopoietic cells or 0.05% of the total bone marrow cells (data
representative of 20 replicates each using ten mice). There was a large amount of variability
in this technique in keeping with prior experience with the number of cells sorted ranging
from 8-10x103 per mouse when using ten mice, with a purity of 95-99% based on flow
cytometry data (data representative of 20 replicates each using ten mice).
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Figure 3.1 – Representative flow cytometry plots demonstrating the gating
strategy for isolating PαS MSC from collagenase digested bone marrow. (a)
Cells were isolated from the long bones of ten C57Bl/6 mice. Gating for live cells was
carried out using PI to exclude dead cells resulting in a viability of 60-80%. (b) Next the
haematopoietic fraction were excluded with a negative gate against PE stained CD45 and
Ter119 cells leaving 0.7-1% of live cells. (c) Finally cells positive for PDGFRα (APC) and
Sca-1 (FITC) were selected which represented 0.05% of all cells with a yield of 8-10x103
cells per mouse when using ten mice, with a purity of 95-99%. Values on the plots represent
percentage of total cells in each gate. Data are representative of 20 replicates each using ten
mice.
Following isolation cells were incubated in standard media in 6 well coated tissue
culture plates at a concentration 50,000 cells per well. Colonies formed as previously
described [150]. Colony forming ability and spindle shaped morphology developed early
on after isolation however (figure 3.2), by passage 4 colony forming ability was lost.
Figure 3.2 – Representative image of the morphology of murine PαS MSC in
culture. The panel shows a representative image of PαS MSC that were isolated by
fluorescent cell sorting and plated into 6 well coated plates at a seeding density of 5x104 per
well and cultured in standard media for 72 hours. Images were captured at 72 hours following
a media change at 100x original magnification. The bar indicates 25µm.
I will next demonstrate the phenotype of isolated murine PαS MSC.
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3.2.2 Surface marker expression of PαS MSC
Previous work in our lab in conjunction with Shankar Suresh has demonstrated that surface
marker expression was examined in cultured PαS MSC at passage one by flow cytometry.
Surface antigen staining was undertaken by me for positive MSC lineage markers (CD29,
CD44, CD49e, CD90, CD105, CD140a and Sca-1) as well as the negative haematopoietic
and leucocyte markers (CD34, CD45 and Ter119). PαS MSC showed expression of all of
the positive markers tested for and none of the haematopoietic markers (figure 3.3) in
keeping with the ISCT description of murine MSC [126, 125].
Figure 3.3 – Cultured PαS MSC express MSC surface antigens when assessed
using flow cytometry. Representative flow cytometry histograms for P1 PαS MSC cultured
in standard media. MSC were trypsinised, stained for cell surface markers and analysed
by flow cytometry. Representative plots shown demonstrate high positivity for positive
MSC markers (CD29, CD44, CD49e, CD90, CD105, CD140a and Sca-1) as well as no
expression of the negative markers (CD34, CD45 and Ter119). Plots shown demonstrate
positive fluorescence (orange lines), negative fluorescence in unstained controls (grey lines)
and isotype matched controls (dotted lines) superimposed for each marker. Percentages
indicate the proportion of positive cells and are representative of 3 experiments. Figure taken
from Suresh [237].
I next sought to develop an assay for examining the immunomodulatory properties of
murine PαS MSC.
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3.2.3 Developing an in vitro immunosuppression assay
MSC have been shown to exert effects on a broad range of immune cells, however one
important effect when considering their use as a cell therapy is their ability to suppress T
cell proliferation. In their paper in 2002 Nicola et al demonstrated that human MSC can
suppress CD4+ and CD8+ T cells in an in vitro assay and the effect was dose dependent
[246]. Work from our lab has demonstrated that murine MSC can suppress T cell
proliferation and activation in a splenocyte reaction when isolated from BALB/c mice
[237].
3.2.3.1 C57BL/6 MSC do not suppress purified lymphocytes when stimu-
lated
Previous work with PαS MSC isolated from BALB/c mice in our lab has demonstrated
their ability to suppress T lymphocytes in a dose dependent manner [237]. To test the
ability of purified PαS MSC to suppress T cells P4 MSC isolated from either BALB/c or
C57BL/6 mice were added to T cell suppression assays in graded concentrations. MSC
were co-cultured with isolated CD4+CD25- T lymphocytes and CD19+ B cells. Stimulation
of the lymphocytes was undertaken using 0.8 μg/ml anti-CD3e antibody. After 72 hours
of co-culture cells were stained and analysed by flow cytometry (figure 3.4). Results were
normalised to a stimulated lymphocyte culture containing no MSC with the non-suppressed
sample being referred to as 100% proliferation. Multiple replicates were undertaken (n=6)
and confirmed that in a purified T cell suppression assay MSC isolated from C57BL/6
appear to be unable to suppress proliferation of CD4+ lymphocytes and indeed there
was a significant increase in T lymphocyte numbers (p=0.001). This increase is not in
keeping with the majority of the published literature suggesting that either PαS MSC
isolated from C57BL/6 are unable to suppress lymphocyte proliferation, or this assay is
not the correct model to study PαS MSC in vitro. I decided to further develop an in
vitro model to enable me to assess the ability of PαS MSC isolated from C57BL/6 to




Figure 3.4 – PαS MSC isolated from C57BL/6 mice do not suppress purified
naive lymphocytes unlike those isolated from BALB/c mice. (a) MSC isolated from
BALB/c mice caused a dose dependent reduction in T lymphocyte proliferation in co-culture
experiments (p<0.0001) whereas (b) MSC isolated from C57BL/6 mice showed a significant
increase in proliferation (P=0.0011). MSC were isolated from either C57BL/6 (n=6) or
BALB/c (n=6) mice. MSC were then co-cultured in increasing concentrations with naive
CD4+CD25- T lymphocytes and CD19+ B lymphocytes activated with 0.8 μg/ml anti-CD3e
(T cell:B cell ratio 2:1). Following 72 hours of culture cells were stained and analysed by
flow cytometry. Stimulated controls without MSC were used to calculate the 100% line.
Percentage of the maximal calculated response normalised to controls cell counts is represented
on the y axis and ratio of MSC to T cells is represented on the x axis. Histograms represent
mean and bars represent SEM and the red line represents 100% stimulation. Statistical
comparison was carried out using a one way ANOVA.
3.2.3.2 Development of a bulk splenocyte reaction to test the efficacy of PαS
MSC
Due to the ability of MSC to influence a large number of cell types I investigated the
ability of PαS MSC to exert their effect in a bulk splenocyte reaction in order to allow
for the use of intermediary cells when responding to inflammatory stimuli. By utilising
immune cells extracted from the spleens of transgenic OT-1 mice I was able to use OVA
peptide to stimulate T cell proliferation. OT-1 mice are transgenic mice with inserts into
the Tcra-V2 and Tcrb-V5 genes which results in a transgenic T cell receptor specifically
designed to recognise ovalbumin peptide residues 257-264 (OVA257-264) in the context
of CD8 co-receptor (H2Kb) interaction with MHC class I, resulting in an MHC class 1
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restricted ovalbumin specific CD8+ T cell [234].
Lymphocyte stimulation has been achieved with a range of doses of OVA257-264 peptide
in the literature [235] so I decided to test low and high doses (2 μg/ml and 10 μg/ml).
Splenocytes were generated by mechanical dissociation of OT-1 spleens and stained with
CellTraceTM violet as a proliferation marker. Either 1x105 or 2x105 cells were seeded
onto a 96 well round bottomed plate in C10 media and stimulated with different doses of
OVA257-264 and 50 U/ml of Il-2. After 96 hours in culture cells were stained for surface
antigens and analysed by flow cytometry. Wells were pooled to enable more accurate
analysis so that 3 wells represent one data point. Stimulation was successful in all groups
(figure 3.5a) with a significant increase in CD8+ lymphocyte number (p<0.0001). A
marginally higher number of divided CD8+ cells was demonstrated when seeding 1x105
immune cells however proliferation proved less consistent between replicates so I decided
to use 2x105 cells for the remaining experiments. Lymphocyte activation was then assessed
using CD25 to demonstrate lymphocyte activation. A significantly greater number of
activated CD8+ lymphocytes was demonstrated (figure 3.5b) when CD8+ cells were
stimulated with 2 μg/ml of OVA257-264 (p<0.0005).
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(a) (b)
Figure 3.5 – Optimisation of OVA257-264dose and splenocyte number in a bulk
splenocyte reaction. (a) Immune cells were isolated by mechanical dissociation of spleens
from OT-1 mice. Either 1x105 or 2x105 cells were seeded into 96 well plates and either 2
μg/ml or 10 μg/ml of OVA257-264was added with 50U/ml of Il-2. At 96 hours analysis by
flow cytometry demonstrated a significant increase in live CD8+ lymphocytes (n=14) with
significantly higher numbers of cells when using the lower dose of OVA257-264 (p<0.0001).
A marginally higher number of cells was found when seeding 1x105immune cells however
proliferation proved less consistent between replicates. (b) When seeding 2x105 cells analysis
of activation using CD25 demonstrated a significantly larger number of activated CD8+
lymphocytes (n=12) when stimulated with 2 μg/ml of OVA257-264 (p<0.0005). Points on the
graphs represent three pooled wells and bars represent the median. Points on the graphs
represent three pooled wells and bars represent the median. Statistical analysis was carried
out using a one way ANOVA.
CellTraceTM violet fluorescence was lower when compared with unstimulated controls
that were stimulated with either 2 μg/ml of OVA257-264 or 10 μg/ml of OVA257-264 (figure
3.6) in the live CD8+ population confirming proliferation of lymphocytes in the splenocyte
reaction.
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(a) 2 μg/ml of OVA257-264 (b) 10 μg/ml of OVA257-264
Figure 3.6 – CellTraceTM violet levels were reduced by similar amounts in CD8+
cells following stimulation with either 2 μg/ml or 10 μg/ml of OVA257-264. Bulk
splenocytes were stained with CellTraceTM violet and stimulated with OVA257-264 and 50
U/ml of Il-2. After 96 hours staining and then flow cytometry were carried out. After gating
for live CD8+ cells levels of CellTraceTM violet were lower in both the 2 μg/ml (a) group and
the 10 μg/ml (b) group confirming cell division of the CD8+ population. Fluorescence graphs
show log10 fluorescence on the x axis and cell count on the y axis. Each colour represents 3
pooled wells. The red peak represents unstimulated controls and all other colours represent
stimulated samples.
The percentage of live divided CD8+ lymphocytes was significantly higher when
stimulated with both 2 μg/ml of OVA257-264 or 10 μg/ml of OVA257-264 (figure 3.7) when
compared with unstimulated cells. When splenocytes were stimulated with 2 μg/ml
of OVA257-264 the percentage of divided CD8+ cells as significantly greater than when
splenocytes were stimulated with 10 μg/ml of OVA257-264 (98.4% ± 1.94% vs. 85.68% ±
8.61%, p=0.0039).
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Figure 3.7 – A significantly greater percentage of CD8 lymphocytes proliferated
when stimulated with OVA257-264. Bulk splenocytes cells were isolated by mechanical
dissociation of spleens from OT-1 mice. 2x105 cells were seeded into 96 well plates and either
2 μg/ml or 10 μg/ml of OVA257-264was added along with 50U/ml of Il-2. At 96 hours analysis
by flow cytometry demonstrated that a significantly greater percentage of CD8+ lymphocytes
proliferated when stimulated with OVA257-264 with a greater percentage seen in the lower
dose group (85.68% ± 8.61% vs. 98.4% ± 1.94%, p=0.0039). Points on the graphs represent
three pooled wells and bars represent the median. The y axis represents percentage of total
CD8+ cells which have divided. Statistical analysis was carried out using a one way ANOVA.
Having determined a dose of 2 μg/ml of OVA257-264 and an initial number of 2x105
splenocytes I next sought to quantify the numbers and activation status of the immune
cells at the beginning of the reaction and over the course of 4 days in culture. Following
mechanical digestion 2x105 splenocytes were seeded per well on a 96 well plate and
stimulated with 2 μg/ml of OVA257-264and 50 U/ml of Il-2. After 1 hour cells were stained
and analysed by flow cytometry. The largest cell population was CD19+ B lymphocytes
representing 71.51% ± 5.69% with CD8+ lymphocytes at 12.56% ± 4.69% and CD4+
lymphocytes only 4.93% ± 9.32% (figure 3.8). This gives a ratio of almost 6:1 B lymphocytes
to CD8+ T lymphocytes and 15:1 B lymphocytes to CD4+ lymphocytes, greater than the
2:1 ratio used in purified assays. Natural killer cells (NK1.1) cells represented 4.13% ±
1.01%. Cell activation markers demonstrated cells were not activated at baseline with
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CD25+ representing 0.96% ± 1.12% of the total CD45+ cells and CD69+ representing
1.16% ± 1.09%. The myeloid population represented a relatively small number of the total
cells. CD11b-F4/80+ macrophages were the least prevalent of the myeloid cells at 2.56%
± 2.04%, with CD11b+Gr1- monocytes representing 3.33% ± 2.12% and CD11b+Gr1+
neutrophils the most prevalent myeloid cell type at 5.29% ± 1.79%.
(a) (b)
(c)
Figure 3.8 – Quantification of the numbers of immune cells on day 0 of a bulk
splenocyte reaction. (a) Immune cells from the spleen of OT-1 mice were seeded and
stimulated with OVA257-264 and 50U/ml of Il-2. After 1 hour cells were stained and analysed
by flow cytometry. CD19+ B lymphocytes represented the largest population 71.51% ± 5.69%
with CD8+ lymphocytes at 12.56% ± 4.69% and CD4+ lymphocytes only 4.93% ± 9.32%
(n=5). (b) Myeloid cells included CD11b-F4/80+ positive macrophages 2.56% ± 2.04%,
CD11b+Gr1- monocytes 3.33% ± 2.12% and CD11b+Gr1+ neutrophils 5.29% ± 1.79% (n=7).
(c) Activation markers were low demonstrating minimal activation at baseline with CD25+
representing 0.96% ± 1.12% of the total CD45+ positive cells and CD69+ representing 1.16%
± 1.09%. Histograms represent mean and bars represent SEM. Points represent 3 pooled
wells. Percentage of cells was calculated as percentage of total CD45+ cells.
At 24 hours following stimulation cells were stained and analysed by flow cytometry
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(figure 3.9). Divided cells were those whose CellTraceTM violet fluorescence had fallen
below the level of unstimulated control. The divided cell population contained a low
percentage of CD8+ cells (0.17% ± 0.46%) with low expression of activation markers
(CD25+ 0.013% ± 0.045%, CD69+ 0.017% ± 0.045%). Undivided cells contained a higher
percentage of CD8+ cells (51% ± 93.1%) and higher levels of activation markers (CD25
12.55% ± 53.76%, CD69 18.93% ± 46.26%).
(a) (b)
Figure 3.9 – Quantification of the numbers of immune cells on day 1 of a splen-
ocyte reaction. Immune cells from the spleen of OT-1 mice were seeded and stimulated
with OVA257-264 and 50U/ml of Il-2. At 24 hours following stimulation cells were stained and
analysed by flow cytometry (n=6). Divided cells were those whose CellTraceTM violet had
fallen below unstimulated control. The divided cell population (a) contained a low percentage
of CD8+ cells (0.17% ± 0.46%) with low expression of activation markers (CD25+ 0.013%
± 0.045%, CD69+ 0.017% ± 0.045%). Undivided cells (b) contained a higher percentage of
CD8+ cells (51% ± 93.1%) and higher levels of activation (CD25+ 12.55% ± 53.76%, CD69+
18.93% ± 46.26%). Histograms represent mean and bars represent SEM. Points represent 3
pooled wells. Percentage of cells was calculated as percentage of total CD45+ cells.
Further analysis was undertaken at 96 hours following stimulation. Again cells were
stained and analysed by flow cytometry (figure 3.10). Divided cells were those whose
CellTraceTM violet fluorescence had fallen below the level of unstimulated control. The
divided cell population contained a high percentage of CD8+ cells (62.05% ± 17.21%) with
high expression of CD25 (60.69% ± 16.5%). Undivided cells contained a lower percentage
of CD8+ cells (13.43% ± 4.6%) and lower levels of CD25 (12.20% ± 3.47%).
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(a) (b)
Figure 3.10 – Quantification of the numbers of immune cells on day 4 of a bulk
splenocyte reaction. Immune cells from the spleen of OT-1 mice were seeded and stimulated
with OVA257-264 and 50 U/ml of Il-2. At 96 hours following stimulation cells were stained
and analysed by flow cytometry (n=6). Divided cells were those whose CellTraceTM violet
had fallen below unstimulated control. (a) The divided cell population contained a high
percentage of CD8+ cells (62.05% ± 17.21%) with high expression of CD25 (60.69% ± 16.5%).
(b) Undivided cells contained a lower percentage of CD8+ cells (13.43% ± 4.6%) and lower
levels of CD25 (12.20% ± 3.47%). Histograms represent mean and bars represent SEM.
Points represent 3 pooled wells. Percentage of cells was calculated as percentage of total
CD45+ cells.
CellTraceTM violet fluorescence at day 4 showed a consistent reduction in all stimulated
samples (figure 3.11).
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Figure 3.11 –CellTraceTM violet fluorescence was reduced in CD8+ cells 96 hours
after stimulation in the splenocyte reaction. Cells were stained with CellTraceTM violet
and stimulated with OVA257-264 and 50 U/ml of Il-2. After 96 hours staining and then flow
cytometry were carried out. After gating for live CD8+ cells levels of CellTraceTM violet were
reduced in all samples confirming cell division of the CD8+ population. Fluorescence graphs
show log10 fluorescence on the x axis and cell count on the y axis. Each colour represents 3
pooled wells, n=6.
3.2.3.3 In vitro efficacy of PαS MSC in a bulk splenocyte reaction
Having optimised a splenocyte reaction I proceeded to test the ability of PαS MSC to
suppress T Cell proliferation in this assay. Immune cells were extraction from the spleens
of OT-1 mice, stained with CellTraceTM violet and then seeded onto a 96 well plate in
C10 media. Cells were stimulated with 2 μg/ml of OVA257-264 and 50 U/ml of Il-2 and
incubated for 24 hours. This was to allow stimulation to occur prior to the addition of
PαS MSC. At 24 hours graded numbers of PαS MSC were added and then incubated for
a further 72 hours. Immune cells were removed and stained leaving behind the plastic
adherent PαS MSC and then analysed by flow cytometry. Proliferation was normalised
to stimulated controls with no PαS MSC added. The percentage of live divided CD8+
lymphocytes was significantly reduced (p<0.0001) in a dose dependent fashion with the
greatest number of PαS MSC added leading to the largest reduction in divided CD8+
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lymphocytes (figure 3.12).
Figure 3.12 – PαS MSC suppress CD8+ proliferation in a bulk splenocyte reac-
tion. Immune cells from the spleen of OT-1 mice were seeded and stimulated with OVA257-264
and 50 U/ml of Il-2 and after 24 hours graded numbers of PαS MSC were added. After a
further 72 hours staining and flow cytometry was undertaken. The percentage of live divided
CD8+ lymphocytes was significantly reduced (p<0.0001) in a dose dependent fashion when
normalised to proliferation controls with the greatest number of PαS MSC leading to the
largest reduction in divided CD8+ lymphocytes. Data are shown a median with range, n=14.
Points represent 3 pooled wells. Percentage of cells was calculated as percentage of total
stimulated cells from the proliferation controls. Statistical analysis was carried out using a
one way ANOVA.
The absolute number of CD8+ lymphocytes was also significantly reduced (figure 3.13)
with the lowest number occurring with the highest number of MSC (p<0.0001). The total
number of live divided CD8+CD25+ lymphocytes was significantly reduced (p<0.0001) in
a dose dependent fashion when compared to proliferation controls.
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(a) (b)
Figure 3.13 – PαS MSC reduce CD8+ and CD8+CD25+ numbers in a bulk splen-
ocyte reaction. Immune cells from the spleen of OT-1 mice were seeded and stimulated
with OVA257-264 and 50 U/ml of Il-2 and after 24 hours graded numbers of PαS MSC were
added. After a further 72 hours staining and flow cytometry was undertaken. (a) The total
number of live divided CD8+ lymphocytes was significantly reduced (p<0.0001) in a dose
dependent fashion when compared to proliferation controls with the greatest number of MSC
leading to the largest reduction in divided CD8+ lymphocytes. (b) The total number of
live divided CD8+CD25+ lymphocytes was also significantly reduced (p<0.0001) in a dose
dependent fashion when compared to proliferation controls. Data are shown a median with
range, n=15. Points represent 3 pooled wells. Percentage of cells was calculated as percentage
of total stimulated cells from the proliferation controls. Statistical analysis was carried out
using a one way ANOVA.
CellTraceTM violet fluorescence demonstrates a dose dependent reduction when com-
pared with stimulated control values (figure 3.14) indicating a reduction in proliferation of
CD8+ lymphocytes following the addition of MSC.
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Figure 3.14 – PαS MSC reduce CellTraceTM violet fluorescence in CD8+ cells
in a bulk splenocyte reaction. Immune cells were stained with CellTraceTM violet and
stimulated with OVA257-264 and 50 U/ml of Il-2 and for 24 hours. Graded numbers of PαS MSC
were then added and after a further 72 hours staining and flow cytometry was performed.
CellTraceTM violet fluorescence in CD8+ cells was reduced in a dose dependent fashion
indicating reduction in proliferation when compared with stimulated controls containing no
PαS MSC. Fluorescence graphs show log10 fluorescence on the x axis and cell count on the y
axis. Each colour represents 3 pooled wells, n=6. Light blue represents stimulated cells with
no PαS MSC added, all other colours indicate stimulated cells with PαS MSC added (top 3
1:4 MSC, middle 3 1:8 MSC and bottom 3 1:16 MSC), n=10).
I next sought to examine the effects of inflammatory stimulus on PαS MSC.
3.2.4 The effects of an infammatory stimulus on PαS MSC
In order to investigate the effects of an inflammatory stimulus on PαS MSC and their
secretome I decided to examine medium passage (passage 4) PαS MSC cultured in standard
media and stimulated with inflammatory cytokines. I decided to stimulate PαS MSC with
TNFα and IFN-γ common inflammatory cytokines, as theses cytokines are found in the
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livers of a number of mouse models of liver injury [247, 98, 248]. Stimulation of MSC
has been carried out successfully in other studies [249, 250] and PαS MSC have also been
successfully stimulated with these cytokines [237].
3.2.4.1 PαS MSC morphology
I prospectively isolated PαS MSC as previously described and expanded in culture to
passage 4. Stimulation of PαS MSC was undertaken by the addition 20 ng/ml TNFα and
IFN-γ to the culture media and cells incubated for a further 24 hours. Following incubation
supernatant was removed and cells washed, fixed and stained with the cytoskeletal stain
Phalloidin and the nuclear stain DAPI. Unstimulated control cells were also stained for
comparison.
The unstimulated PαS MSC showed a distinctive spindle shaped morphology. The
stimulated PαS MSC showed the same morphological structure with no clear differences
between groups (figure 3.2).
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(a) (b)
Figure 3.15 – Representative fluorescent histochemical images of PαS MSC stim-
ulated with TNFα and IFN-γ. PαS MSC were prospectively isolated and expanded in
culture to passage 4. Stimulation of PαS MSC was undertaken by the addition 20 ng/ml
TNFα and IFN-γ added to the culture media and cells incubated for a further 24 hours.
Following incubation supernatant was removed and cells washed, fixed and stained with the
cytoskeletal stain Phalloidin and the nuclear stain DAPI. Unstimulated control cells were
also stained for comparison. (a) The unstimulated PαS MSC showed a distinctive spindle
shaped morphology. (b) The stimulated PαS MSC showed the shame morphological structure
with no clear differences between groups. Images were taken at 400x magnification. Scale
bars represent 25 μm.
I next sought to assess the cytokines secreted by PαS MSC following stimulation with
inflammatory cytokines.
3.2.4.2 Cytokines secreted by PαS MSC
Prospectively isolated PαS MSC were expanded in culture to passage 4. Stimulation of
PαS MSC was undertaken by the addition 20 ng/ml TNFα and IFN-γ to the culture
media and cells incubated for a further 24 hours. Following incubation supernatant was
removed and the cytokine profile was assessed using a Proteome ProfilerTM (R&D Systems,
US).
Following stimulation PαS MSC (figure 3.16a) the anti-inflammatory cytokines Il-10
and osteoprotegerin showed a significant increase in their levels (p=0.00453 and p=0.00363).
The pro-inflammatory cytokine CCL19 also showed a significant increase (p=0.00457,
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figure 3.16b). When specifically looking at cytokines involved in the Th2 response (figure
3.16c) only Il-10 showed a significant increase (p=0.00453).
(a) (b)
(c)
Figure 3.16 –Cytokine profile in the secretome of PαS MSC following stimulation
with TNFα and IFN-γ. PαS MSC were prospectively isolated and expanded in culture
to passage 4. Stimulation of PαS MSC was undertaken by the addition 20 ng/ml TNFα and
IFN-γ to the culture media and cells incubated for a further 24 hours. Following incubation
supernatant was removed and the cytokine profile was assess using a Proteome ProfilerTM.
(a) The anti-inflammatory cytokines Il-10 and osteoprotegerin showed significant increases
in their levels (p=0.00453 and p=0.00363). (b) The pro-inflammatory cytokine CCL19
also showed a significant increase following stimulation (p=0.00457). (c) When specifically
looking at cytokines involved in the Th2 response only Il-10 showed a significant increase
(p=0.00453). Bars represent mean values and lines represent the standard error of the mean.
Statistical analysis was undertaken using multiple t-tests with Bonferroni’s correction for
multiple comparisons.
I also examined the chemokine and adhesion molecule profile using the Proteome
ProfilerTM (figure 3.17). Chemerin (p=0.000533), Chemokine (C-X-C motif) Ligand
(CXCL)9 (p=0.000780), CXCL10 (p=0.00432), CXCL11 (p=0.00238), CXCL16 (p=0.00132)
and VCAM-1 (p=0.00497) all showed statistically significant increases following stimulation
with TNFα and IFN-γ.
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Figure 3.17 – Chemokine and adhesion molecule profile of PαS MSC following
stimulation with TNFα and IFN-γ. PαS MSC were prospectively isolated and expanded
in culture to passage 4. Stimulation of PαS MSC was undertaken by the addition 20 ng/ml
TNFα and IFN-γ to the culture media and cells incubated for a further 24 hours. Following
incubation supernatant was removed and the cytokine profile was assess using a Proteome
ProfilerTM. Chemerin (p=0.000533), CXCL9 (p=0.000780), CXCL10 (p=0.00432), CXCL11
(p=0.00238), CXCL16 (p=0.00132) and VCAM-1 (p=0.00497) all showed statistically signi-
ficant increases following stimulation with TNFα and IFN-γ. Bars represent mean values
and lines represent the standard error of the mean. Statistical analysis was undertaken using
multiple t-tests with Bonferroni’s correction for multiple comparisons.
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3.3 Discussion
3.3.1 Isolation, culture expansion and phenotype of murine PαS
MSC
Whilst plastic adherence is a described property of MSC using this as an isolation technique
leads to a heterogeneous population of cells and even after a number of passages of culture
expansion contaminating cells are still present [251]. Prospective isolation with cell sorting
is one way of overcoming this heterogeneity. By utilising a technique originally described
by Morikawa [150], and subsequently refined in our lab [233, 245], I was able to isolate
purified murine PαS MSC from the bone marrow of C57BL/6 mice using the positive
lineage markers Sca-1 and PDGFRα and the negative lineage markers CD45 and Ter119
with a high degree of purity (95-99%). On culture expansion these cells took on a spindle
shaped morphology and demonstrated colony forming potential as originally described
[150]. The cell yield following isolation was 8-10x103 per mouse which was also in keeping
with numbers previously described.
By examining surface markers that have been recommended as required for MSC
classification by the ISCT [126], I was able to show that murine PαS MSC express all of
the positive lineage markers expected of an MSC with a high degree of positivity, with less
than 1% expression of the negative haematopoietic lineage markers. These findings, taken
alongside other extensive work undertaken in our lab support the published literature in
claiming that PαS MSC are MSC as described by the ISCT definition [236, 245, 237].
PαS MSC have not been extensively studied in the literature despite the potential
benefits of a highly purified cell type with a repeatable isolation technique. Reasons for
this may include difficulty with the isolation technique and a lack of access to the requisite
facilities such as a high speed cell sorter. The logistical difficulties with using this technique
are also a concern as an isolation requires 8-10 hours and will only yield approximately
1x105 cells meaning that culture expansion is a requirement prior to most experiments
due to the number of cells needed. There also needs to be a consideration of the number
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of mice required in order to yield a useful number of MSC. Each isolation requires the use
of 10 mice and multiple isolations may be required for each experiment. As such wherever
possible tissue not required for the isolation was used in other experiments in order to be
compliant with the 3Rs [252].
3.3.2 The ability of murine PαS MSC to suppress lymphocyte
proliferation in vitro
A key mechanism by which human MSCs exert their effects when used as a cell therapy
is a reduction in lymphocyte proliferation [1, 253]. When testing PαS MSC isolated
from BALB/c mice in a purified naive lymphocyte assay there was a demonstrable dose
dependent reduction in lymphocyte proliferation. When this experiment was repeated
with cells isolated from C57BL/6 mice no suppression of lymphocyte proliferation was
seen. There are many reasons why this finding might have been true. I undertook enough
controlled replications in order to rule out experimental error. BALB/c mice have a
tendency towards Th2 responses and have been described as models of the Th2 response
[254], they are used in models of asthma due to their ability to generate Th2 type allergic
responses in the lungs [255]. With this in mind a possible explanation could be that
BALB/c MSC respond differently in an inflammatory micro-environment and release
cytokines in keeping with Th2 response such as Il-10, which would inhibit the proliferation
of CD4+ but not CD8+ T lymphocytes. Yang et al have demonstrated that Il-10 secreted
from BALB/c MSC can inhibit T cell proliferation in vitro [256]. A limitation of this
study is the lack of cytokine data in the splenocyte reaction which would go some way
to demonstrate the mechanistic differences between PαS MSC isolated from BALB/c
mice and those isolated from C57BL/6 mice. Another explanation for the differences
found between the purified naive lymphocyte reaction and the splenocyte reaction is a
difference in type of lymphocyte studied. The naive lymphocyte reaction looked at the
effects on CD4+ lymphocytes, whereas the splenocyte reaction directly stimulated CD8+
lymphocytes, although there was still a considerable number of CD4+ cells present in the
110
assay. Whilst the decision to switch cell type was taken due to assay design concerns, it
was felt that as an in vitro model of the effects of PαS MSC on the proposed models of
liver injury the difference would be acceptable as both the MDR2-/- model and the hepatic
ischaemia reperfusion model have been shown to have immune mediated damage caused by
CD4+ and CD8+ lymphocytes [98, 74]. Another consideration in the splenocyte reaction
is the ratio of other cells found in the splenocyte culture, in particular the large number
of CD19+ B cells, a ratio of 6:1 when compared with CD8+ cells and almost 15:1 when
compared with CD4+ cells. It has been shown that MSC can exert their effects through
the induction of regulatory B cells [257] and it is possible that this mechanism is utilised
by PαS MSC. With lower numbers of CD19+ cells to act as an immune system regulator
suppression may not be seen. Further study would be needed to confirm this hypothesis.
PαS MSC isolated from C57BL/6 mice did suppress CD8+ lymphocyte proliferation and
activation when tested in a splenocyte reaction in a dose dependent fashion. By optimising
the stimulation and cell number I was able to create a robust means of demonstrating this
important effect of PαS MSC, confirming their potential for immunomodulation in models
of liver injury with a lymphocyte mediated component and setting the scene for further in
vitro and in vivo work.
3.3.3 The secretome of PαS MSC exposed to an inflammatory
stimulus
Various types of MSC have been studied in the literature and a number have papers
have postulated mechanisms by which MSC can exert their immunosuppressive effects.
A common mechanism of immunomodulation in the MSC literature is suppression of T
cell proliferation as discussed earlier. MSC have been shown to exert their suppressive
effect on T cells better when they are in direct contact [246] and this interaction can be
facilitated by the expression of adhesion molecules including VCAM-1 and ICAM-1 [258].
In this study I have demonstrated that PαS MSC significantly increase their production
of VCAM-1 following an inflammatory stimulus, suggesting they also possess the ability
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to bind to T cells. Further work would need to be carried out in order to confirm this
hypothesis. MSC have also been shown to attract T cells via expression of a number of
leucocyte chemokines including CXCL9, CXCL10 and CXCL11 [259], with neutralisation
of the T cell chemokine receptor CXCR3 reversing this effect. I have shown that PαS
MSC produce significantly higher amounts of CXCL9, CXCL10 and CXCL11 following
exposure to an inflammatory stimulus. I have also shown a significant increase CXCL, an
NKT cell chemoattractant. This increase in production of leucocyte attractant chemokines
could account for the ability of PαS MSC to suppress T lymphocyte proliferation either
on its own or in conjunction with the secretion of other immunosuppressive cytokines such
as Il-10 [260].
There exists debate in the MSC literature about the ability of MSC to secrete Il-10
with some studies demonstrating that MSC secrete Il-10 [240, 241], whilst other studies
suggest that it is the effects of MSC on intermediary cells that leads to an increase in
Il-10 levels [242, 243]. It has been suggested that MSC can stimulate the differentiation of
macrophages into an M2 phenotype leading to the secretion of Il-10 by M2 macrophages
[244, 128]. In this study I have clearly demonstrated that PαS MSC are able to secrete
Il-10 following stimulation with TNFα and IFN-γ. I did not however study the effects of
other inflammatory cytokines on the secretome of PαS MSC and whilst the combination
of TNFα and IFN-γ seem to lead to the production of Il-10 it is possible that priming
with other cytokines may lead to a different response. The choice of TNFα and IFN-γ
was based on previous studies and an attempt to recapitulate the in vivo inflammatory
environment in models of liver injury and as such this finding is important and relevant.
Increased Il-10 production could lead to a multitude of abilities including induction of Th2
response [261], the ability to inhibit neutrophil and macrophage function [262, 263, 264],
inhibit T cell growth [260] and to suppress the secretion of pro-inflammatory cytokines
[261]. MSC induced to overexpress Il-10 have been shown to be beneficial in models of
graft versus host disease [164] indicating a role for Il-10 in inflammatory conditions and
suggesting that MSC with the ability to secrete Il-10 in response to inflammatory stimuli
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such as PαS MSC may be beneficial in inflammatory disease.
The chemokine CCL19 has been shown to aid the recruitment of CD4+ and CD8+ T
lymphocytes into inflamed tissue [265, 266], as well as activating dendritic cells [267]. MSC
have been shown to interfere with the CCL19 induced migration and antigen presentation
of dendritic cells [268] so it was surprising to find that PαS MSC produce CCL19 in
response to inflammatory cytokines. This could be a reflection of the ability of MSC to
exert both pro and anti-inflammatory effects in vivo, the significance of this response needs
further study.
In this chapter I have also demonstrated an increase in the production of osteopro-
tegerin by PαS MSC. It has previously been demonstrated that human MSC produce
osteoprotegerin in response to inflammation [269] and that the interaction between MSC
and macrophages may be responsible for MSC mediated inhibition of osteogenesis during
inflammation [270]. This finding demonstrates a potential role of PαS MSC in bone remod-
elling during inflammation. Osteoprotegerin forms a part of the OPG/RANK/RANKL
pathway and acts as an inhibitor of RANKL preventing the activation of the RANK
signalling pathway [271]. The RANK/RANKL system is present on a number of immune
cells and has a modulatory effect on the inflammatory response, and as such the ability of
PαS MSC to secrete osteoprotegerin may represent a mechanism by which they are able
to suppress the immune system. Further study is need to confirm this hypothesis.
3.3.4 Chapter summary
I prospectively isolated Murine PαS MSC from the bone marrow of C57BL/6 mice
with cell yields similar to those found in the published literature. Following culture
expansion I demonstrated PαS MSC morphology and also demonstrated that there are
no morphological changes following an inflammatory stimulus. Following isolation I also
demonstrated the expression of cell surface markers for MSC as defined by the ISCT. A
splenocyte reaction was developed and optimised which allowed the ability of PαS MSC to
suppress lymphocyte proliferation to be adequately demonstrated. PαS MSC were able to
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suppress CD8+ lymphocyte proliferation and activation in a dose dependent fashion with
higher numbers of MSC leading to a greater level of suppression. I also demonstrated the
secretome of PαS MSC following an inflammatory stimulus which included significantly
increased levels of Il-10. These results support the hypothesis that murine PαS MSC
may be a viable cell therapy in vivo in models of T cell mediated liver injury but further
experiments will be is required.
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CHAPTER 4
THE IN VIVO EFFICACY OF PαS MSC IN THE
MDR2-/- MODEL OF LIVER INJURY
4.1 Chapter introduction and aims
I have demonstrated that PαS MSC can be isolated from the bone marrow of C57BL/6
mice and that following culture expansion these cells are able to suppress lymphocyte
proliferation in a bulk splenocyte reaction. I have also demonstrated the ability of PαS
MSC to secrete a broad range of cytokines in response to an inflammatory stimulus. In
this chapter I tested the ability of PαS MSC to modulate the immune system in a mouse
model of biliary injury.
4.1.1 Non-anastomotic biliary complications following liver trans-
plantation
Following the development of the surgical technique for liver transplantation in the 1960’s
it has rapidly become the standard treatment for end stage liver disease and remains
so today due to a paucity of other effective therapies. As has always been the case the
number of transplantations performed is limited by the number of donor organs meaning
that patients often die whilst waiting for a donor liver to become available. In recent years
this has led to the use of more marginal donor livers and extension of the donor criteria. A
number of UK centres now use Maastricht class III non-heart beating donors [29]. The use
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of more marginal donors, in particular DCD livers causes a different complication profile
with a greater number of biliary complications when compared with DBD livers with DCD
giving a 2-3 fold increased risk of biliary complications (30%-50% vs 10%-25%) [272, 273].
There is conflicting evidence regarding the overall morbidity and mortality of DCD
transplantation when compared with DBD transplantation with some centres reporting
a difference in mortality [42], and others suggesting that with careful patient selection
there is no difference in outcome [31]. Biliary complications include bile leakage, bile duct
strictures and ischaemic cholangiopathy. By reducing these complications, in particular
in the more marginal grafts, graft survival may be increased and re-transplantation rate
reduced thereby increasing the number of available organs for transplantation. I set out to
test the ability of PαS MSC to reduce immune mediated injury in the MDR2-/- model
of liver injury, a model I selected as the phenotype of injury is close to that seen in post
DCD transplant liver injury.
4.1.2 MDR2-/- mouse model of liver injury
The MDR2-/- Mouse model [95] is a model utilised extensively by Fickert et al [96] to study
liver injury. With targeted disruption of the multi-drug resistance gene 2 (Abcb4), an
absence of biliary phospholipids is seen, resulting in the leaking of bile acids and cytotoxic
injury to the biliary tree. This leads to extra- and intra-hepatic biliary strictures and
dilatation with onion skin fibrosis. Whilst proposed as a model of sclerosing cholangitis
there are clear parallels with the injury seen in DCD liver transplantation in the medium
term and so this model was chosen to test the hypothesis that PαS MSC may reduce this
immune mediated damage.
Experiments were limited to male mice due to the propensity of female mice to form
bile stones in an unpredictable manner leading to heterogeneous results [99]. An age
below 15 weeks was determined as the appropriate time course as peak CD4+ and CD8+
cell infiltration within the liver occurs during this time period as does early fibrosis and
stricture development [98]. After 14 weeks fibrosis becomes established and the immune
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component of the injury appears to be reduced with less infiltrating immune cells present
and lower levels of serum markers of liver injury [95, 97, 98]. Formation of gallstones also
seems to be more prevalent from 15 weeks of age [99]. Whilst the MDR2-/- model has been
studied extensively the majority of papers seem to use immunohistochemistry to assess
immune cell infiltration in the liver so I decided to complement this with flow cytometry
in order to better quantify the immune cell infiltrate in the liver of MDR2-/- mice.
4.1.3 MSC as a therapy in immune mediated liver injury
MSC from a variety of sources have been extensively studied, however a limitation of the
field is the heterogeneity of cell types isolated and cultured and the duplicity of effects
often seen. Isolation of more homogeneous populations of cells may enable more robust
and repeatable testing of the efficacy of MSC as a cell therapy. With this in mind I have
focussed on the use of PαS MSC which represent a more homogeneous group of MSC.
Little work has been carried out with these cells as previously discussed and their efficacy
as a cell therapy has yet to be tested in the published literature. Previous work in our
laboratory has shown that these cells can suppress the immune response in a model of
autoimmune hepatitis [237, 245], and I have demonstrated the ability of PαS MSC to
suppress lymphocyte proliferation and activation in a previous chapter.
4.1.4 Specific chapter aims
Previous chapters have demonstrated the ability of PαS MSC to suppress CD8+ T cell
proliferation in vitro in a dose dependent fashion. I have also demonstrated a number of
cytokines secreted following stimulation which have the potential to modulate the immune
response. The aim of this chapter was to characterise the ability of PαS MSC to modulate
the immune system in vivo in the MDR2-/- model of liver injury. The specific aims of this
chapter were:
1. To establish the MDR2-/- model of liver injury
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2. To optimise techniques to study infiltrating immune cells in the livers of MDR2-/-
mice
3. To characterise the inflammatory injury seen in the MDR2-/- model over time
4. To test the in vivo efficacy of PαS MSC in the MDR2-/- model
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4.2 Results
4.2.1 Genotyping of MDR2-/- breeding pairs
The MDR2-/- model is a homozygous knockout model and a colony was maintained at the
. Mice were bred on an FVB background as
the majority of the published literature using this model is in FVB mice and MDR2-/- mice
bred on a C57BL/6 background had low litter numbers and as such their use was unfeasible
for this study. Whilst this model was a homozygous model and therefore genotyping of
all litters was not necessary periodic genotyping was undertaken to confirm no significant
genetic drift. Genotyping was undertaken by TransnetXY®. Results demonstrated that
all breeding pairs were homozygous for the mdr2/abcb4 gene.
4.2.2 Time course of liver injury in the MDR2-/- mouse model
The MDR2-/- model of liver injury is a spontaneous and progressive model of liver injury.
There is increased flow of toxic bile acids and by 3 weeks of age mice demonstrate ductular
proliferation and a mixed inflammatory infiltrate [97]. As the literature describes an
inflammatory infiltrate which develops from week 3 to peak at around 8 weeks I decided
to look at a number of time points during the peak inflammatory period. By 14 weeks
fibrosis should become established and the risk of ductal lithiasis increases so time points
beyond this were not considered [99]. ALT has been used as the primary outcome measure
in the MDR2-/- model in the majority of studies. Given that young mice tend to release
ALP during bone turnover which could cloud the results [274] I decided to use use ALT as
a primary measure but considered ALP and bile acids as secondary measures.
4.2.2.1 Serum markers of liver injury over time
MDR2-/- mice were sacrificed at different time points after birth. Samples from male 8
week old uninjured FVB wild type mice were also analysed for control values (figure 4.1).
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Serum ALT showed a significant increase over time (p<0.0001) with a peak at 11 weeks
(801.7 ± 142.9 IU/L). There appeared to be a plateau between weeks 8 and 10 where there
were no significant changes in ALT value. Serum ALP also demonstrated a significant
increase over time (p=0.0012) with a peak at 11 weeks (1289 ± 572 U/L), although levels
were not significantly higher than those between 8 and 10 weeks. Bile acids followed the
same pattern with a significant increase over time (p=0.045) with a peak at 11 weeks (72.5
± 26.9 μmol/L), although again levels were not significantly higher than those between 8
and 10 weeks. ALT was the only marker that continued to increase up to 12 weeks with




Figure 4.1 –MDR2-/- serum markers of liver injury show changes over time. Male
MDR2-/- mice or FVB wild type controls were sacrificed at different time points after birth.
MDR2-/- mouse serum was analysed at multiple time points for ALT, ALP and bile acids. (a)
Serum ALT showed a significant increase over time (p<0.0001) with a peak at 11 weeks (801.7
± 142.9 IU/L, n=30). (b) Serum ALP also demonstrated a significant increase over time
(p=0.0012) with a peak at 11 weeks (1289 ± 572 U/L), although levels were not significantly
higher than those between 8 and 10 weeks (n=27). (c) Bile acids followed the same pattern
with a significant increase over time (p=0.045) with a peak at 11 weeks (72.5 ± 26.9 μmol/L),
although levels were not significantly higher than those between 8 and 10 weeks (n=27).
Points represent individual mice, bars represent the median and lines represent the range.
Statistical analysis was carried out using a one way ANOVA and multiple comparison testing
was undertaken.
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4.2.2.2 Liver immunohistochemistry over time
Following sacrifice of MDR2-/- mice liver tissue was removed and fixed in formalin. Fixed
liver tissue was embedded in paraffin and processed for immunohistochemistry. H &
E staining (figure 4.2) was performed and demonstrated inflammation of the portal
regions (zone I) at all time points with inflammatory cell infiltration around the bile
ducts as described by Maud et al [97], with sparing of the peri-central (zone III) areas.






Figure 4.2 – Representative haematoxylin and eosin staining of MDR2-/- livers
between 7 and 14 weeks. Either male MDR2-/- mice or FVB wildtype controls were
sacrificed at different time points after birth and liver tissue was removed and processed
sectioned. H & E staining was performed and demonstrated inflammation of the portal
regions (zone I) at (a) 7 weeks, (b) 8 weeks, (c) 9 weeks, (d) 10 weeks and (e) 14 weeks.
Quantification was not undertaken. All images are generated from whole slide scans and are
at 400x magnification. Scale bars represent 100 μm.
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Immunohistochemical staining for CD45 was used to demonstrate total leucocyte
infiltration in MDR2-/- mouse livers (figure 4.4), and F4/80 staining was used to delineate
hepatic macrophages (figure 4.5). Staining was undertaken using a chromogenic technique.
Whole slide images from stained slides were captured using a Zeiss AxioScanner. Between
5 and 10 images were taken from each scan to cover the whole slide and quantification
of each image was performed using Image J software. CD45 staining was greatest at 7
weeks (3.71 ± 0.31) and significantly lower at weeks 8-10, although there was no difference
found in the levels between weeks 8-10 (figures 4.3,4.4). F4/80 staining was greatest at 14
weeks (5.06 ± 11.0) but not significantly different at any time point and showed a large
confidence interval (figures 4.3,4.5).
(a) (b)
Figure 4.3 – Time course quantification of CD45 and F4/80 staining levels in
MDR2-/- mice. Either male MDR2-/- mice or FVB wild type controls were sacrificed
at different time points after birth and liver tissue was removed and processed sectioned.
Immunohistochemical staining was undertaken using a chromogenic technique. (a) CD45
staining was greatest at 7 weeks and significantly lower at weeks 8-10 (n=19). (b) F4/80
staining was greatest at 14 weeks but not significantly different at any time point (n=18).
Slides were captured using a Zeiss AxioScanner. Between 5 and 10 images were taken from
each scan to cover the whole slide and quantification of each image was performed using
Image J software. Histograms represent the median value and lines represent the range.






Figure 4.4 – Representative immunohistochemical staining for CD45 of MDR2-/-
livers between 7 and 14 weeks. Either male MDR2-/- mice or FVB wild type controls
were sacrificed at different time points after birth and liver tissue was removed, processed
and sectioned. Immunohistochemical staining was undertaken using a chromogenic technique.
Slides were captured using a Zeiss AxioScanner. There was an apparent peri-portal distribution
of CD45 positive cells with localisation in zone 1 around the bile ducts present at (a) 7 weeks,
(b) 8 weeks, (c) 9 weeks, (d) 10 weeks and (e) 14 weeks. All images are generated from whole





Figure 4.5 – Representative immunohistochemical staining for F4/80 of MDR2-/-
livers between 7 and 14 weeks. Either male MDR2-/- mice or FVB wild type controls
were sacrificed at different time points after birth and liver tissue was removed, processed
and sectioned. Immunohistochemical staining was undertaken using a chromogenic technique.
Slides were captured using a Zeiss AxioScanner. There was an apparent peri-portal concen-
tration of F4/80 positive cells with localisation in zone 1 around the bile ducts, however
F4/80 cells were also distributed throughout the liver. This pattern was seen at (a) 7 weeks,
(b) 8 weeks, (c) 9 weeks, (d) 10 weeks and (e) 14 weeks. All images are generated from whole
slide scans and are at 400x magnification. Scale bars represent 100 μm.
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4.2.2.3 Western blotting for CK19 expression
In the MDR2-/- model ductular proliferation has been described as occurring as early as
4 weeks of age [98]. Whilst this can be seen on H & E staining, quantification can be
better achieved by investigating levels of the cytoskeletal protein cytokeratin 19 (CK19). I
decided to perform western blotting in order to examine CK19 expression levels in keeping
with other studies into the MDR2-/- model [100]. Mechanical liver tissue homogenisation
was undertaken followed by protein lysis. Determination of protein concentration was
performed using the Biuret assay. Following optimisation 40 µg of protein was loaded per
well and samples run and subsequently transferred to a PVDF membrane. A primary
antibody for CK17/19 (New England BioLabs, US) followed by a secondary conjugated to
Horseradish Peroxidase (HRP) was used and imaging undertaken using X Ray film. Films
were scanned and analysed using ImageStudio Lite (LI-COR Biosciences, GB). Membranes
were stripped and re-probed using α-actinin as a loading control. Samples were normalised
to the loading control and represented as fold change using samples from uninjured FVB
wild type mice as reference values.
CK19 levels were variable throughout the time course of the MDR2-/- model but demon-
strated broad confidence intervals (figure 4.6). The only time point which demonstrated a
significant increase from the baseline level was 10 weeks (P=0.03).
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(a) CK19 fold change in the MDR2-/- model (b) Representative CK19 western blots
Figure 4.6 – Western blot of the time course of CK19 levels in the MDR2-/-
mouse model. Either male MDR2-/- mice or FVB wild type controls were sacrificed at
different time points after birth and liver tissue was removed and processed. Protein was
extracted from the liver tissue and 40 µg was loaded per well. Blotting was performed and
images were scanned and analysed. α-actinin was used as a loading control and samples
were normalised to the loading control and represented as fold change using samples from
uninjured FVB wild type mice as reference values. (a) CK19 levels were variable throughout
the time course of the MDR2-/- model but demonstrated broad confidence intervals (n=20).
Group analysis showed no significant difference with multiple comparisons however at 10
weeks there was a significant increase in CK19 when compared with uninjured FVB (P=0.03).
(b) representative western blots at 7 and 10 weeks compared with FVB controls demonstrate
higher expression of CK19. Histograms represent the median value and lines represent the
range. Statistical analysis was carried out using a one way ANOVA and multiple comparison
testing was undertaken. Individual T-tests were also performed.
Based on these results I decided to focus my investigations at 7, 10 and 11 weeks in
order to determine the most beneficial time point for MSC therapy in the MDR2-/- model.
4.2.2.4 Characterisation of liver lymphocytes by flow cytometry
I next sought to quantify the immune cell populations in the livers of MDR2-/- mice. Male
mice aged 8 weeks old were sacrificed and liver lobes were removed and mechanically
homogenised and following washing were passed over a density gradient using Lympholyte®
(Cedarlane, CA). Cells were stained and analysed by flow cytometry. Values are normalised
to liver weight.
Following the first isolation run it was clear that the cell yield was well below what I
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expected based on the serum markers of liver injury (figure 4.7). Total CD3+ cell numbers
were low (2905 ± 2951) with CD4+ and CD8+ lower still (986 ± 307, 257.1 ± 121.4).
Whilst I have successfully used this technique to isolate immune cells from the livers
of OVA-Bil mice [245], I hypothesised based on that Lympholyte® was not the correct
gradient to enable isolation of immune cells in the MDR2-/- model.
Figure 4.7 – Flow cytometric analysis of immune cell numbers from 8 week old
MDR2-/- mouse liver following extraction with Lympholyte®. Male mice aged 8
weeks old were sacrificed and liver lobes were removed and mechanically homogenised and
following washing were passed over a density gradient using LympholyteTM (Cedarlane, CA).
Cells were stained and analysed by flow cytometry. Following the first isolation run it was
clear that the cell yield was well below what I expected based on the serum markers of liver
injury. Total CD3+ cell numbers were low (2905 ± 2951) with CD4+ and CD8+ lower still
(986 ± 307, 257.1 ± 121.4). Values are normalised to liver weight and shown as cells per
gramme of liver tissue. Points represent individual mice, bars represent the median and lines
represent the range.
Previous studies have reported successful isolation of immune cells from models of liver
fibrosis using OptiprepTM as the density gradient [275]. I decided to investigate this as an
alternative to Lympholyte® in the MDR2-/- model. Mouse livers from 8 week old male
MDR2-/- mice were processed as previously described but using OptiprepTM as the density
gradient.
Cell numbers isolated using the modified protocol were greatly improved (figure 4.8)
with a 56 fold increase in the number of CD8+ lymphocytes isolated using OptiprepTM
(p=0.006). Based on these results I used OptiprepTM for all subsequent immune cell
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isolation from MDR2-/- mouse liver.
Figure 4.8 – OptiprepTM yields a greater number of immune cells from liver
digest then Lympholyte® in MDR2-/- mice. Mouse livers from male 8 week old
MDR2-/- mice were homogenised and immune cells separated using either OptiprepTM (n=4)
or Lympholyte® (n=5) as the density gradient. Immune cells were then stained and analysed
by flow cytometry. Cell numbers isolated using OptiprepTM were greater than when using
with the number of CD8+ lymphocytes isolated using OptiprepTM 56 times higher (p=0.006).
Values are normalised to liver weight and shown as cells per gramme of liver tissue. Points
represent individual mice, bars represent the median and lines represent the range. Statistical
analysis was performed using a Student’s t-test.
I next investigated liver immune cell infiltration at 7, 10 and 11 weeks in order to
determine the most beneficial time point for MSC therapy in the MDR2-/- model (figure
4.9).
Between 7 and 10 weeks there was a significant increase in CD8+ and CD19+ lymph-
ocytes with CD8+ cells falling significantly between 10 and 11 weeks back to a similar
level to that seen at 7 weeks of age. Between 10 and 11 weeks CD4+, CD19+ and NK1.1





Figure 4.9 – FACS analysis of MDR2-/- mouse livers demonstrating the immune
cell profile between 7 and 11 weeks of age. Liver lobes from MDR2-/- mice aged 7
(n=5), 10 (n=2) or 11 (n=6) weeks were mechanically homogenised and following washing
were passed over a density gradient using OptiprepTM. Cells were stained and analysed by
flow cytometry. All cells studied showed significant changes throughout the time course
studied and peak values of all immune cells were seen in mice aged 10 weeks. (a) CD4+
lymphocytes showed a non significant increase between 7 and 10 weeks but fell significantly
between 10 and 11 weeks. (b) CD8+ lymphocytes increased significantly between 7 and 10
weeks and following a significant reduction between 10 and 11 weeks returned below the
levels at 7 weeks. (c) CD19+ lymphocytes increased significantly between 7 and 10 weeks and
then decreased significantly between 10 and 11 weeks. (d) Total CD45+ cells demonstrated a
non significant increase between weeks 7 and 10 and then fell significantly between weeks 10
and 11. (e) NK1.1 numbers remained high between weeks 7 and 10 and then fell significantly
between weeks 10 and 11. Values are normalised to liver weight and shown as cells per
gramme of liver tissue. Points represent individual mice, bars represent the median and
lines represent the range. Statistical analysis was carried out using a one way ANOVA and
multiple comparison testing was undertaken.
The immune cell profile in the livers of MDR2-/- mice showed a peak immune cell
infiltration at week 10 with a subsequent fall by week 11, in keeping with the published
literature [98]. Levels of CD4+, CD45+ and NK1.1 cells were all high from 7 weeks peaking
at 10 weeks and falling by 11 weeks.
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4.2.3 In vivo efficacy of PαS MSC in the MDR2-/- model
Having demonstrated that serum markers of liver injury in the MDR2-/- model are high
between 8 and 10 weeks of age and infiltrating immune cells peak in mice aged 10 weeks
old I determined that treating mice aged 6-8 weeks with cell therapy followed by analysis
2 weeks later should allow enough time for cells to exert an anti-inflammatory effect at
the time of peak inflammatory liver injury.
In order to test the efficacy of PαS MSC in the MDR2-/- model I used MSC cultured in
standard media which were expanded to passage 4. This passage was chosen based on my
findings when testing their efficacy in vitro as well as previous experience with these cells
in other models of liver injury [245]. Doses of either 1x105 or 2x105 PαS MSC suspended
in PBS were tested using the intravenous route with control animals receiving PBS alone.
Male mice aged between 6 and 8 weeks were injected with PαS MSC and culled 2 weeks
later. Analysis of serum markers, liver infiltrating immune cells and immunohistochemistry
were performed.
4.2.3.1 Effects of PαS MSC on serum markers of liver injury in the MDR2-/-
model
Following treatment with PαS MSC mice were culled at 2 weeks and serum analysed for
markers of liver injury. Serum ALT showed a significant dose dependent reduction after
treatment with MSC (figure 4.10a). Treatment with 1x105 showed no difference when
compared with PBS treated controls (562 IU/L ± 87.3 vs 558.1 IU/L ± 119.5), however
treatment with 2x105 MSC led to a significant reduction in ALT when compared with
controls (325.7 IU/L ± 191.7 vs 562 IU/L ± 87.3, p=0.002). Serum ALP demonstrated a
similar pattern (figure 4.10b) with the control group and the group treated with 1x105
MSC showing similar values (1067 IU/L ± 319.1 vs 1007 IU/L ± 92.8) whereas the group
treated with 2x105 MSC showing a significant reduction in ALP (1067 IU/L ± 319.1 vs
635.1 IU/L ± 178.7, p=0.0055). Serum Bile acids did not show any significant changes
following treatment (figure 4.10c) with either 1x105 MSC (41.47 μmol/L ± 10.14 vs 42.93
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Figure 4.10 – PαS MSC significantly reduce ALT and ALP but not Bile acids in
MDR2-/- mice. MDR2-/- mice aged 6-8 weeks were given either 1x105 or 2x105 PαS MSC
via the tail vein and culled at 2 weeks. Serum ALT (a) showed a non-significant reduction
after treatment with 1x105 MSC compared with PBS treated controls (562 IU/L ± 87.3 vs
558.1 IU/L ± 119.5), however treatment with 2x105 MSC led to a significant reduction in ALT
(325.7 IU/L ± 191.7 vs 562 IU/L ± 87.3, p=0.002, n=38). Serum ALP (b) demonstrated a
similar pattern with the control group and the group treated with 1x105 MSC showing similar
values (1067 IU/L ± 319.1 vs 1007 IU/L ± 92.8) whereas the group treated with 2x105 MSC
showed a significant reduction in ALP (1067 IU/L ± 319.1 vs 635.1 IU/L ± 178.7, p=0.0055,
n=42). Serum Bile (c) acids did not show any significant changes following treatment with
either 1x105 MSC (41.47 μmol/L ± 10.14 vs 42.93 μmol/L ± 12.85) or 2x105 MSC (39.07
μmol/L ± 11.27 vs 42.93 μmol/L ± 12.85) when compared with controls (n=45). Points
represent individual mice, bars represent the median and lines represent the interquartile
range. Statistical analysis was carried out using a one way ANOVA.
133
4.2.3.2 Histological changes in MDR2-/- mouse livers when treated with PαS
MSC
Liver tissue from MDR2-/- mice treated with PαS MSC was removed, processed and
embedded in paraffin and then sectioned and stained. H & E staining was performed
in order to demonstrate the morphology of the liver (figure 4.11). There was almost no
morphological disruption seen in uninjured FVB control with few infiltrating immune cells.
Infiltrating immune cells were demonstrated showing a peri-portal (Zone I) distribution in




Figure 4.11 – Representative images of haematoxylin and eosin staining in
MDR2-/- mice treated with either PBS or PαS MSC at 6-8 weeks of age and
culled 2 weeks later. MDR2-/- mice aged 6-8 weeks were given either 1x105 or 2x105
PαS MSC via the tail vein and culled at 2 weeks and liver tissue was removed, processed
and sectioned. H & E staining was performed. Minimal morphological disruption was seen
in (a) uninjured FVB control with almost no infiltrating immune cells seen. Infiltrating
immune cells were demonstrated showing a peri-portal (Zone I) distribution in (b) PBS
treated controls, (c) mice treated with 1x105 PαS MSC IV and (d) mice treated with 2x105
PαS MSC IV. All images are generated from whole slide scans and are at 400x magnification.
Scale bars represent 100 μm.
Immunohistochemical antibody staining was undertaken to allow quantification of
the expression of the pan-leucocyte marker CD45. Slides were scanned using a Zeiss
AxioScanner providing a whole slide image and quantification of the amount of staining
was analysed and represented as a percentage total area. MDR2-/- control animals showed
a marginal increase in CD45 expression (figures 4.12, 4.13) when compared with wild
type FVB uninjured controls (2.198 ± 0.947 vs 1.90 ± 0.59). There was a no significant
difference in CD45 expression in mice treated with 1x105 PαS MSC (2.198 ± 0.947 vs
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2.289 ± 0.265), but a significant increase in CD45 expression when mice were treated with
2x105 MSC (2.198 ± 0.947 vs 3.432 ± 1.073, p=0.026).
Figure 4.12 – CD45 expression in the livers of MDR2-/- mice treated with either
PBS or PαS MSC at 6-8 weeks of age and culled 2 weeks later. MDR2-/- mice
aged between 6 and 8 weeks were treated with either 1x105 or 2x105 PαS MSC suspended
in PBS with control animals receiving PBS alone. Mice were culled 2 weeks later and liver
tissue was removed, processed and sectioned. Immunohistochemical staining was undertaken
using a chromogenic technique. MDR2-/- control animals demonstrated slightly higher CD45
expression when compared with wild type FVB uninjured controls (2.198 ± 0.947 vs 1.90 ±
0.59). There was a no significant difference in CD45 expression in mice treated with 1x105
PαS MSC when compared with controls (2.198 ± 0.947 vs 2.289 ± 0.265), but a significant
increase in CD45 expression when mice were treated with 2x105 MSC (2.198 ± 0.947 vs 3.432
± 1.073, p=0.026) n=33. Slides were captured using a Zeiss AxioScanner. Between 5 and 10
images were taken from each scan to cover the whole slide and quantification of each image
was performed using Image J software. Bars represent median values and lines represent the






Figure 4.13 – Representative images of CD45 staining in MDR2-/- mice treated
with either PBS or PαS MSC at 6-8 weeks of age and culled 2 weeks later.
MDR2-/- mice aged between 6 and 8 weeks were treated with either 1x105 or 2x105 PαS MSC
suspended in PBS with control animals receiving PBS alone. Mice were culled 2 weeks later
and liver tissue was removed, processed and sectioned. Immunohistochemical staining was
undertaken using a chromogenic technique. There were scattered CD45+ cells distributed
across all zones in the (a) uninjured FVB controls. Infiltrating CD45+ cells were demonstrated
showing a peri-portal (Zone I) distribution in (b) PBS treated controls, (c) mice treated with
1x105 PαS MSC IV and (d) mice treated with 2x105 PαS MSC IV. There was no staining
seen in the (e) isotype matched controls. All images are generated from whole slide scans
and are at 400x magnification. Scale bars represent 100 μm.
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I next sought to quantify the liver macrophage population using the murine antigen
F4/80. Staining was undertaken using an F4/80 antibody in order to delineate the hepatic
macrophage population (figures 4.14, 4.15). MDR2-/- control animals showed a significant
increase in F4/80 expression when compared to wild type FVB mice (4.257 ± 0.896 vs 2.537
± 0.514, p=0.0185). Mice treated with 1x105 PαS MSC showed a significant reduction in
F4/80 expression when compared with control animals (4.257 ± 0.896 vs 2.725 ± 0.46,
p=0.0011), as did those treated with 2x105 PαS MSC (4.257 ± 0.896 vs 2.322 ± 0.235,
p=0.0006).
Figure 4.14 – F4/80 expression in the livers of MDR2-/- mice treated with either
PBS or PαS MSC at 6-8 weeks of age and culled 2 weeks later. MDR2-/- mice aged
between 6 and 8 weeks were treated with either 1x105 or 2x105 PαS MSC suspended in PBS
with control animals receiving PBS alone. Mice were culled 2 weeks later. Immunohistochem-
ical staining was undertaken using a chromogenic technique. Staining was undertaken using
an F4/80 antibody in order to delineate the hepatic macrophage population. MDR2-/- control
animals showed a significant increase in F4/80 expression when compared to wild type FVB
mice (4.257 ± 0.896 vs 2.537 ± 0.514, p=0.0185). Mice treated with 1x105 PαS MSC showed a
significant reduction in F4/80 expression when compared with control animals (4.257 ± 0.896
vs 2.725 ± 0.46, p=0.0011), as did those treated with 2x105 PαS MSC (4.257 ± 0.896 vs 2.322
± 0.235, p=0.0006) n=31. Slides were captured using a Zeiss AxioScanner. Between 5 and 10
images were taken from each scan to cover the whole slide and quantification of each image
was performed using Image J software. Bars represent median values and lines represent the
range. Statistical analysis was carried out using a one way ANOVA and multiple comparison





Figure 4.15 – Representative images of F4/80 staining in MDR2-/- mice treated
with either PBS or PαS MSC at 6-8 weeks of age and culled 2 weeks later.
MDR2-/- mice aged between 6 and 8 weeks were treated with either 1x105 or 2x105 PαS
MSC suspended in PBS with control animals receiving PBS alone. Mice were culled 2
weeks later and liver tissue was removed, processed and sectioned. Immunohistochemical
staining was undertaken using a chromogenic technique. There were scattered F4/80 cells
distributed across all zones in the (a) uninjured FVB controls. Some infiltrating F4/80 cells
were demonstrated showing a peri-portal (Zone I) distribution on a background of scattered
F4/80 cells across all zones were seen in (b) PBS treated controls, (c) mice treated with
1x105 PαS MSC IV and (d) mice treated with 2x105 PαS MSC IV. There was no staining
seen in the (e) isotype matched controls. All images are generated from whole slide scans
and are at 400x magnification. Scale bars represent 100 μm.
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In order to assess biliary proliferation I next sought to assess the distribution of CK19
expression. Antibody staining for CK19 was undertaken in selected sections in order to
generate representative images of CK19 distribution (figure 4.16). Quantification was not






Figure 4.16 – Representative images of CK19 staining in MDR2-/- mice treated
with either PBS or PαS MSC at 6-8 weeks of age and culled 2 weeks later.
MDR2-/- mice aged between 6 and 8 weeks were treated with either 1x105 or 2x105 PαS MSC
suspended in PBS with control animals receiving PBS alone. Mice were culled 2 weeks later
and liver tissue was removed, processed and sectioned. Immunohistochemical staining was
undertaken using a chromogenic technique. CK19 expression was demonstrated around the
bile ducts in (a) uninjured FVB control, (b) PBS treated control, (c) mice treated with 1x105
PαS MSC IV and (d) mice treated with 2x105 PαS MSC IV. No staining was demonstrated
in (e) isotype matched control. All images are generated from whole slide scans and are at
400x magnification. Scale bars represent 100 μm.
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I next undertook western blotting for quantification of CK19 expression.
4.2.3.3 Effects on ductular proliferation in MDR2-/- mouse livers when treated
with PαS MSC
In MDR2-/- knockout mice cytotoxic biliary injury leads to ductular proliferation. CK19
is a cytoskeletal protein present in biliary cells and is therefore a marker of bile duct
proliferation and hence level of injury. CK19 quantification by western blotting is used in
the literature to assess for the extent of injury in the MDR2-/- model [100].
Following treatment with PαS MSC mice were culled at 2 weeks and liver lobes
removed and homogenised. Protein lysis and quantification was undertaken and then
western blotting was performed using the lysed protein. A CK17/19 antibody was used
for detection of CK19 and α-actinin was used as a loading control.
CK19 expression showed a significant increase between uninjured FVB mice and PBS
treated MDR2-/- mice (p=0.018). There was also a significant dose dependent reduction
in CK19 expression following treatment with PαS MSC (p=0.0185, n=40, figure 4.17).
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(a) (b)
Figure 4.17 – CK19 quantification by western blotting in MDR2-/- mice treated
with PαS MSC. MDR2-/- mice aged 6-8 weeks were treated with either 1x105 or 2x105
PαS MSC and then culled 2 weeks later. Liver lobes were removed and homogenised. Protein
lysis and quantification was undertaken and then western blotting was performed using the
lysed protein. A CK17/19 antibody was used for detection of CK19 and α-actinin was used
as a loading control. Expression levels were normalised to loading controls and are expressed
as fold change. (a) CK19 expression showed a significant increase between uninjured FVB
mice and PBS treated MDR2-/- mice (p=0.018). There was also a significant dose dependent
reduction in CK19 expression following treatment with PαS MSC (p=0.0185, n=40). (b)
Representative western blots for CK19 expression are shown with loading controls below.
Bars represent median values and lines represent the range. Statistical analysis was carried
out using a Mann-Whitney U test and Kruskal-Wallis analysis due to the unequal variance
and multiple comparison testing was undertaken.
I next sought to quantify the immune cell infiltration in MDR2-/- mouse livers by flow
cytometry.
4.2.3.4 Characterisation of immune cell populations in MDR2-/- micee fol-
lowing treatment with PαS MSC
In order to quantify the infiltrating immune cells in the livers of MDR2-/- mice I undertook
flow cytometric analysis. Two weeks after treatment with PαS MSC liver lobes were
removed, weighed and processed to allow flow cytometry to be performed. Single cell
suspensions were stained with relevant antibodies including a live/dead marker. Cell
counts were normalised to liver weight and presented as cells per gramme.
There was no difference in infiltrating CD45+ cells (figure 4.18) between control animals,
mice treated with 1x105 PαS MSC and mice treated with 2x105 PαS MSC (213224 cells/g
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± 76453 vs 204766 cells/g ± 105192 vs 219788 cells/g ± 101257). This pattern was also
true for CD4+ (69071 cells/g ± 44144 vs 34508 cells/g ± 14384 vs 70588 cells/g ± 42034),
CD8+ (23597 cells/g ± 16426 vs 9790 cells/g ± 5268 vs 27693 cells/g ± 16303), CD19+
(50651 cells/g ± 22227 vs 36774 cells/g ± 8540 vs 45149 cells/g ± 29662) and NK1.1+
(8750 cells/g ± 7612 vs 11432 cells/g ± 5203 vs 9001cells/g ± 7078) cells. There was
however a significant increase in F4/80+ cells in mice treated with 1x105 PαS MSC when
compared with controls (16462 cells/g ± 4005 vs 30571 cells/g ± 21086, p=0.0355) but
not when mice were treated with 2x105 PαS MSC (16462 cells/g ± 4005 vs 12712 cells/g
± 4626). Myeloid Derived Suppressor Cells (MDSC) delineated by CD11b and Gr1 also
followed this pattern with an increase following treatment with 1x105 PαS MSC (13210
cells/g ± 8300 vs 30585 cells/g ± 18476, p=0.0217) but not when mice were treated with





Figure 4.18 – Flow cytometric analysis of immune cell infiltrates in the livers of
MDR2-/- mice treated with PαS MSC. Two weeks following treatment with PαS MSC
liver lobes from MDR2-/- mice were removed, weighed and processed to allow flow cytometry
to be performed. Single cell suspensions were stained with relevant antibodies including a
live/dead marker. Cell counts were normalised to liver weight and presented as cells per
gramme. There was no difference in infiltrating (a) CD45+ (213224 cells/g ± 76453 vs 204766
cells/g ± 105192 vs 219788 cells/g ± 101257), (b) CD4+ (69071 cells/g ± 44144 vs 34508
cells/g ± 14384 vs 70588 cells/g ± 42034) (c) CD8+ (23597 cells/g ± 16426 vs 9790 cells/g
± 5268 vs 27693 cells/g ± 16303) (d) CD19+ (50651 cells/g ± 22227 vs 36774 cells/g ±
8540 vs 45149 cells/g ± 29662) (e) NK1.1+ (8750 cells/g ± 7612 vs 11432 cells/g ± 5203 vs
9001cells/g ± 7078) cells between control animals, mice treated with 1x105 PαS MSC and
mice treated with 2x105 PαS MSC. The was a significant increase in (f) F4/80 (16462 cells/g
± 4005 vs 30571 cells/g ± 21086, p=0.0355) and (g) CD11b+Gr1+ (13210 cells/g ± 8300
vs 30585 cells/g ± 18476, p=0.0217) cells treated with 1x105 PαS MSC. Points represent
individual mice and bars represent the median value. Statistical analysis was carried out
using a one way ANOVA and multiple comparison testing was undertaken. Comparison
between groups was undertaken using Student’s t-test.
I next decided to examine a subset of regulatory immune cells in order to determine if
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the reduction in ALT seen in treated mice was related to a regulatory effect rather than a
change in absolute numbers of infiltrating immune cells. Mice aged 6-8 weeks old were
treated with 2x105 PαS MSC and liver lobes removed after 2 weeks. Antibody staining for
regulatory cells was undertaken including intra-cytoplasmic staining for FoxP3.
Mice treated with PαS MSC (figure 4.19) showed no significant differences in their
defensive macrophage (F4/80+CD11b+Ly6C+) and regulatory macrophage (F4/80-Ly6C-)
populations (7571 cells/g ± 1178 vs 11867 cells/g ± 3726 and 176285 cells/g ± 85463
vs 187871 cells/g ± 89156). There was however a significant increase in the number
of restorative macrophages (F4/80-CD11b+Ly6C+) when compared with controls (7630
cells/g ± 3758 vs 12597 cells/g ± 1848). There was no change in CD4+CD25+FoxP3+
Tregs (5879 cells/g ± 764 vs 7870 cells/g ± 2856) or CD8+CD25+FoxP3+ Tregs (3324




Figure 4.19 – Flow cytometric analysis of regulatory immune cell infiltrates in
the livers of MDR2-/- mice treated with PαS MSC. MDR2-/- mice aged 6-8 weeks old
were treated with 2x105 PαS MSC and liver lobes removed after 2 weeks. Antibody staining for
regulatory cells was undertaken. Mice treated with PαS MSC showed no significant differences
in their (a) defensive macrophage (F4/80+CD11b+Ly6C+) and (b) regulatory macrophage
(F4/80-Ly6C-) populations (7571 cells/g ± 1178 vs 11867 cells/g ± 3726 and 176285 cells/g
± 85463 vs 187871 cells/g ± 89156). There was however a significant increase in the number
of (c) restorative macrophages (F4/80-CD11b+Ly6C+) when compared with controls (7630
cells/g ± 3758 vs 12597 cells/g ± 1848). There was no change in (d) CD4+CD25+FoxP3+
Tregs (5879 cells/g ± 764 vs 7870 cells/g ± 2856) or (e) CD8+CD25+FoxP3+ Tregs (3324
cells/g ± 1920 vs 3894 cells/g ± 2141). Points represent individual mice and bars represent
the median value. Statistical analysis was carried out using a Student’s t-test.
I also analysed whole blood from MDR2-/- mice to assess the circulating immune cell
populations. Red cells were lysed from whole blood and the remaining immune cells
stained and analysed. Results are presented as cells per ml of whole blood.
A similar pattern to that in the liver was seen in whole blood with a significant increase
in restorative macrophages (44105 cells/ml ± 158906 vs 91911 cells/ml ± 10841, p=0.0036).
There was no difference in circulating defensive macrophages (3343 cells/ml ± 7015 vs 3314
cells/ml ± 818), regulatory macrophages (675527 cells/ml ± 444164 vs 876057 cells/ml ±
436793), CD4+ Tregs (8818 cells/ml ± 6617 vs 10385 cells/ml ± 3808) or CD8+ Tregs




Figure 4.20 – Flow cytometric analysis of circulating regulatory immune cells in
MDR2-/- mice treated with PαS MSC. MDR2-/- mice aged 6-8 weeks old were treated
with 2x105 PαS MSC and culled after 2 weeks. Red cells were lysed from whole blood and
the remaining immune cells stained and analysed. Results are presented as cells per ml of
whole blood. There was no difference in circulating (a) defensive macrophages (3343 cells/ml
± 7015 vs 3314 cells/ml ± 818) or (b) regulatory macrophages (675527 cells/ml ± 444164 vs
876057 cells/ml ± 436793). There was a significant increase in (c) restorative macrophages
(44105 cells/ml ± 158906 vs 91911 cells/ml ± 10841, p=0.0036). There was also no difference
in (d) CD4+ Tregs (8818 cells/ml ± 6617 vs 10385 cells/ml ± 3808) or (e) CD8+ Tregs (2292
cells/ml ± 822 vs 3090 cells/ml ± 781). Points represent individual mice and bars represent
the median value. Statistical analysis was carried out using a Student’s t-test.
I also analysed the CD4+: CD8+ ratio in both liver tissue and serum by looking at
the ratio of cells analysed by flow cytometry (figure 4.21). In the liver tissue the CD4+ :
CD8+ ratio showed a significant reduction (p=0.023) in the mice treated with 2x105 PαS
MSC, whereas the serum ratio was not significantly different (P=0.17).
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(a) (b)
Figure 4.21 – The CD4/CD8 ratio assessed by flow cytometry in the livers and
whole blood of MDR2-/- mice aged 6-8 weeks old were treated with PαS MSC
and culled after 2 weeks. Liver lobes removed and antibody staining was undertaken.
Red cells were lysed from whole blood and the remaining immune cells stained and analysed.
(a) In the liver tissue the CD4/CD8 ratio showed a significant reduction (p=0.023) in the
mice treated with 2x105 PαS MSC. (b) The whole blood CD4/CD8 ratio was not significantly
different (P=0.17) between treated and control mice. Points represent individual mice and
bars represent the median value. Statistical analysis was carried out using a Student’s t-test.
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4.3 Discussion
The MDR2-/- model of liver injury has been extensively studied, however a lot of the work
done uses this model as either a model of PSC or a model of hepatocellular carcinoma,
as mice develop an inflammatory type hepatocellular carcinoma by 12 months of age
[97, 276]. In this chapter I used the MDR2-/- model for its phenotypic similarities to biliary
injuries seen more commonly after a DCD liver transplantation. One key undertaking in
this chapter was to first characterise the injury pattern in the first 14 weeks in order to
determine the time point most representative of DCD liver injury to enable translatable
testing of MSC therapy.
4.3.1 Characterisation of the injury pattern MDR2-/- mouse model
Originally described by Smit [95] the disruption in biliary transport due to a modified
P-glycoprotein in the MDR2-/- model was shown to cause portal expansion on histological
examination and immune cell infiltration. There was also an increase in circulating bile
acids. Work by Fickert et al expanded on the description of this model and demonstrated
that it could also be used as a model of liver fibrosis and PSC [277].
4.3.1.1 Classical markers of injury in the MDR2-/- mouse model
Analysis of the MDR2-/- model in the literature has focussed more on markers of hepatic
fibrosis such as hydroxyproline levels and picosirius red staining. When immune cells have
been examined it is usually by immunohistochemistry and limited to CD4+and CD8+ cells.
Fickert [98, 100] used ALT, ALP and serum bile acids as markers of liver injury in the
MDR2-/- model and demonstrated that concentrations of ALT and ALP peak at 8 weeks
of age and remain at a similar level for a further 4 weeks, with serum bile acids peaking at
2 weeks but remaining moderately raised at 8 weeks. I demonstrated a different pattern of
serum markers with levels of ALT continuing to rise until 11 weeks and remaining high
up to 14 weeks. ALT in this study at 8 weeks was 432.0 IU/ml ± 207.6, in keeping with
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the 406 IU/ml ± 68 described by Fickert et al, however this continued to climb to a peak
of 801 IU/ml ± 142.9 at 11 weeks. This difference could be explained by the paucity of
published data looking at ALT beyond 8 weeks as when used as a model of fibrosis or
hepatocellular carcinoma ALT is a less useful marker of disease progression. ALP followed
the same pattern described in the published literature with a peak at 8-9 weeks. Serum
bile acids also showed a different pattern demonstrating a rise between 7 and 8 weeks with
a peak level at 11 weeks. In this study I did not look at time points earlier than 7 weeks,
whereas Fickert et al had compared 2 and 4 week old mice. The levels demonstrated at 8
weeks were in keeping with those published.
Analysis of the morphological changes in liver architecture were reassuring in this
study and demonstrated the same pattern of injury to that in the original description of
the MDR2-/- model [95] with portal expansion and infiltration progressing as the mice
aged. Immunohistochemical analysis of CD45 expression showed a significant reduction
in expression from 7 weeks of age, with F4/80 expression showing no significant changes,
again in keeping with published findings that immune cell infiltration is greater around 8
weeks.
Another marker utilised in the literature to demonstrate biliary proliferation is CK19.
This intermediate filament forming protein is found in biliary endothelium and is increased
in the MDR2-/- model. I demonstrated a significant increase in CK19 in the injured
MDR2-/- mice when compared with wild type FVB mice, again in keeping with the
published literature, however over the time course studied there was no significant difference
in the levels observed. It is not surprising that the pattern of CK19 injury follows that
of serum ALP and serum bile acids as these are all markers of biliary tract injury and
regeneration.
4.3.1.2 Liver immune cell profile in the MDR2-/- model
Whilst histological analysis has been commonly used in the MDR2-/- model there is little
published data using flow cytometry to assess total infiltrating immune cells. Arguably
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flow cytometry allows for more accurate quantification of immune cells in mouse livers
than immunohistochemistry alone. In this study I modified the usual technique carried
out in our laboratory as after initial attempts using Lympholyte® as the density gradient
to extract immune cells led to a considerably lower yield than expected. By changing to
OptiprepTM and reducing the total number of centrifugation steps I was able to reliably
isolate significantly more immune cells per gramme of liver tissue. Whilst I have been
successful in isolating immune cells from the livers of injured mice in other models of liver
injury such as the OVA-Bil model it is possible that the nature of the MDR2-/- model,
with fibrosis present from 4 weeks, does not lend itself to the use of Lympholyte®. As
Lympholyte® is patented it is unclear as to what is contained in the gradient formulation
and so further hypothesis testing is difficult. A further advantage of using OptiprepTM
was the ability to isolate other immune cells such as granulocytes.
I examined the levels of lymphocyte (CD4+, CD8+ and CD19+) as well as natural
killer cells (NK1.1+) in the livers of MDR2-/- mice between 7 and 11 weeks of age. When
analysing the immune cell infiltration into the livers of MDR2-/- mice over time all cells
examined showed a peak at 10 weeks and began to fall again at 11 weeks.
4.3.2 PαS MSC reduce markers of injury in the MDR2-/- model
I decided on a systemic route of administration for to the PαS MSC in order test their
efficacy in the MDR2-/- model based on previous experience and success with this route
of administration in other mouse models [245]. Whilst other routes of administration
have been published and are feasible intravenous administration is commonly used in the
clinical environment and would be easily translatable.
4.3.2.1 Timing and dose of PαS MSC
Timing of MSC therapy is important, but also challenging. It is likely that after systemic
administration MSC are trapped in capillary beds, in particular those in the pulmonary
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circulation. It has been demonstrated that in the first 24 hours systemically administered
MSC are trapped in the pulmonary capillary bed [278], however after 24 hours MSC
appear to redistribute to other organs such as the liver and spleen [279]. This initial ’lung
trap’ is likely due to the size of cultured MSC being greater than the size of the pulmonary
capillaries. Interestingly MSC cultured from humans, mice or other animals appear to be
similar in size [280, 281]. It has also been demonstrated that MSC leave the circulation
after 24 hours, suggesting that they exert their immunomodulatory effects by exerting a
lasting effect on other intermediary cells [279], as the effects of systemic MSC therapy are
seen long after this time period.
Given the profile of injury demonstrated in the MDR2-/- model in this chapter it is
clear that the peak immune cell infiltration, and therefore the peak immune mediated
injury occurs between 7 and 11 weeks of age, with markers of hepatocyte death greatest at
11 weeks. Based on these findings I decided to treat mice with PαS MSC between 6 and
8 weeks of age [167]. This would mean that cell therapy would be given as the immune
mediated injury occurs. By analysing these mice 14 days later I would then be assessing
injury at or close to the peak injury. Whilst it is likely that systemically administered
MSC would have been cleared from the mouse, the lasting effects seen in other studies
would likely still be present after the first 24 hours based on previous work that we have
undertaken [237, 245], whilst giving enough time for those effects to be reflected in markers
of liver injury.
Dose of MSC is also an important consideration and a wide range of doses have been
employed in the literature with doses in human studies ranging from 0.5x106 cells/kg to
8.45x108 cells/kg [1]. It is also unclear if doses between species and even MSC isolated by
different techniques are comparable, and given the relative differences in purity of cells
achieved by different techniques it is reasonable to conclude that doses are not equivalent.
With this in mind the only data to guide doses of PαS MSC available is that generated in
our lab [237, 245]. Systemic administration of doses over 5x105 leads to mortality due to
embolic phenomena, and even at doses of 5x105 occasional problems have been seen. I
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decided to test doses of 1x105 and 2x105 rather than attempting to tailor dose to weight
as this was logistically challenging and almost impossible to perform with any degree
of accuracy. This equates to a dose of 4 ± 0.7x106 cells/kg and 8 ± 1.4x106 cells/kg
respectively, doses in the middle and at the top of the dose ranges in human studies.
4.3.2.2 Reduction in markers of liver injury with PαS MSC therapy
Treatment of MDR2-/- mice with PαS MSC led to a significant reduction in ALT and
ALP when a high dose was administered via the systemic route. The same was not seen
in the lower dose group with no significant changes. As ALT was the primary outcome
measure for this study it was encouraging to see a significant reduction following PαS MSC
therapy. ALT is a predominantly intracellular enzyme whose concentration is high in the
cytoplasm of hepatocytes so an increase in ALT is relatively specific for hepatocyte injury
therefore the reduction seen in these experiments is indicative of a decrease in hepatocyte
death. Since the half-life of ALT is 47 hours this reduction implies a prolonged action
of PαS MSC therapy as the MDR2-/- model is a model that continues to develop injury
through the study period as demonstrated. ALP is a transport enzyme with the ability
to transport metabolites across the cell membrane. ALP is found in a large number of
cell types but the greatest concentrations are found in liver and bone. By using mice
with an FVB background problems seen with low hepatic production of ALP are not seen
[274] and allow interpretation in the context of liver injury. The reduction in ALP in
these experiments is suggestive of reduced biliary injury as ALP is found in the biliary
endothelium and released when this is damaged. ALP has a longer half life than ALT and
tends to remain raised as ALT resolves implying that the reduction in both these markers
is due to a sustained effect of PαS MSC therapy. Serum bile acids were not reduced
following PαS MSC therapy. Whilst other researchers have used bile acids as a marker of
injury in the MDR2-/- model this may be inappropriate when assessing immune mediated
damage. Excess bile acids occur in the MDR2-/- model due to a mutation of a biliary
transporter and leads to immune system activation. Suppressing the immune system
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should therefore have no effect on serum bile acid concentration. Bile acids are involved in
normal signalling pathways for cholesterol metabolism at physiological concentrations by
activating the intestinal farnesoid X receptor and intestinal fibroblast growth factor 15
which culminates in the inhibition of CYP7A1 [282]. However at pathological levels bile
acids have been shown to drive inflammation and recruit neutrophils into the liver [283].
Whilst reduction in ALT and ALP are an important marker of reduced liver injury the
ongoing stimulus in this model is still present and confirmed by the lack of a change in
bile acid levels.
The cytokeratin CK19 has been used as a marker of biliary proliferation and hence
injury in the MDR2-/- model [100] with lower levels representing less injury. In this study
there was a significant reduction in CK19 levels with PαS MSC therapy. As a marker of
biliary injury the levels of CK19 do not reflect the damage seen in other parts of the liver.
I have established that CK19 is localised to the biliary epithelium through chromogenic
immunohistochemistry and as such it is the most sensitive marker used for isolated biliary
injury. However I have already demonstrated that injury in the MDR2-/- model is not
confined to the biliary tree and therefore PαS MSC therapy may reduce immune mediated
parenchymal and biliary injury in this model.
4.3.2.3 Changes in infiltrating immune cells in MDR2-/- mouse livers
In this study I assessed levels of immune cells in the livers of MDR2-/- mice using traditional
techniques published in the MDR2-/- literature (immunohistochemistry for CD45 and
F4/80 expression) as well as flow cytometric analysis of liver tissue. Analysis of CD45
expression showed a significant increase when assessed by immunohistochemistry which was
not the case when flow cytometry was used. Whilst an unchanged CD45 expression level
can be explained by changes in the ratio of cell types or their function rather than absolute
numbers as CD45 is a pan-leucocyte marker, an increase in CD45 expression is not in
keeping with the earlier findings that PαS MSC therapy reduces liver injury. The changes
in CD45 expression assessed by flow cytometry seem to only be present when therapy
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is undertaken with 1x105 PαS MSC and not when mice were treated with 2x105 PαS
MSC. Flow cytometric analysis demonstrated a significant increase in F4/80 expression
with 1x105 PαS MSC whereas analysis of immunohistochemistry however demonstrated
a significant reduction in F4/80 expression. Neutrophil count was also increased in
mice treated with 1x105 PαS MSC. The discrepancies found between the flow cytometric
analysis and the immunohistochemical analysis are difficult to explain by a biologically
plausible mechanism. In theory flow cytometry should be a more accurate technique for
quantifying immune cells, however in this study there were difficulties with optimising
the technique to isolate immune cells from MDR2-/- livers. The technique for isolating
immune cells was also very time consuming and as such proved logistically challenging.
This meant that n numbers for flow cytometry were considerably lower than those for
immunohistochemistry (n=10-20 vs n=33). It is possible that there is a threshold effect for
PαS MSC whereby too few cells can lead to a different effect than the correct treatment
dose. Indeed mesenchymal precursor cells, a subset of MSC have been shown to increase
myocardial remodelling at lower concentrations when compared with higher concentrations
or control [284]. This may explain the increase in neutrophil and macrophage numbers
in the lower dose group, however it does not explain the discrepancy between the flow
cytometric and immunohistochemical analysis of F4/80 and CD45 expression.
It is possible that the beneficial effects of PαS MSC cannot be described in terms of
immune cell numbers as MSC have been shown to alter function as well as proliferation.
A change of lymphocyte phenotype has been described in the literature with MSC driving
CD4+ lymphocytes into an anti-inflammatory state [163]. Interestingly the CD4/CD8
ratio significantly decreased following treatment with PαS MSC. The CD4/CD8 ratio has
primarily been used in patients with HIV infection as in the chronic phase it gives a better
indication of disease status than CD4+ cell count alone, and in the context of treated
HIV a low count is predictive of all cause mortality [285]. The CD4/CD8 ratio has also
been suggested as a prognostic factor in fibrotic liver disease secondary to hepatitis C
virus infection with a low level being associated with a greater degree of fibrosis [286].
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Whilst viral illness appears to reduce the CD4/CD8 ratio, primarily due to a reduction in
CD4 count and and increase in CD8 count, in this study the CD4/CD8 ratio never fell
below the usual accepted threshold level of 1.5. Despite this being a relative reduction it
potentially highlights a move towards a regulatory phenotype and away from a cytotoxic
phenotype which supports the hypothesis that PαS MSC reduce injury by changing the
function, rather than absolute numbers of immune cells. Further work would need to be
done to validate the CD4/CD8 ratio in the context of non-viral liver disease.
The analysis of regulatory immune cells in a subset of experiments showed an increase
in both infiltrating and circulating restorative macrophages (F4/80-CD11b+Ly6C+). This
finding may support the immunohistochemical analysis that F4/80 cells are reduced in the
treated groups as restorative macrophages do not express F4/80 and so a global reduction
in expression may be seen if more F4/80+ monocytes are converted into F4/80- restorative
macrophages. In acute liver injury circulating pro-inflammatory monocytes infiltrate
the liver and eventually mature into a restorative phenotype. These pro-inflammatory
monocytes release inflammatory cytokines, whereas the restorative macrophages have
a positive effect on recovery from injury and this change in phenotype of monocyte
populations could explain the reduction in markers of liver injury following PαS MSC
therapy. In a previous chapter I have demonstrated that PαS MSC exposed to an
inflammatory environment greatly increase their secretion of Il-10, a cytokine which has
anti-inflammatory properties and has been shown to support the generation of restorative
macrophages [263]. In models of paracetamol induced liver injury depletion of Ly6C+
monocytes leads to a worse injury phenotype [287]. The increase in infiltrating neutrophils
seen in the lower dose group, whilst seemingly inconsequential in terms of markers of liver
injury, may represent a marker of the change in balance of infiltrating and circulating
monocytes as infiltrating Ly6C+ monocytes have been shown to regulate neutrophil
recruitment to injured liver [287]. The balance of pro and anti-inflammatory monocyte
populations may be dependent on the number of PαS MSC present. Further work would




In this chapter I demonstrated that the MDR2-/- model in our institution is a viable
and reproducible model of immune cell mediated liver injury. The model shows the
same serological and histological pattern of injury to those published, however I have
examined markers of hepatocyte injury and immune cell infiltration over a longer time
period than usually published. This has enabled me to confirm that the peak injury period
for hepatocytes and biliary cells is between 7 and 11 weeks. I have also optimised the
isolation of immune cells from MDR2-/- mouse livers and used flow cytometry to quantify
the infiltrating immune cell populations, demonstrating a peak immune cell infiltration at
10 weeks which rapidly falls by 11 weeks.
Treatment of MDR2-/- mice with systemically administered PαS MSC led to a significant
reduction in ALT and ALP with bile acids remaining unchanged and CK19 expression was
significantly reduced in the treated mice when assessed by western blotting. The immune
cell profile in PαS MSC treated mice was difficult to illicit with differences found between
immunohistochemical and flow cytometric analysis of these cells. It is likely that global
F4/80 expression is significantly reduced, whereas the number of restorative macrophages
found in the liver and the serum are significantly increased. Taken together these findings
suggest a role for MSC therapy in cholestatic immune mediated liver injury.
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CHAPTER 5
THE DISTRIBUTION AND REMOTE ACTION OF
PαS MSC
5.1 Chapter introduction and aims
I have demonstrated the isolation and culture of PαS MSC from murine bone marrow, as well
as the ability of PαS MSC to develop an immunomodulatory phenotype followed exposure
to a pro-inflammatory micro-environment. I have also demonstrated that intravenous
administration of PαS MSC in the MDR2-/- model of liver injury leads to a reduction
in markers of liver injury. In this chapter I aim to examine the distribution of PαS
MSC administered via the intravenous route and to investigate the ability of PαS MSC
administered by the subcutaneous route to exert remote immunomodulatory effects.
5.1.1 Distribution of parenterally administered mesenchymal stem
cells
There have been varying routes of administration tested when using MSC as a cell therapy.
Due to its clear advantage as a translatable route of administration intravenous infusion is
a commonly studied route. Bio-distribution of MSC following intravenous infusion is an
important consideration both due to its implications when studying mechanism of action,
but also as it is a requirement to demonstrate bio-distribution when seeking approval for
clinical trials.
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Human MSC have been demonstrated to become trapped in the lungs after systemic
administration in mouse models [288], with less than 0.1% of cells found in other organs
at 48 hours. Tracking MSC in this study was limited by its use of PCR methods and
so the resolution was limited to 100 cells. Studies have been undertaken on systemically
administered murine MSC and have again demonstrated trapping in the lungs at 24 hours
[278]. This study demonstrated that in cardiac injury more cells migrate to the heart, but
the majority are still trapped in the lungs. MSC levels in other organs remained low. It has
also been demonstrated that murine MSC are rapidly eliminated from mice after systemic
administration with the majority of cells disappearing after 24 hours [279]. However when
administered to immunocompromised mice MSC appear to persist for a number of weeks
[289], although different imaging techniques have been used in all of these studies and
different types of MSC have been tested and this may account for the differences seen.
Whilst a variety of techniques have been used to study the bio-distribution of systemically
administered MSC the resolution and quantification techniques are limited. As yet no
research exists on the bio-distribution of systemically administered PαS MSC.
5.1.2 Remote effects of mesenchymal stem cells
MSC as a therapy have been studied in a number of disease states due to their ability to
exert their effects on a broad range of immune cells. Whilst a large number of mechanistic
studies have been undertaken, due to the broad range of effects it is not clear whether
MSC need to be located in the area in which they are to exert their effect or whether they
are able to communicate with circulating immune cells and exert their effects through
an intermediary cell type. In models of cardiac injury human MSC have been shown
to become trapped in the lungs after systemic infusion with in the first 24 hours and
exert their effects remotely [288]. It has been demonstrated that murine bone marrow
derived MSC can exert their effects via a remote action in a model of graft versus host
disease [155], and it has been suggested that subcutaneous injection either with or without
encapsulation in a carrier such as alginate may improve the ability of MSC to suppress
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immune mediated injury. Study into different sites of intravascular administration in rat
models of acute liver failure have demonstrated increased numbers of MSC present in the
liver when injection is performed by the hepatic artery, however there was no difference
in outcome suggesting that MSC do not need to be at the site of injury to exert their
effects [290]. So far there have been limited numbers of studies demonstrating remote
effects of MSC when administered by the subcutaneous route and the studies that have
been performed seem to be limited to systemic disease such as graft versus host disease.
There have been no studies looking at the the remote effects of PαS MSC or subcutaneous
administration of these cells.
5.1.3 Specific chapter aims
The previous findings have demonstrated that PαS MSC given systemically can lead to a
reduction in liver injury in the MDR2-/- model. The aims of this chapter are to establish
a system to track systemically administered PαS MSC and to test the ability of PαS MSC
to exert immunomodulatory effects remotely by subcutaneous injection. The specific aims
of this chapter were:
1. To establish and optimise a high resolution method of tracking systemically admin-
istered PαS MSC in mice
2. To characterise the distribution of systemically administered PαS MSC in the
MDR2-/- model over time




5.2.1 In vivo tracking of systemically administered PαS MSC
Whilst I have demonstrated that systemically administered PαS MSC can decrease markers
of liver injury in the MDR2-/- model it is not clear if these cells need to be located in the
liver in order to exert their effects. In order to track systemically administered PαS MSC
I decided to use a novel block face cryoimaging system which enables the generation of
whole mouse images at microscopic resolution [291, 292].
5.2.1.1 The effects of QDot605 staining on PαS MSC
In order to highlight PαS MSC during processing cells were labelled with QDot605 prior to
injection into MDR2-/- mice. I first set out to ensure that QDot605 would adequately label
PαS MSC and to assess the effect that labelling may have on cell survival.
PαS MSC were culture expanded to passage 4 and then stained with QDot605 as well as
a live/dead marker. As quantum dots are an intra-cytoplasmic stain and rely on a carrier
to cross the cell membrane, and live/dead staining works on the principle of membrane
disruption during cell death to allow positive staining in dead cells, I tested live/dead
staining alone and in conjunction with QDot605 to test if there was any effect on the
live/dead stain. There appeared to be no difference between any of the groups with a
greater than 95% viability meaning that QDot605 did not appear to give false positive
results when assessing viability using an intra-cytoplasmic live/dead marker, regardless
of whether cells were first stained with QDot605 or the live/dead marker (figure 5.1a). I
then proceeded to look at the viability of the cells stained with QDot605 and in particular
ensure dead cells would stain for QDot605 and a live/dead marker. Four groups of 2x105
PαS MSC were stained with QDot605 and then a live/dead marker. Overall viability of
QDot605 stained cells was 89.57% ± 10.42 (figure 5.1b). As the percentage of dead cells
was low in this series of experiments I decided to confirm that it was possible to accurately
identify dead cells using a live/dead marker when staining with QDot605. I induced cell
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death by heating 2x105 PαS MSC in a water bath at 40°C for 30 minutes. I then mixed
these cells with fresh, live cells and followed the previously described staining protocols.
Cell viability was 66% with 95% of live cells and 92% of dead cells staining positive for
QDot605(figure 5.1c). As my previous analysis of the effects of PαS MSC was carried out
over a two week time course I next sought to assess the extent of QDot staining over
time. In order to do so I carried out the staining protocol as previously with 5x105 cells
stained and analysed immediately and 5x105 cells plated onto a T75 culture flask without
the addition of a live/dead stain and cultured for 7 days. At day 7 cells were removed
and stained with a live/dead marker and analysed. There was a small reduction in the
percentage of live QDot positive cells from 98% to 92% but I deemed this an acceptable




Figure 5.1 – QDot605 staining of PαS MSC demonstrates no effect on viability
and a small reduction in intensity over a 7 day period. PαS MSC were cultured
to passage 4 and then stained with a live/dead marker with some also being stained with
QDot605. (a) There was no effect on viability or QDot staining when cells were stained with
QDot605 first or the live/dead marker when compared with cells only stained with a live/dead
marker (n=3). (b) Average viability of QDot605 stained cells was high at 89.57% ± 10.42
(n=4). (c) Following induced cell death using a water bath set at 60°C for 30 minutes an
equal mixture of cells showed a viability of 66% with 95% of live cells and 92% of dead cells
staining positive for QDot605 (n=4). (d) After 7 days in culture following QDot605 staining
5x105 cells demonstrated a small reduction in the percentage of live QDot605 positive cells
from 98% to 92% (n=5). Bars represent median values and lines represent the range.
5.2.1.2 Tracking QDot605 labelled PαS MSC in the MDR2-/- model of liver
injury
Having already demonstrated a reduction in liver injury in the MDR2-/- model I next
sought to track QDot605 labelled PαS MSC following intravenous injection into the tail
vein in order to assess their distribution. In order to calibrate the CryoVizTM image
analysis software I first needed to ensure I could visualise labelled PαS MSC in individual
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organs. Male MDR2-/- mice aged 8 weeks old were culled and organs removed by careful
dissection. 1x105 PαS MSC labelled with QDot605were injected into ex-vivo lungs, liver,
spleen and heart and organs then embedded in OCT and frozen to -80°C. Sectioning and
image reconstruction was undertaken by BioInVision Inc (http://www.bioinvision.com).
Cells were visible in all organs and automatic quantification of cells injected into lung gave
a value of 73742 (figure 5.2) which was felt to be an accurate reading in the context of
these experiments.
Figure 5.2 – Representative bright field and fluorescent images of QDot605 la-
belled PαS MSC injected ex-vivo into MDR2-/- lung tissue. Male MDR2-/- mice
aged 8 weeks old (n=1) were sacrificed and organs removed by careful dissection. 1x105 PαS
MSC labelled with QDot605were injected ex-vivo into explanted lungs. The organ was then
embedded in OCT and frozen to -80°C using dry ice. Sectioning and image reconstruction
was undertaken by BioInVision Inc (http://www.bioinvision.com) using the CryoVizTM
system. Samples were used for calibration of the imaging system. Cells were visible in
all organs and automatic quantification of cells injected into lung gave a value of 73742.
Representative paired bright field and fluorescence images from the CryoVizTM system are
shown with green fluorescence demonstrating liver tissue and red/orange staining highlighting
QDot605 labelled PαS MSC.
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I next sought to examine the location of PαS MSC following systemic administration
and whether this distribution changes over time. Male 8 week old MDR2-/- mice were
injected into the tail vein with 1x105 passage 4 QDot605 labelled PαS MSC. Mice were culled
at different time points and examined using the CryoVizTM imaging system. Whole mouse
sectioning and imaging in both bright field and fluorescent microscopy was undertaken and
computerised 3 dimensional reconstructions were created. Automatic quantification was





Figure 5.3 – Representative images from whole mouse CryoVizTM imaging showing bright field, fluorescent and 3 dimen-
sional reconstructions in MDR2-/- mice injected with QDot605 labelled PαS MSC. Male 8 week old MDR2-/- mice were injected
into the tail vein with 1x105 passage 4 QDot605 labelled PαS MSC. Time points including 1 hour, 1 day, 3 days and 7 days were investigated
(n=12). Whole mouse sectioning in 40 µm sections and imaging in both bright field and fluorescent microscopy was undertaken and
computerised 3 dimensional reconstructions were created. Automatic quantification was undertaken by the CryoVizTM system. Images of
(a) 1 hour bright field, (b) 1 hour fluorescent, (c) 1 hour 3 dimensional reconstruction, (d) 24 hour bright field, (e) 24 hour fluorescent, (f)
24 hour 3 dimensional reconstruction, (g) 72 hour bright field, (h) 72 hour fluorescent, and (i) 72 hour 3 dimensional reconstruction are
included. Representative paired bright field, fluorescence and 3 dimensional reconstructions are shown. Lungs are highlighted in red, liver
green and spleen blue with QDot605 labelled PαS MSC highlighted in yellow.
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At 1 hour following injection there were a total of 8146 cells ± 4693 detectable in the
MDR2-/- mice (table 5.1). Over the course of the experiment detectable PαS MSC declined
rapidly with only 688.3 cells ± 439.8 at 24 hours and 494.7 cells ± 545.3 at day 7 (table
5.1, figure 5.4).
Sample Global Lung Liver Spleen
1 Hour 1 10,325 7,452 2,321 87
2 6,964 4,467 1,544 12
3 7,149 5,466 1,247 4
1 Day 1 509 184 181 25
2 693 178 100 130
3 863 123 369 41
3 Day 1 139 4 20 4
2 1,046 70 395 14
3 887 15 365 22
7 Day 1 289 144 49 0
2 469 166 229 2
3 726 41 264 32
Table 5.1 – Quantification of QDot605 labelled PαS MSC in different organs
following tail vein injection into MDR2-/- mice. Male 8 week old MDR2-/- mice were
injected into the tail vein with 1x105 passage 4 QDot605 labelled PαS MSC. Mice were culled
at different time points and examined using the CryoVizTM imaging system (n=12).
Following injection of PαS MSC there was a rapid decline in all organs of QDot605
labelled cells during the first 24 hours, followed by a slower continuous decline over the 7
days studied (figure 5.4).
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Figure 5.4 – PαS MSC cell numbers decline rapidly in all organs following sys-
temic administration in MDR2-/- mice. Following injections with 1x105 passage 4
QDot605 labelled PαS MSC Male 8 week old MDR2-/- mice were culled at different time
points and examined using the CryoVizTM imaging system (n=12). There was a rapid decline
in all organs of QDot605 labelled cells during the first 24 hours, followed by a slower continuous
decline over across the 7 days studied. Each line represents the mean number of cells in each
organ of 3 MDR2-/- mice. Point represent mean number of cells, red demonstrates the global
number of QDot605 labelled PαS MSC, blue represents cells found in the lungs, green the
liver and yellow the spleen.
Whilst the total number of PαS MSC declines quickly following injection, as does the
rate of decline of cells in the lungs the rate of decline of PαS MSC in the liver is 5 times
lower in the first 24 hours (table 5.1a). During the subsequent 6 days the rate of decline is
slower in all groups with the lungs and the liver declining 4 times sower than the total
number of cells. The majority of cells appear to stay in the lungs during the first hour
with 71.1% of cells being found in the lungs after 1 hour compared with just 20.9% of cells
being found in the liver (table 5.1b). However at 24 hours only 23.5% of cells are found in
the lungs, with 31.5% being found in the liver. This trend appear to be maintained over




Location Initial rate of decline Rate of decline after 1 day
(cells/day) (cells/day)






(hours) Lung (%) Liver (%) Spleen (%)
1 71.1 20.9 0.4
24 23.5 31.5 9.5
72 4.3 37.6 1.9
168 23.7 26.4 2.3
Table 5.2 – Tables demonstrating the rate of decline and percentages in different
organs of PαS MSC when administered to MDR2-/- mice. Male 8 week old MDR2-/-
mice were injected into the tail vein with 1x105 passage 4 QDot605 labelled PαS MSC. Mice
were culled at different time points and examined using the CryoVizTM imaging system. (a)
The total number of PαS MSC declines quickly following injection, as does the rate of decline
of cells in the lungs the rate of decline of PαS MSC in the liver is 5 times lower in the first
24 hours. During the subsequent 6 days the rate of decline is lower in all groups with the
lungs and the liver declining 4 times sower than the total number of cells (n=12). (b) The
majority of cells appear to stay in the lungs during the first 1 hour with 71.1% of cells being
found in the lungs compared with just 20.9% of cells being found in the liver. However at 24
hours only 23.5% of cells are found in the lungs, with 31.5% being found in the liver. This
trend appear to be maintained over the 7 day period with a greater percentage of cells being
found in the liver when compared with the lungs (n=12).
Having demonstrated that very few cells remain detectable 24 hours after systemic
administration I next sought to assess the remote action of subcutaneously administered
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PαS MSC.
5.2.2 In vivo efficacy of subcutaneously administered PαS MSC
in the MDR2-/- model of liver injury
It has been demonstrated that MSC may be more efficacious when administered by the
subcutaneous route in graft versus host disease [155]. I tested the hypothesis that this
may also be true in immune mediated liver injury. As in the previous chapter I treated
mice aged 6-8 weeks with cell therapy followed by analysis 2 weeks later.
PαS MSC cultured in standard media were expanded to passage 4. and doses of either
1x105 or 2x105 PαS MSC suspended in PBS were tested using the subcutaneous route with
control animals receiving PBS alone. Male mice aged between 6 and 8 weeks were injected
with PαS MSC and culled after 2 weeks. Analysis of serum markers, liver infiltrating
immune cells and immunohistochemistry were performed.
5.2.2.1 Effects of subcutaneous PαS MSC on serum markers of liver injury
in the MDR2-/- model
Following subcutaneous injection of PαS MSC mice were analysed 2 weeks later. There
was a significant increase in ALT when mice were treated with 2x105 PαS MSC (figure
5.5a) when compared with controls (652.5 ± 28.8 vs 497.8 ± 46.9), with no significant
difference in ALT when mice were treated with 1x105 PαS MSC. ALP (figure 5.5b) and





Figure 5.5 – Subcutaneous treatment with PαS MSC does not reduce ALT, ALP
or bile acids in MDR2-/- mice. MDR2-/- mice aged between 6 and 8 weeks were treated
by subcutaneous injection with either 1x105 or 2x105 PαS MSC suspended in PBS with
control animals receiving PBS alone. Mice were culled 2 weeks later. There was a significant
increase in (a) ALT when mice were treated with 2x105 PαS MSC when compared with
controls (652.5 ± 28.8 vs 497.8 ± 46.9) with no significant difference in ALT when mice
were treated with 1x105 PαS MSC (528.1 ± 62.2 vs 497.8 ± 46.8). (b) ALP and (c) bile
acids showed no significant changes in mice treated with PαS MSC by the subcutaneous
route. Points represent individual mice, bars represent the median and lines represent the
interquartile range. Statistical analysis was carried out using a one way ANOVA and multiple
comparison testing was undertaken.
5.2.2.2 Histological changes in MDR2-/- mouse livers when treated with sub-
cutaneous PαS MSC
Liver tissue from MDR2-/- mice treated with PαS MSC was removed, processed and
embedded in paraffin and then sectioned and stained as previously described. Liver
morphology was assessed with H & E staining (figure 5.6). Minimal morphological
disruption was seen in uninjured FVB control with almost no infiltrating immune cells seen.
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Infiltrating immune cells were demonstrated showing a peri-portal (Zone I) distribution in
PBS treated controls as well as mice treated with PαS MSC.
(a) (b)
(c) (d)
Figure 5.6 – Representative images of haematoxylin and eosin staining in
MDR2-/- mice treated with either subcutaneous PBS or PαS MSC at 6-8 weeks
of age and culled 2 weeks later. (a) Minimal morphological disruption was seen in
uninjured FVB control with almost no infiltrating immune cells seen. (b) Infiltrating immune
cells were demonstrated showing a peri-portal (Zone I) distribution in PBS treated controls,
(c) mice treated with 1x105 PαS MSC IV and (d) mice treated with 2x105 PαS MSC IV.
All images are generated from whole slide scans and are at 400x magnification. Scale bars
represent 100μm.
The pan-leucocyte marker CD45 was quantified following immunohistochemical stain-
ing. Slides were scanned using a Zeiss AxioScanner providing a whole slide image and
quantification of the amount of staining was analysed and represented as a percentage
total area. MDR2-/- control animals showed no difference in CD45 expression (figures 5.7,
5.8) when compared with wild type FVB uninjured controls (1.707 ± 0.312 vs 2.173 ±
0.27). There was no significant difference in CD45 expression in mice treated with 1x105
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PαS MSC, but a significant increase in CD45 expression when mice were treated with
2x105 MSC (1.707 ± 0.312 vs 2.640 ± 0.643, p=0.020).
Figure 5.7 – CD45 expression in the livers of MDR2-/- mice treated with either
subcutaneous PBS or PαS MSC at 6-8 weeks of age and culled 2 weeks later.
MDR2-/- mice aged between 6 and 8 weeks were treated by subcutaneous injection with
either 1x105 or 2x105 PαS MSC suspended in PBS with control animals receiving PBS alone
(n=31). Mice were culled 2 weeks later. Immunohistochemical staining was undertaken using
a chromogenic technique. MDR2-/- control animals demonstrated no difference in CD45
expression when compared with wild type FVB uninjured controls (1.707 ± 0.312 vs 2.173 ±
0.27). There was a no difference in CD45 expression in mice treated with 1x105 PαS MSC
1.707 ± 0.312 vs 1.867 ± 1.163) when compared with controls, but a significant increase
in CD45 expression when mice were treated with 2x105 MSC (1.707 ± 0.312 vs 2.640 ±
0.643, p=0.020). Slides were captured using a Zeiss AxioScanner. Between 5 and 10 images
were taken from each scan to cover the whole slide and quantification of each image was
performed using Image J software. Bars represent median values and lines represent the






Figure 5.8 – Representative images of CD45 staining in MDR2-/- mice treated
with either subcutaneous PBS or PαS MSC at 6-8 weeks of age and culled 2
weeks later. MDR2-/- mice aged between 6 and 8 weeks were treated by subcutaneous
injection with either 1x105 or 2x105 PαS MSC suspended in PBS with control animals
receiving PBS alone. Mice were culled 2 weeks later. Immunohistochemical staining was
undertaken using a chromogenic technique. (a) There were scattered CD45 cells distributed
across all zones in the uninjured FVB controls. (b) Infiltrating CD45+ cells were demonstrated
showing a peri-portal (Zone I) distribution in PBS treated controls, (c) mice treated with
1x105 PαS MSC IV and (d) mice treated with 2x105 PαS MSC IV. (e) There was no staining
seen in the isotype matched controls. All images are generated from whole slide scans and
are at 400x magnification. Scale bars represent 100μm.
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Staining was next undertaken using an F4/80 antibody in order to delineate the hepatic
macrophage population (figures 5.9, 5.10). MDR2-/- control animals showed an increase in
F4/80 expression when compared to wild type FVB mice. Mice treated with PαS MSC
showed a no difference in F4/80 expression when compared with control animals.
Figure 5.9 – F4/80 expression in the livers of MDR2-/- mice treated with either
subcutaneous PBS or PαS MSC at 6-8 weeks of age and culled 2 weeks later.
MDR2-/- mice aged between 6 and 8 weeks were treated with either 1x105 or 2x105 PαS
MSC suspended in PBS with control animals receiving PBS alone via the subcutaneous
route (n=37). Mice were culled 2 weeks later. Immunohistochemical staining was undertaken
using a chromogenic technique. Staining was undertaken using an F4/80 antibody in order
to delineate the hepatic macrophage population. MDR2-/- control animals showed a no
difference in F4/80 expression when compared to wild type FVB mice (3.296 ± 0.598 vs 2.109
± 0.36, p=0.32). Mice treated with 1x105 PαS MSC showed no difference in F4/80 expression
when compared with control animals (3.296 ± 0.598 vs 3.209 ± 0.609, p=0.92), neither did
those treated with 2x105 PαS MSC (3.296 ± 0.598 vs 2.583 ± 0.187, p=0.186). Slides were
captured using a Zeiss AxioScanner. Between 5 and 10 images were taken from each scan to
cover the whole slide and quantification of each image was performed using Image J software.
Bars represent median values and lines represent the range. Statistical analysis was carried
out using a one way ANOVA and multiple comparison testing was undertaken. Comparison





Figure 5.10 – Representative images of F4/80 staining in MDR2-/- mice treated
with either subcutaneous PBS or PαS MSC at 6-8 weeks of age and culled 2
weeks later. MDR2-/- mice aged between 6 and 8 weeks were treated by subcutaneous
injection with either 1x105 or 2x105 PαS MSC suspended in PBS with control animals
receiving PBS alone. Mice were culled 2 weeks later. Immunohistochemical staining was
undertaken using a chromogenic technique. (a) There were scattered F4/80 cells distributed
across all zones in the uninjured FVB controls. (b) Some infiltrating F4/80 cells were
demonstrated showing a peri-portal (Zone I) distribution on a background of scattered F4/80
cells across all zones were seen in PBS treated controls, (c) mice treated with 1x105 PαS
MSC IV and (d) mice treated with 2x105 PαS MSC IV. There was no staining seen in the (e)
isotype matched controls. All images are generated from whole slide scans and are at 400x
magnification. Scale bars represent 100μm.
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I next sought to quantify CK19 expression using western blotting.
5.2.2.3 Effects on ductular proliferation in MDR2-/- mouse livers when treated
with PαS MSC
Following treatment with PαS MSC mice were culled at 2 weeks and liver lobes removed and
homogenised. Protein lysis and quantification was undertaken and then western blotting
was performed using the lysed protein. A CK17/19 antibody was used for detection of
CK19 and α-actinin was used as a loading control.
CK19 expression showed no difference between uninjured FVB mice and PBS treated
MDR2-/- mice. There was no difference CK19 expression following treatment with PαS
MSC in either the 1x105 or 2x105 groups (figure 5.11).
(a) (b)
Figure 5.11 – CK19 quantification by western blotting in MDR2-/- mice treated
with subcutaneous PαS MSC. MDR2-/- mice aged 6-8 weeks were treated with either
1x105 or 2x105 PαS MSC via the subcutaneous route and then culled 2 weeks later. Liver
lobes were removed and homogenised. Protein lysis and quantification was undertaken and
then western blotting was performed using the lysed protein. A CK17/19 antibody was
used for detection of CK19 and α-actinin was used as a loading control. Expression levels
were normalised to loading controls and are expressed as fold change. (a) CK19 expression
showed no differnece between uninjured FVB mice and PBS treated control MDR2-/- mice.
Mean CK19 expression was not different following treatment with PαS MSC (n=38). (b)
Representative western blots for CK19 expression are shown with loading controls below.
Bars represent median values and lines represent the range. Statistical analysis was carried
out using a one way ANOVA and multiple comparison testing was undertaken.
I next sought to quantify the immune cell infiltration in MDR2-/- mouse livers by flow
cytometry.
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5.2.2.4 Characterisation of liver and serum immune cell populations in MDR2-/-
mouse livers following sucutaneous treatment with PαS MSC
Infiltrating immune cells in the livers of MDR2-/- mice were quantified using flow cytometric
analysis. Two weeks after treatment with PαS MSC liver lobes were removed, weighed and
processed to allow flow cytometry to be performed. Single cell suspensions were stained
with relevant antibodies including a live/dead marker. Cell counts were normalised to
liver weight and presented as cells per gramme.
There was a significant reduction in infiltrating CD45+ cells (figure 5.12) between
control animals and mice treated with 2x105 PαS MSC (306551 cells/g ± 18165 vs 194496
cells/g ± 15135, p=0.009). This pattern was also true for CD8+ (31855 cells/g ± 5589
vs 13079 cells/g ± 4787, p=0.0385) cells. There was a no significant difference in CD4+
(65013 cells/g ± 6779 vs 45840 cells/g ± 9250), CD19+ (54495 cells/g ± 6957 vs 42663
cells/g ± 6514), NK1.1+ (11390 cells/g ± 2120 vs 11056 cells/g ± 802.7), F4/80+ (19983
cells/g ± 480.7 vs 28510 cells/g ± 4616) cells, or neutrophils delineated by CD11b and





Figure 5.12 – Flow cytometric analysis of immune cell infiltrates in the livers of
MDR2-/- mice treated with subcutaneous PαS MSC. Two weeks following treatment
with subcutaneous PαS MSC liver lobes from MDR2-/- mice were removed, weighed and
processed for cytometry. Single cell suspensions were stained with relevant antibodies
including a live/dead marker. Cell counts were normalised to liver weight and presented as
cells per gramme. (a) There was a significant reduction in infiltrating CD45+ cells between
control animals and mice treated with 2x105 PαS MSC (306551 cells/g ± 18165 vs 194496
cells/g ± 15135, p=0.009, n=7). There was no difference in (b) CD4+ (65013 cells/g ± 6779
vs 45840 cells/g ± 9250, p=0.235, n=12). (c) CD8+ cells were also significantly reduced
(31855 cells/g ± 5589 vs 13079 cells/g ± 4787, p=0.0385, n=12). There was no difference
in (d) CD19+ (54495 cells/g ± 6957 vs 42663 cells/g ± 6514, p=0.287, n=12), (e) NK1.1+
(11390 cells/g ± 2120 vs 11056 cells/g ± 802.7, p=0.856, n=7), (f) F4/80+ (19983 cells/g
± 480.7 vs 28510 cells/g ± 4616, p=0.320, n=7) cells or neutrophils delineated by CD11b+
and Gr1+ (21037 cells/g ± 59.53 vs 30634 cells/g ± 5024, p=0.305, n=7). Points represent
individual mice and bars represent the median value. Statistical analysis was carried out
using a one way ANOVA and multiple comparison testing was undertaken. Comparison
between groups was undertaken using Student’s t-test.
I also analysed the CD4/CD8 ratio in liver tissue by looking at the ratio of cells
analysed by flow cytometry (figure 5.13). In the liver tissue the CD4/CD8 ratio showed a
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significant increase (p=0.0078) in the mice treated with 2x105 PαS MSC.
Figure 5.13 – The CD4/CD8 ratio assessed by flow cytometry in the livers of
MDR2-/- mice aged 6-8 weeks old were treated with subcutaneous PαS MSC
and culled after 2 weeks. MDR2-/- mice aged 6-8 weeks were treated with 2x105 PαS
MSC via the subcutaneous route and then culled 2 weeks later. Liver lobes removed and
antibody staining was undertaken and analysed by flow cytometry. In the liver tissue the
CD4/CD8 ratio showed a significant reduction (p=0.0078) in mice treated with 2x105 PαS
MSC compared with control mice. Points represent individual mice and bars represent the
median value. Statistical analysis was carried out using a Student’s t-test.
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5.3 Discussion
Systemically administered MSC have been shown to exert a broad range of effects in both
organ specific and systemic models of immune mediated disease. A number of techniques
have been used to track the location of systemically administered MSC. In this study I
opted to use a novel block face cryoimaging technique which enabled quantification and
imaging of QDot605 labelled PαS MSC at a single cell resolution.
5.3.1 Tracking systemically administered PαS MSC
In order to examine the distribution of systemically administered PαS MSC I utilised
the CryoVizTM imaging system which required cells to be stained using quantum dots.
Whilst quantum dot technology has been around nearly 20 years [293], its use in MSC
research has been limited. CryoVizTM is a recently developed technology and studies
using this technique to track MSC distribution have only started to be seen in the last 12
months [294, 295]. There are no published papers demonstrating quantum dot staining or
CryoVizTM imaging using PαS MSC. In this study I have demonstrated that staining PαS
MSC is feasible and does not lead to significant cell death. I have also demonstrated that
QDot605 is compatible with live/dead staining using an intra-cytoplasmic viability marker.
Whilst it is not a new finding that MSC can be stained with quantum dots there is no
literature describing their use with PαS MSC. I have also demonstrated that QDot605 is
persistent at 7 days and therefore can be reliably used to track PαS MSC in vivo over this
time period. In this study I did not look at the function of PαS MSC following quantum
dot staining, and whilst it is conceivable that the use of quantum dots could lead to a
change in function of PαS MSC this has not been seen in the literature when quantum
dots have been used to stain MSC [296].
In this study I examined the distribution of systemically administered PαS MSC in
the MDR2-/- model of liver injury. Whilst the aim of this study was to examine the
distribution of cells in the MDR2-/- model, a benefit of using this model when studying
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MSC trafficking is that the model is a spontaneous injury model which was continuous
through the studied time course. This means that even with a reduction in injury due
to MSC therapy, there should remain an inflammatory stimulus at the site of injury
making the localisation of MSC to the liver during the later time periods still valid. One
hour following injection of 1x105 PαS MSC only around 10% of cells were still detectable.
Whilst it is possible that cells were left in the syringes during injection, initial testing and
calibration using ex vivo organs showed nearly 75% of injected cells still visible. Levels
were similar between replicates making experimental error unlikely. This reduction in
cell number either represents rapid clearance from the mice, an inability to resolve low
numbers of cells, cell death and clearance or an inability to quantify cells grouped together.
As seen in other studies of MSC the greatest number of cells were found in the lungs
(66% total) [279]. As pulmonary ’trapping’ is at least in part a physical property of MSC
[297], and PαS MSC are similar in size to their human counterparts, this is not surprising.
Approximately 20% of the total cells were found in the liver, with very few found in the
spleen. There appeared to be a rapid decrease in the number of detectable cells over the
first 24 hours. After 24 hours the rate of decline levelled out with the greatest reduction
occurring in cells not found in the lung, liver or spleen. The ratio of cells found in the
liver, compared with cells found in the lung also changed over the remaining 6 days with
the percentage of cells found in the lungs falling below those found in the liver by 24 hours
and remaining there throughout the 7 day experiment. Whilst on the surface it appears
that this is a retention phenomenon with cells being more readily retained in the liver,
it is possible that the clearance rates from each organ are similar, but that those cells
leaving the lungs then become redistributed to the liver. It is not possible to determine
if this is the case from the data presented in this study, further work would need to be
done to confirm this hypothesis. It is also not possible to determine the exact location of
MSC within the liver in this study which may be important when trying to understand
the interaction between MSC and the immune system. By 7 days there were very few
cells remaining in any organ. This finding supports the hypothesis that PαS MSC are
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able to reduce injury by the use of intermediary cells, however it does not clearly answer
the question as to whether PαS MSC need to be co-located in the injured area in order
to exert these effects. To answer this question I examined the effects of subcutaneously
administered PαS MSC.
5.3.2 The effect of PαS MSC administered subcutaneously in the
MDR2-/- model
The ability of MSC to exert an immunomodulatory effect on models of liver disease has
been demonstrated in the literature where both human and murine MSC have been tested.
In models of acute liver failure murine bone marrow derived MSC have been shown to
attenuate liver injury via paracrine effects on regulatory T-cells [298]. It has also been
demonstrated that in a fatal model of hepatic failure extracellular vesicles secreted from
MSC are able to reduce injury by reducing hepatocyte apoptosis [299]. MSC encapsulated
in alginate have also been demonstrated to reduce injury in a model of graft versus host
disease [155], suggesting that MSC are able to exert remote effects on the immune system.
In this study MDR2-/- mice injected with subcutaneous PαS MSC showed a significant
increase in injury when examining ALT, the primary outcome measure. ALP and bile acids
were unchanged. This is in contrast to the experiments using intravenously administered
PαS MSC which showed a significant reduction in both ALT and ALP. Histological
examination revealed an increase in total CD45 expression, similar to that seen in the
mice treated via the intravenous route. There was no difference in F4/80 expression in
these experiments. On the surface these findings appear unusual as the serum markers
of injury are contrary to those seen in the intravenous group yet the histological findings
appear to be similar. Flow cytometric analysis of liver infiltrating immune cells showed a
significant reduction in CD45+ and CD8+ cells, with no changes in CD4+ cells. All other
cell types analysed showed no significant changes in numbers. The reduction in CD45
expression is in keeping with a reduction in CD8+ cells, however this is an unexpected
finding given that systemic administration of PαS MSC did not lead to changes in CD8+
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cells. In the MDR2-/- model CD4+ and CD8+ lymphocytes have been shown to increase
in numbers at time of injury [98], however it has never been conclusively demonstrated
that an increase in infiltrating immune cells is responsible for an increase in injury in this
model. The CD4/CD8 ratio significantly increased in the mice treated with subcutaneous
PαS MSC, the opposite effect to that seen following intravenous injection. The importance
of an increase in the CD4/CD8 ratio in this context is difficult to interpret, however
it could represent a change towards a cytotoxic rather than restorative phenotype and
hence provide an explanation for the increase in ALT after treatment with subcutaneous
PαS MSC. The difference between the effects of subcutaneous and intravenous PαS MSC
therapy could then be explained by the differing effects of the MSC. The published models
which have shown a benefit in encapsulated MSC are models where injury is driven by
lymphocytes, and the reduction in lymphocyte numbers mediated by MSC has been
possible remotely. In the MDR2-/- model I have shown that PαS MSC may decrease injury
by a more complex mechanism, specifically a change in macrophage phenotype. It is
possible that this change in macrophage type requires cell to cell contact or close proximity
in order to reduce injury, this being prevented by subcutaneous administration. Further
work would need to be done to confirm this hypothesis including cell tracking to ascertain
if subcutaneously administered PαS MSC remain at the site of injection.
5.3.3 Chapter summary
In this chapter I have demonstrated that it is feasible to label PαS MSC with quantum dots
to facilitate cell tracking with the CryoVizTM block face cryoimaging technique without
any change in viability. By utilising this technique I have demonstrated that systemically
administered PαS MSC rapidly reduce in number over the first hour after injection. I
have also demonstrated that in keeping with studies of other types of MSC that PαS
MSC are temporarily ’trapped’ in the lungs following systemic administration. After 24
hours however there appeared to be a greater reduction in cells found in the lungs when
compared with those in the liver. This finding is potentially due to redistribution from
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the lungs to the liver.
I have also demonstrated that subcutaneously administered PαS MSC increase liver
injury in the MDR2-/- mouse model. The mechanism by which this occurs is not clear,
although a change in the balance of cytotoxic and restorative cell types is a potential
mechanism, however this requires further study. These findings suggest that systemic
administration of MSC may be required in complex conditions where injury is not primarily
driven by lymphocytes alone.
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CHAPTER 6
DEVELOPMENT AND IN VIVO EFFICACY
TESTING OF PαS MSC IN A MODEL OF
HEPATIC ISCHAEMIA REPERFUSION INJURY
6.1 Chapter introduction and aims
I have so far demonstrated the isolation and culture expansion of PαS MSC as well as
their ability to suppress lymphocyte proliferation in a bulk splenocyte reaction. I have also
demonstrated the ability of PαS MSC to reduce injury in the MDR2-/- model which has a
similar injury pattern to the medium term complications seen post liver transplantation.
In this chapter I developed a mouse model of hepatic ischaemia reperfusion injury and
tested the ability of PαS MSC to modulate the immune system in this model.
6.1.1 Hepatic ischaemia reperfusion injury
Liver transplantation has become a standard of care for suitable patients with end stage
liver disease with no other therapies able to prevent the mortality associated with this
condition. With a shortage of donor organs worldwide the use of more marginal organs,
such as those from Maastricht class III and IV donation after circulatory death donors
has increased in recent years [29]. During both liver resection and liver transplantation
an inevitable ischaemic injury occurs to the liver, either due to organ preservation and
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transport, major haemorrhage or deliberate vascular inflow occlusion with an aim to
reduce surgical blood loss [52, 53, 54, 55]. Liver ischaemia can be categorised as warm
or cold ischaemia. Cold ischaemia occurs during cold preservation of explanted liver and
is defined as occurring from the beginning of cold preservation to the removal from 4°C
cold storage. Warm ischaemic time can be subdivided into donor warm ischaemic time,
occurring between withdrawal of life support and the initiation of cold storage, or graft
warm ischaemic time which occurs between removal from cold storage and establishment
of reperfusion [57].
The ischaemic phase of ischaemia reperfusion injury occurs in cells that require mi-
tochondrial oxidative phosphorylation due to a lack of oxygen supply. This initial phase
leads to glycogen consumption and depletion of ATP which impairs ATP dependent Na+
and Ca2+ pumps. The resultant electrolyte imbalance, osmotic stress and mitochondrial
permeability leads to necrotic/non-apoptotic cell death. Following reperfusion of ischaemic
tissue a further injury process has been described which has been characterised as occurring
in two phases [300]. The first phase occurs during the first 6 hours following reperfusion
injury and is caused by activation of resident Kupffer cells, whereas the later stage which
occurs between 6 and 24 hours is characterised by infiltration of polymorphonuclear cells.
This description is an oversimplification of the complex cellular interactions occurring in
hepatic ischaemia reperfusion injury which are not fully understood but involve both the
innate and the adaptive immune system. Whilst a large number of potential therapies
have been trialled in animal models with an aim at reducing injury due to warm ischaemia
almost none have made the translation into clinical practice. Most therapies focus on
oxidative stress and aim to reduce this insult, however given there is a significant immune
component to reperfusion injury there is potential for a therapeutic benefit by targetting
the immune system. Whilst there has been some preclinical work looking at MSC and
their vesicles in liver ischaemia reperfusion injury [301, 302, 299] most of this work has
used human MSC into mouse models and there have been no studies looking at PαS MSC
in this disease. Earlier work with MSCs in liver ischaemia reperfusion injury focussed on
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supporting hepatocyte differentiation rather than immune modulation [186].
6.1.2 Mouse models of liver ischaemia reperfusion injury
One of the first descriptions of reperfusion injury as a result of superoxide generation
used a feline model of gastrointestinal tract ischaemia and reperfusion [51]. Since this
publication nearly 40 years ago there has been a considerable amount of work done to
illicit the causes of reperfusion injury. The use of small animal models to investigate liver
ischaemia reperfusion injury has predominated over the last 10 years but a variety of
techniques still persist making comparison between studies difficult. In this study I decided
to use male C57BL/6 mice as these are the same strain of mice from which the PαS MSC
were isolated. I used a model of partial hepatic ischaemia to avoid back pressure into the
intestines and bacterial translocation. I also chose an inhalational anaesthetic technique
using isoflurane with opiate analgesia whilst avoiding Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) as this has a good correlation with liver surgical practice in the clinical
environment. Whilst animal models of liver transplantation do exist and can incorporate
both cold and warm ischaemia, the logistical challenges and complexity make these difficult
to reproduce [303].
6.1.3 Specific chapter aims
Previous chapters have demonstrated the ability of PαS MSC to suppress CD8+ T cell
proliferation in vitro in a dose dependent fashion. I have also demonstrated a number of
cytokines secreted following stimulation which have the potential to modulate the immune
response. The aim of this chapter was to develop a model of partial hepatic ischaemia
reperfusion injury in which I could adequately test the ability of PαS MSC to modulate
the immune system in vivo, and to subsequently test the effects of PαS MSC as a therapy
for hepatic ischaemia reperfusion injury. The specific aims of this chapter were:
1. To establish a model of hepatic ischaemia reperfusion injury
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2. To optimise the duration of ischaemia and reperfusion in the model to provide an
adequate testing environment for PαS MSC therapy.
3. To characterise the inflammatory injury seen in the hepatic ischaemia reperfusion
injury model




6.2.1 Developing a model of hepatic ischaemia reperfusion injury
Models of hepatic ischaemia reperfusion injury are not new and have been carried out in
multiple different species using a variety of surgical techniques. In this study 8 week old
male C57BL/6 wild type mice were chosen in keeping with other published literature in
liver injury [102]. I opted to perform a portal triad clamp of 70% of the liver (figure 6.1),
leaving the lower lobes perfused to act as a portal shunt and prevent back pressure into
the portal system which has been shown to lead to gut bacterial translocation.
Figure 6.1 – Graphic of 70% partial liver ischaemia. Diagrammatic representation of
normal murine liver anatomy and the clamp position representing 70% partial ischaemia.
Perfused liver is demonstrated as dark brown and ischaemic liver as light brown. The
microvascular clamp is shown in silver. Image from Abe et al. [102]
Following a number of cadaveric practice runs in order to optimise the surgical technique
I developed a method of administering analgesia before and after surgery using bupren-
orphine with titrated isoflurane anaesthesia. I used an upper quadrant limited midline
laparotomy incision (figure 6.2a) in order to reduce pain and recovery time. Following
the initial incision and insertion of a micro-spreader an atraumatic clamp was applied to
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the portal triad, sparing the lower liver lobes in order to achieve 70% ischaemia (figures
6.2b and 6.2c). Following reperfusion explanted livers showed a characteristic mottled




Figure 6.2 – Images demonstrating hepatic ischaemia reperfusion surgery. (a)
Image demonstrating limited laparotomy of approximately 2cm with micro-spreader inserted.
(b) An atraumatic microvascular clamp was inserted into the abdominal cavity superior to
the lower liver lobes. (c) Ischaemic liver can be seen as pale in colour whilst perfused liver
is red/brown. (d) Following 24 hours of reperfusion, saline flushing and removal of livers,
lobes which have undergone ischaemia show a mottled, haemorrhagic appearance whereas
non-ischaemic lobes can be seen as homogeneous light brown in colour.
Having optimised the surgical technique I next sought to investigate the effect of
different durations of reperfusion on liver injury in the hepatic ischaemia reperfusion injury
model.
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6.2.2 Time course of hepatic ischaemia reperfusion injury
6.2.2.1 Serum transaminases in hepatic ischaemia reperfusion injury
I decided to use serum ALT as the primary outcome measure in the ischaemia reperfusion
injury model as based on the published literature this is a good indicator of degree of
liver injury in an ischaemic injury model [102]. Two distinct phases of liver injury have
been described following prolonged interruption of blood flow to the liver [304]. The acute
phase occurs during the first 6 hours following reperfusion and the sub-acute phase occurs
between 6 and 24 hours. I first sought to investigate the profile of transaminases over the
first 24 hours of reperfusion following hepatic ischaemia reperfusion injury.
Male C57BL/6 mice aged 8 weeks underwent 60 minutes of 70% ischaemia which
was achieved by applying a microvascular clamp across the portal triad via a midline
laparotomy incision. Following ischaemia varying durations of reperfusion were undertaken
and serum ALT analysed (figure 6.3). Baseline ALT following 60 minutes of ischaemia
was taken at 0 hours which demonstrated an increase in ALT (647.5 IU/L ± 279.4). There
was a time dependent increase in ALT which peaked at 6 hours (15893.3 IU/L ± 3059.6).
At 24 hours of reperfusion ALT remained raised (2825.0 IU/L ± 873.3) with sham controls
having an almost normal ALT (37.5 IU/L ± 3.2).
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Figure 6.3 – Time course of serum ALT following 60 minutes of hepatic ischaemia.
Male C57BL/6 mice aged 8 weeks underwent 60 minutes of 70% ischaemia. Following ischaemia
varying durations of reperfusion were undertaken. Baseline ALT at 0 hours demonstrated an
increase in ALT (647.5 IU/L ± 279.4, n=4). There is a time dependent increase in ALT
which peaked at 6 hours (15893.3 IU/L ± 3059.6, n=3). At 24 hours of reperfusion ALT
remained raised (2825.0 IU/L ± 873.3, n=4) with sham controls having an almost normal
ALT (37.5 IU/L ± 3.2, n=4). Histograms represent mean values and bars represent standard
error of the mean. n=18.
I next sought to assess the associated histological changes following ischaemia reperfu-
sion injury.
6.2.2.2 Histochemical analysis in hepatic ischaemia reperfusion injury
Various techniques for assessing hepatic necrosis in ischaemia reperfusion injury models
have been described including semi-quantitative analysis of H & E stained sections [102]
and TUNEL staining [305]. One technique that has been shown to delineate necrotic
cells following ischaemia in otherwise well mice is Periodic Acid-Schiff (PAS) staining,
a glycogen stain[306]. This stain is used regularly in our clinical lab for assessment of
hepatic necrosis in pre and post transplant liver tissue. I undertook H & E staining to
assess liver architecture and PAS staining to assess necrosis.
Following sacrifice of C57BL/6 mice liver tissue was removed from the lobes which
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underwent ischaemia and the lobes that were spared and fixed in formalin. Fixed liver
tissue was embedded in paraffin and processed for histochemistry and H & E staining
(figures 6.4 and 6.5) was performed. At baseline 0 hours reperfusion extravasation of red
blood cells was seen in the spaces between hepatocytes with minimal apparent necrosis.
Between 0 and 6 hours necrosis became more apparent with sparing around the portal
vessels. At 24 hours necrotic areas were better delineated with islands of non-necrotic





Figure 6.4 – Representative haematoxylin and eosin staining of ischaemic mouse
livers following 60 mins ischaemia and varied reperfusion injury. Male C57BL/6
mice aged 8 weeks underwent 60 minutes of 70% ischaemia. Following ischaemia varying
durations of reperfusion were undertaken. Ischaemic liver lobes were removed and stained
with Haematoxylin and Eosin. (a) At baseline 0 hours reperfusion extravasation of red blood
cells was seen into the spaces between hepatocytes with minimal apparent necrosis. At (b) 2,
(c) 4 and (d) 6 hours necrosis became more apparent with sparing around the portal vessels.
(e) At 24 hours necrotic areas were better delineated with islands of non-necrotic hepatocytes
surrounding the portal vessels. (f) Sham controls showed no necrosis or abnormalities. All
images are generated from whole slide scans and are at 400x magnification. Scale bars
represent 100 μm.
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In the non-ischaemic lobes at baseline 0 hours reperfusion minimal changes were seen.
At 4 hours some morphological changes in hepatocytes were seen and by 6 hours there were
small areas of necrosis and some red cell extravasation. At 24 hours the morphological






Figure 6.5 – Representative haematoxylin and eosin staining of non-ischaemic
mouse liver lobes following 60 mins ischaemia and varied reperfusion injury. Male
C57BL/6 mice aged 8 weeks underwent 60 minutes of 70% ischaemia. Following ischaemia
varying durations of reperfusion were undertaken. Non-ischaemic liver lobes were removed
and stained with H & E. (a) At baseline 0 hours reperfusion minimal changes were seen.
(b) At 2 and (c) 4 hours some morphological changes in hepatocytes were seen. (d) At 6
hours there were small areas of necrosis and some red cell extravasation. (e) At 24 hours
the morphological changes in hepatocytes had almost completely resolved and there were no
apparent necrotic areas. (f) Sham controls showed no necrosis or abnormalities. All images
are generated from whole slide scans and are at 400x magnification. Scale bars represent 100
μm.
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In order to quantify the extent of liver ischaemia I next performed PAS staining (figures
6.6, 6.7 and 6.8). Glycogen depletion was used as a surrogate of hepatic ischaemia and
hepatocyte function as previously described [306].
Following 60 minutes of ischaemia (n=17) the baseline 0 hours reperfusion ischaemic
liver lobes showed considerable necrosis assessed by glycogen depletion (71.00% ± 7.69).
The amount of glycogen depletion remained relatively constant at 2 hours (74.36% ± 1.72)
and 4 hours (69.85%) with a peak at 6 hours (83.26% ± 2.69). By 24 hours there was
a small reduction in glycogen depletion (66.74% ± 11.86). Sham controls showed much
lower levels of glycogen depletion (17.05% ± 0.90). In the non-ischaemic lobes there was a
similar pattern of injury but with lower levels of glycogen depletion.
Figure 6.6 – Histogram showing the time course of glycogen depletion in
ischaemic and non-ischaemic livers of mice after hepatic ischaemia reperfusion
injury assessed by PAS staining. Male C57BL/6 mice aged 8 weeks underwent 60 minutes
of 70% ischaemia. Following ischaemia varying durations of reperfusion were undertaken.
Ischaemic and non-ischaemic liver lobes were removed and stained with PAS. The baseline 0
hours reperfusion ischaemic liver lobes showed considerable glycogen depletion (71.00% ±
7.69). The amount of glycogen depletion remained constant at 2 hours (74.36% ± 1.72) and
4 hours (69.85%) with a peak at 6 hours (83.26% ± 2.69). By 24 hours there was a small
reduction in glycogen depletion (66.74% ± 11.86). Sham controls showed much lower levels
of glycogen depletion (17.05% ± 0.90). The non-ischaemic lobes showed a similar pattern but
with lower levels of glycogen depletion at 0 (43.31% ± 6.16), 2 (48.80% ± 6.20), 4 (39.81%),
6 (65.21% ± 18.13 and 24 (33.60% ± 6.99) hours. Sham controls again showed lower levels
of glycogen depletion (12.45% ± 0.43). Histograms represent mean values and bars represent
standard error of the mean, n=17.
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In the ischaemic lobes the pattern of PAS staining at baseline 0 hours showed a global
reduction in staining when compared with sham controls with no changes in architecture.
This pattern continued at 2 and 4 hours. At 6 hours reperfusion there was both global
fade in PAS staining as well as some underlying architectural changes in keeping with
those seen in the H & E stained livers. At 24 hours of reperfusion there were higher levels
of PAS staining seen in the peri-portal regions showing some recovery with widespread






Figure 6.7 – Representative histology of PAS stained ischaemic liver lobes fol-
lowing 60 minutes of 70% ischaemia. Male C57BL/6 mice aged 8 weeks underwent
60 minutes of 70% ischaemia. Following ischaemia varying durations of reperfusion were
undertaken. Ischaemic and non-ischaemic liver lobes were removed and stained with PAS.
(a) The pattern of PAS staining at baseline 0 hours showed a global reduction in PAS
staining when compared with sham controls with no changes in architecture. (b) At 2
and (c) 4 hours the same pattern of global reduction in PAS staining was seen. (d) At 6
hours reperfusion there was both global fade in PAS staining as well as some underlying
architectural changes in keeping with those seen in the H & E stained livers. (e) At 24 hours
of reperfusion there was higher levels of PAS staining seen in the peri-portal regions showing
some recovery with widespread necrotic areas throughout the parenchyma. (f) Sham controls
demonstrated normal staining. All images are generated from whole slide scans and are at
400x magnification. Scale bars represent 100 μm.
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In the non-ischaemic lobes the pattern of PAS staining at baseline 0 hours showed a
global patchy reduction in PAS staining when compared with sham controls but less than
the ischaemic lobes with no changes in architecture. This pattern continued at 2 and 4
hours. At 6 hours reperfusion there was both global fade in PAS staining as well as some
underlying architectural changes in keeping with those seen in the H & E stained livers
but again less than the ischaemic lobes. At 24 hours of reperfusion there were higher levels
of PAS staining than the earlier time points but less than the sham controls with global






Figure 6.8 – Representative histology of PAS stained non-ischaemic liver lobes
following 60 minutes of 70% ischaemia. Male C57BL/6 mice aged 8 weeks underwent
60 minutes of 70% ischaemia. Following ischaemia varying durations of reperfusion were
undertaken. Ischaemic and non-ischaemic liver lobes were removed and stained with PAS.
(a) The pattern of PAS staining at baseline 0 hours showed a global patchy reduction when
compared with sham controls but less than the ischaemic lobes with no changes in architecture.
(b) At 2 and (c) 4 hours the same pattern of global reduction in PAS staining was seen. (d)
At 6 hours reperfusion there was global fade in PAS staining as well as some underlying
architectural changes in keeping with those seen in the H & E stained livers but again less
than the ischaemic lobes. (e) At 24 hours of reperfusion levels of PAS staining were higher
than earlier time points but less than sham controls with global involvement across the lobes
and no architectural changes. (f) Sham controls demonstrated normal PAS staining. All
images are generated from whole slide scans at 400x magnification. Scale bars represent 100
μm.
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I next sought to examine the infiltrating immune cells in livers of mice after ischaemia
reperfusion injury by flow cytometry.
6.2.2.3 Analysis of liver infiltrating immune cells by flow cytometry in hep-
atic ischaemia reperfusion injury
Whilst the published literature in hepatic ischaemia reperfusion injury has focussed on
immunohistochemical analysis of immune cells I decided that utilising flow cytometric
analysis would give a more accurate quantification of the immune cells found in the
livers of mice following ischaemia reperfusion injury. Following sacrifice liver lobes were
mechanically homogenised and following washing were passed over a density gradient using
OptiprepTM. Cells were stained and analysed by flow cytometry (figure 6.9).
Total CD45+ cells increased from baseline to peak at 24 hours in the ischaemic lobes,
whereas there was a relatively constant level in the non-ischaemic lobes throughout the
time course. CD3+CD4+ cells appeared to decrease in number during reperfusion in the
ischaemic lobes but levels increased again at 24 hours. The pattern in the non-ischaemic
lobes showed a peak at 6 hours with a return to baseline at 24 hours. CD3+CD8+ cell
numbers initially fell in the ischaemic lobe but by 24 hours were higher than the baseline
levels. In the non-ischaemic lobe levels again remained relatively constant. NK1.1+ natural
killer cell levels appeared unchanged in the ischaemic lobes during reperfusion injury,
however in the non-ischaemic lobes NK1.1+ cells showed relatively high levels at baseline
and decreased by 24 hours. Platelets, represented by CD41+ cells, increased from baseline
to a peak at 2 hours in the ischaemic lobes and then fell to below baseline by 24 hours. In
the non-ischaemic lobes levels increased from baseline and remained relatively constant
throughout the 24 hour time course. Neutrophil cell numbers (SSCIntLy6GHi) remained
low for the first 6 hours and then showed a large increase in number by 24 hours in the
ischaemic lobes, but remained at low levels in the non-ischaemic lobes for the duration of





Figure 6.9 – Flow cytometric analysis of mouse livers following ischaemia reper-
fusion injury. Male C57BL/6 mice aged 8 weeks underwent 60 minutes of 70% ischaemia.
Liver lobes were homogenised and passed over a density gradient. Cells were stained and
analysed by flow cytometry. (a) Total CD45+ cells increased to peak at 24 hours in the
ischaemic lobes, in the non-ischaemic lobe they remained constant. (b) CD3+CD4+ cells
decreased initially in the ischaemic lobes increased again at 24 hours. The non-ischaemic
lobes showed a peak at 6 hours with a return to baseline at 24 hours. (c) CD3+CD8+ cell
numbers initially fell in the ischaemic lobe but by 24 hours were higher than the baseline
levels. In the non-ischaemic lobe numbers again remained relatively constant. (d) Nk1.1+ cell
numbers appeared unchanged in the ischaemic lobes during reperfusion injury, however in
the non-ischaemic lobes NK1.1+ cells showed relatively high levels at baseline and decreased
by 24 hours. (e) Platelets, represented by CD41+ cells, increased from baseline to a peak at 2
hours in the ischaemic lobes and then fell to below baseline by 24 hours. In the non-ischaemic
lobes levels increased from baseline and remain relatively constant throughout the 24 hour
time course. (f) Neutrophils remained low for the first 6 hours but showed a large increase in
number by 24 hours in the ischaemic lobes, but remained at low levels in the non-ischaemic
lobe for the duration of the 24 hour experiment. Histograms represent mean and bars
represent standard error of the mean, n=15.
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Having quantified the injury profile during reperfusion I next assessed the impact of
clamp duration on injury.
6.2.3 The effect of clamp duration in ischaemia reperfusion injury
In the published literature ischaemia reperfusion injury models in the liver use a broad
range of clamp times [307, 308]. I decided to compare clamp times of 30 and 60 minutes
in order to determine the minimum duration required to illicit prolonged liver necrosis
in keeping with the equivalent clinical picture. As in the previous experiments mice
underwent general anaesthesia and a laparotomy with the use of an atraumatic clamp to
interrupt the hepatic blood supply at the portal triad. A 70% model was used, however
clamp times were varied at either 30 or 60 minutes and analysis was undertaken after
different durations of reperfusion.
6.2.3.1 Serum transaminases following different clamp durations in hepatic
ischaemia reperfusion injury
Male C57BL/6 mice aged 8 weeks underwent either 30 minutes or 60 minutes of 70%
hepatic ischaemia. Following ischaemia varying durations of reperfusion were undertaken
and serum ALT analysed (figure 6.10).
At baseline 0 hours ALT was raised in both the 30 minute (368.3 IU/L ± 81.7) and
60 minute (647.5 IU/L ± 279.4) clamp group, with the 60 minute group having nearly
double the ALT of the 30 minute group. By 6 hours levels in both groups had raised with
the 60 minute group demonstrating a considerably higher level (15893.3 IU/L ± 3059.6)
than the 30 minute group (1170.0 IU/L ± 665.1). At 24 hours ALT levels in both groups
had decreased with the 30 minute group (185.0 IU/L ± 155.0) lower than the 60 minute
group (2825.0 IU/L ± 873.3).
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Figure 6.10 – Time course of serum ALT following either 30 or 60 minutes of
hepatic ischaemia. Male C57BL/6 mice aged 8 weeks underwent either 30 or 60 minutes
of 70% ischaemia. Following ischaemia varying durations of reperfusion were undertaken. At
baseline 0 hours ALT was raised in both the 30 minute (368.3 IU/L ± 81.7) and 60 minute
(647.5 IU/L ± 279.4) clamp group. By 6 hours levels in both groups had raised with the 60
minute group demonstrating a considerably higher level (15893.3 IU/L ± 3059.6) than the 30
minute group (1170.0 IU/L ± 665.1). At 24 hours ALT levels in both groups had decreased
with the 30 minute group (185.0 IU/L ± 155.0) lower than the 60 minute group (2825.0 IU/L
± 873.3). Histograms represent mean and bars represent standard error of the mean, n=23.
I next assessed the histological changes when using different clamp durations in the
hepatic ischaemia reperfusion model.
6.2.3.2 Histochemical analysis of different clamp durations in hepatic ischaemia
reperfusion injury
Following sacrifice of C57BL/6 mice liver tissue was removed from the lobes which
underwent ischaemia and the lobes that were spared and fixed in formalin. Fixed liver
tissue was embedded in paraffin and processed for histochemistry.
H & E staining (figure 6.11) was performed. At 0 hours baseline there was some
red cell extravasation but no necrosis or architectural changes seen in the ischaemic lobe,
and no clear change in the non-ischaemic lobe. After 6 hours of reperfusion there were
a few small areas which demonstrated fading of the nucleus in hepatocytes along with
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small infiltrating cells in both the ischaemic lobes and the non-ischaemic lobes. By 24






Figure 6.11 – Representative haematoxylin and eosin staining of non-ischaemic
mouse liver lobes following 30 minutes ischaemia and varied duration of reper-
fusion injury. Male C57BL/6 mice aged 8 weeks underwent 30 minutes of 70% hepatic
ischaemia. Following sacrifice liver tissue was removed and fixed in formalin. H & E staining
was performed on processed liver tissue. (a) At 0 hours baseline there was some red cell
extravasation but no necrosis or architectural changes seen in the ischaemic lobe, and (b) no
clear change in the non-ischaemic lobe. (c) After 6 hours of reperfusion there was a few small
areas which demonstrated fading of the nucleus in hepatocytes along with small infiltrating
cells in both the ischaemic lobes (d) and the non-ischaemic lobes. (e) By 24 hours there was
no architectural changes or necrotic areas in either the ischaemic (f) or the non-ischaemic
lobes. All images are generated from whole slide scans and are at 400x magnification. Scale
bars represent 100 μm.
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In order to quantify the extent of liver ischaemia I next performed PAS staining (figures
6.12 and 6.13). Glycogen depletion was used as a surrogate of ischaemia. Over the 24
hour time course the ischaemic lobe in the 60 minute clamp group showed consistently
more glycogen depletion than the 30 minute group (66.7% ± 11.6 vs 64.6% ± 15.6 at
24 hours) however these findings did were not statistically significant. As expected the
amount of glycogen depletion was lower in the non-ischaemic lobes when compared with
the ischaemic lobes at all time points and for both 30 and 60 minutes clamp duration.
At 0 hours the non-ischaemic lobes in the 30 and 60 minute groups were broadly similar
(47.2% ± 1.36 vs 43.3% ± 6.16), however at 24 hours the non-ischaemic lobe in the 60
minute group showed less glycogen depletion than the 30 minute group (33.6% ± 7.0 vs
56.3% ± 0.5) although this also did not reach statistical significance (p=0.0957).
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Figure 6.12 – Histogram showing the time course of glycogen depletion in
ischaemic and non-ischaemic livers of mice after either 30 or 60 minutes of hep-
atic ischaemia reperfusion injury assessed by PAS staining. Male C57BL/6 mice
aged 8 weeks underwent either 30 or 60 minutes of 70% ischaemia. Following ischaemia
varying durations of reperfusion were undertaken. Glycogen depletion was used as a surrogate
of ischaemia. At 0, 6 and 24 hours the ischaemic lobe in the 30 minute clamp group showed
consistently less glycogen depletion than the 60 minute group (70.0% ± 2.8 vs 71.0% ± 7.7,
70.3% ± 6.2 vs 83.3% ± 2.7 and 64.6% ± 15.6 vs 66.7% ± 11.6) however these findings
did not reach statistical significance. The amount of glycogen depletion was lower in the
non-ischaemic lobes when compared with the ischaemic lobes at all time points and for
both 30 and 60 minutes clamp duration. At 0 hours the non-ischaemic lobes in the 30
and 60 minute groups were broadly similar (47.2% ± 1.36 vs 43.3% ± 6.16), however at
24 hours the non-ischaemic lobe in the 30 minute group showed more glycogen depletion
than the 60 minute group (56.3% ± 0.5 vs 33.6% ± 7.0) although this also did not reach
statistical significance (p=0.0957). Statistical analysis was undertaken using Student’s t-test.
Histograms represent mean and bars represent standard error of the mean, n=19.
In the livers of mice undergoing 30 minutes of ischaemia there was visibly more glycogen
staining than in the mice undergoing 60 minutes of ischaemia at all time points. The
pattern of staining showed a global patchy reduction in staining in the ischaemic lobes
of the 30 minute group at baseline 0 hours and 6 hours. By 24 hours there was visually
more glycogen staining across all of the liver lobe. The non-ischaemic lobes of the mice
in the 30 minute group showed a similar pattern to those in the 60 minute group with a
reduction in glycogen deposition in the parenchyma with some sparing of the peri-portal
region. There did appear to be less recovery of glycogen staining in the 30 minute group





Figure 6.13 – Representative PAS staining of ischaemic and non-ischaemic mouse
liver lobes following 30 minutes of ischaemia and varied duration of reperfusion
injury. Male C57BL/6 mice aged 8 weeks underwent 30 minutes of 70% hepatic ischaemia.
Following sacrifice liver tissue was removed and fixed in formalin. PAS staining was performed
on processed liver tissue. (a) At baseline 0 hours there was a patchy reduction in staining in
the ischaemic lobe with the (b) non-ischaemic lobe showing a reduction in staining with some
peri-portal sparing. (c) at 6 hours a similar pattern in the ischaemic and (d) non-ischaemic
lobes was present with less overall staining in both. At (e) 24 hours there was an increase
in overall staining in the ischaemic lobe but the (f) non-ischaemic lobe appeared to show
less recovery of staining. Images are generated from whole slide scans and are at 400x
magnification. Scale bars represent 100 μm.
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I next sought to assess the effects of clamp duration on infiltrating immune cells in the
livers of mice undergoing hepatic ischaemia reperfusion injury.
6.2.3.3 The effect of clamp duration on liver infiltrating immune cells in
hepatic ischaemia reperfusion injury
Male C57BL/6 mice aged 8 weeks underwent 30 minutes of 70% hepatic ischaemia.
Following sacrifice liver lobes were mechanically homogenised and following washing were
passed over a density gradient using OptiprepTM. Cells were stained and analysed by flow
cytometry (figure 6.14).
Mice that had undergone 30 minutes of ischaemia showed peak levels of CD45+, CD4+,
CD8+, NK1.1+ cells and platelets (CD41+) in their livers at baseline 0 hours with levels
reducing at 6 hours and again at 24 hours. This pattern was repeated in the non-ischaemic
lobes with the exception of CD8+ cells which appeared to continue to increase at 6 hours
and then decrease at 24 hours. Neutrophils (SSCintLy6GHi) in the ischaemic lobes were
static between 0 and 6 hours, but then increased at 24 hours, whereas the non-ischaemic





Figure 6.14 – Flow cytometric analysis of mouse livers following 30 minutes of
ischaemia and a variable duration of reperfusion injury. Male C57BL/6 mice aged 8
weeks underwent 30 minutes or 60 of 70% hepatic ischaemia. Following sacrifice liver lobes
were mechanically homogenised and following washing were passed over a density gradient.
Cells were stained and analysed by flow cytometry. In the ischaemic and non-ischaemic lobes
peak levels of cells occurred at 0 hours baseline and decreased at 6 and 24 hours in the (a)
CD45+ and (b) CD3+CD4+ populations. (c) This pattern was present in the ischaemic lobes
of CD3+CD8+ cells but the non-ischaemic lobes showed a peak at 6 hours and a decrease
again at 24 hours. (d) NK1.1+ cells decreased in number in the ischaemic and non-ischaemic
lobes at 6 and 24 hours. (e) Platelets (CD41+) decreased in number in the ischaemic lobes
at 6 and 24 hours, however in the non-ischaemic lobes there was an initial reduction between
0 hours and 6 hours followed by an increase at 24 hours. (f) Neutrophils (SSCintLy6GHi)
showed an increase between 0, 6 and 24 hours in the ischaemic lobes, and a reduction in the
non-ischaemic lobes. Histograms represent mean and bars represent standard error of the
mean, n=8.
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I next sought to test the hypothesis that PαS MSC could reduce the injury in hepatic
ischaemia reperfusion injury. Based on the above results I decided to use a clamp time of
60 minutes rather than 30 minutes as this represented a more stable injury pattern with
less recovery and a duration of 24 hours.
6.2.4 In vivo efficacy of PαS MSC in the hepatic ischaemia reper-
fusion model
Bone marrow derived MSC have been shown to reduce hepatocyte apoptosis in a rat model
of hepatic ischaemia reperfusion injury and hepatectomy [193]. Given the findings earlier
in this chapter I decided to use a clamp time of 60 minutes in order to induce a persistent
severe injury. Given the amount of injury induced and the findings of the previous chapter
demonstrating low numbers of PαS MSC in the liver after systemic injection I decided
that a higher dose would be required in order to adequately test the hypothesis that PαS
MSC reduce injury in a model of hepatic ischaemia reperfusion injury. I chose a dose of
1x106 PαS MSC and based on previous experience with doses in this range and the risk of
embolic complications [245] I opted to administer the PαS MSC via the intra-peritoneal
route. Experience with this route has demonstrated efficacy in other models of liver injury
with PαS MSC [237], has been shown to improve MSC engraftment [309], and in the
context of liver surgery this route is feasible in the clinical environment and therefore
readily translatable. Whilst the use of the portal venous route has potential advantages
[310], other studies have shown that MSC can embolise and cause worse outcomes [311],
due to the potential risk I decided to avoid this route of administration.
Male C57BL/6 mice aged 8 weeks were injected via the intra-peritoneal route with
1x106 PαS MSC 1 hour prior to undergoing surgery. Mice were then subjected to 60
minutes of 70% hepatic ischaemia followed by 24 hours of reperfusion.
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6.2.4.1 Serum transaminases in hepatic ischaemia reperfusion injury follow-
ing PαS MSC therapy
Following injection with PαS MSC and 60 minutes of ischaemia mice were allowed 24
hours of reperfusion and then culled and serum analysed for ALT. There was no significant
difference in ALT between control and treated mice following treatment with PαS MSC
(4585 IU/L ± 1567 vs 5877 IU/L ± 1491).
Figure 6.15 – Serum ALT in mice following 60 minutes of ischaemia and treatment
with PαS MSC. Male C57BL/6 mice aged 8 weeks were injected via the intra-peritoneal
route with 1x106 PαS MSC. Mice were then subjected to 60 minutes of 70% hepatic ischaemia
followed by 24 hours of reperfusion and then culled and serum analysed for ALT. There was
no significant difference in ALT between control and treated mice following treatment with
PαS MSC (4585 IU/L ± 1567 vs 5877 IU/L ± 1491). Points represent individual mice, bars
represent the median and lines represent the interquartile range. Statistical analysis was
carried out using a Student’s t-test.
6.2.4.2 Histochemical analysis in hepatic ischaemia reperfusion injury follow-
ing PαS MSC therapy
Liver tissue from mice who have undergone hepatic ischaemia and treatment with PαS
MSC was removed, processed and embedded in paraffin and then sectioned and stained.
Haematoxylin and eosin staining was performed in order to demonstrate the morphology of
the liver (figure 6.16). Both ischaemic and non-ischaemic lobes in the sham controls showed
normal morphology. The ischaemic lobes in the PBS control mice showed widespread
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necrosis with sparing around the portal region with red cell extravasation. The non-
ischaemic lobes showed some ischaemia but less than the ischaemic lobes and again
demonstrated portal sparing. The ischaemic and non-ischaemic lobes in mice treated with





Figure 6.16 – Representative images of haematoxylin and eosin staining in
C57BL/6 mice having undergone 60 minutes of ischaemia treated with either
PBS or PαS MSC. C57BL/6 mice aged 8 weeks were injected via the intra-peritoneal
route with 1x106 PαS MSC. Mice were then subjected to 60 minutes of 70% hepatic ischaemia
followed by 24 hours of reperfusion and following sacrifice liver tissue was removed and fixed
in formalin. H and E staining was performed on processed liver tissue. (a) Ischaemic lobes in
sham controls showed normal morphology as did (b) non-ischaemic lobes in sham controls.
(c) Ischaemic lobes in PBS controls showed widespread necrosis with sparing around the
portal region with red cell extravasation. (d) Non-ischaemic lobes in PBS controls showed
some ischaemia but less than the ischaemic lobes and again demonstrated portal sparing. (e)
Ischaemic lobes in mice treated with PαS MSC showed a similar pattern to PBS controls
and (f) non-ischaemic lobes in mice treated with PαS MSC showed a similar pattern to their
non-ischaemic PBS counterparts. Images are generated from whole slide scans and are at
400x magnification. Scale bars represent 100 μm.
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PAS staining was also carried out on paraffin embedded sections (figures 6.17 and
6.18). Quantification was undertaken using ImageJ software. Glycogen depletion was used
as a surrogate of ischaemia. Sham surgical controls showed a low amount of glycogen
depletion in the ischaemic and non-ischaemic lobes. In the mice undergoing ischaemia
those treated with PαS MSC showed a significant reduction in glycogen depletion in the
ischaemic lobes when compared with controls (91.7% ± 2.8 vs 80.1% ± 4.6, p=0.03),
whereas the non-ischaemic lobes showed no significant difference (43.6% ± 6.4 vs 48.4% ±
2.7).
Figure 6.17 – PAS staining in the livers of C57BL/6 mice following 6o minutes
70% ischaemia and treatment with either PBS or PαS MSC. C57BL/6 mice aged
8 weeks were injected via the intra-peritoneal route with 1x106 PAS MSC. Mice were then
subjected to 60 minutes of 70% hepatic ischaemia followed by 24 hours of reperfusion and
following sacrifice liver tissue was removed and fixed in formalin. PAS staining was performed
on processed liver tissue. Sham surgical controls showed a low amount of glycogen depletion in
the ischaemic and non-ischaemic lobes (19.4% ± 2.8 vs 17.5% ± 3.2). In the mice undergoing
ischaemia mice treated with PαS MSC showed a significant reduction in glycogen depletion
in the ischaemic lobes when compared with controls (91.7% ± 2.8 vs 80.1% ± 4.6, p=0.03),
whereas the non-ischaemic lobes showed no significant difference (43.6% ± 6.4 vs 48.4% ±
2.7). Statistical analysis was undertaken using Welch’s t-test. Histograms represent mean
and bars represent standard error of the mean, n=12.
Mice undergoing sham surgery showed no reduction staining in either the ischaemic
or non-ischaemic lobes. Mice treated with PαS MSC showed a reduction in staining in
the liver parenchyma with sparing of the portal regions in the ischaemic lobe. A less
pronounced reduction in staining was seen in the non-ischaemic lobe with no clear sparing
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Figure 6.18 – Representative images of PAS staining in C57BL/6 mice having un-
dergone 60 minutes of ischaemia treated with either PBS or PαS MSC. C57BL/6
mice aged 8 weeks were injected via the intra-peritoneal route with 1x106 PαS MSC. Mice were
then subjected to 60 minutes of 70% hepatic ischaemia followed by 24 hours of reperfusion
and following sacrifice liver tissue was removed and fixed in formalin. PAS staining was
performed on processed liver tissue. (a) Mice undergoing sham surgery showed no reduction
staining in either the ischaemic or (b) non-ischaemic lobes. (c) Mice treated with PαS MSC
showed a reduction in staining in the liver parenchyma with sparing of the portal regions in
the ischaemic lobe. (d) A less pronounced reduction in staining was seen in the non-ischaemic
lobe with no clear sparing of the portal region. (e) A reduction in staining in the liver
parenchyma with sparing of the portal regions in the ischaemic lobe of the PBS treated
controls, (f) with a less pronounced reduction in staining in the non-ischaemic lobe with no
clear sparing of the portal region. Images are generated from whole slide scans and are at
400x magnification. Scale bars represent 100 μm.
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6.2.4.3 The effect of PαS MSC therapy on circulating and liver infiltrating
immune cells in hepatic ischaemia reperfusion injury
Male C57BL/6 mice aged 8 weeks were treated with either PBS or PαS MSC and then
underwent 60 minutes of 70% hepatic ischaemia. Following sacrifice whole blood was
sampled and liver lobes were mechanically homogenised and following washing were passed
over a density gradient using OptiprepTM. Cells were stained and analysed by flow
cytometry (figures 6.19, 6.20 and 6.21).
There were no significant differences in the infiltrating immune cell populations in mice






Figure 6.19 – Flow cytometric analysis of ischaemic liver lobes of mice treated
with PαS MSC and undergoing 60 minutes of 70% hepatic ischaemia. Male
C57BL/6 mice aged 8 weeks were treated with either PBS or PαS MSC and then underwent
60 minutes of 70% hepatic ischaemia. Following sacrifice liver lobes were mechanically
homogenised and following washing were passed over a density gradient using OptiprepTM.
Cells were stained and analysed by flow cytometry. There were no significant changes in
(a) CD45+, (b) CD3+CD4+, (c) CD3+CD8+, (d) NK1.1+ cells, (e) CD41+ platelets or (f)
Neutrophils (SSCIntLy6GHi). Points represent individual mice and bars represent the mean






Figure 6.20 – Flow cytometric analysis of the non-ischaemic liver lobes of mice
treated with PαS MSC and undergoing 60 minutes of 70% hepatic ischaemia.
Male C57BL/6 mice aged 8 weeks were treated with either PBS or PαS MSC and then under-
went 60 minutes of 70% hepatic ischaemia. Following sacrifice liver lobes were mechanically
homogenised and following washing were passed over a density gradient using OptiprepTM.
Cells were stained and analysed by flow cytometry. There were no significant changes in
(a) CD45+ (b) CD3+CD4+, (c) CD3+CD8+, (d) NK1.1+ cells, (e) CD41+ platelets or (f)
Neutrophils (SSCIntLy6GHi). Points represent individual mice and bars represent the mean






Figure 6.21 – Flow cytometric analysis of the whole blood of mice treated with
PαS MSC and undergoing 60 minutes of 70% hepatic ischaemia. Male C57BL/6
mice aged 8 weeks were treated with either PBS or PαS MSC and then underwent 60 minutes
of 70% hepatic ischaemia. Following sacrifice whole blood was sampled and following washing
was passed over a density gradient using OptiprepTM. Cells were stained and analysed by flow
cytometry. There were no significant changes in (a) CD45+, (b) CD3+CD4+, (c) CD3+CD8+,
(d) NK1.1+cells, (e) CD41+ or, (f) Neutrophils (SSCIntLy6GHi). Points represent individual
mice and bars represent the mean value with the standard error of the mean. Statistical
analysis was carried out using a Student’s t-test.
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6.3 Discussion
Models of ischaemia reperfusion injury have been around for nearly 40 years and extensive
study has been undertaken in murine hepatic ischaemia reperfusion injury. When comparing
studies however, there is a considerable amount of variation in the methodology [101]
making direct comparisons between studies challenging. Some of the common variables
are listed in table 6.1.















Ischaemic time (mins) 20-180
Liver ischaemia (%) 40-100
Table 6.1 – A table of methodological variables seen in hepatic ischaemia reper-
fusion injury in the published literature.
In this study I sought to develop a model based on the published literature in which
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the surgical insult was limited as much as possible to the introduction of a surgical
clamp and induction of ischaemia and reperfusion injury. Techniques performed describe
the exteriorisation of the liver or bowel contents in order to facilitate clamp placement
[102, 101]. In studies in which this technique is used and recapitulated in sham controls
the ALT levels in the sham group tend to be over 100 IU/L indicating liver injury. In
this study the sham controls had near normal ALT levels (37.5 IU/L ± 3.2). In order to
achieve this I applied best clinical practice to mouse surgery [312]. This included some
of the principles of enhanced recovery (table 6.2), an evidence based strategy employed
in a number of surgical specialities. This strategy coupled with a surgical technique that
did not involve externalising organs led to minimal surgical insult above and beyond that
intended.
Preoperative Intraoperative Postoperative
Minimal starvation time Minimal anaesthetic Early mobilisation
Good preoperative nutrition Normovolaemia Early oral intake
Active pre-warming Normothermia Good analgesia
Pre-emptive analgesia Blood conservation
Minimal surgical insult
Minimal surgical incision
Table 6.2 – A list of considerations to improve recovery from surgery.
6.3.1 Injury pattern in the hepatic ischaemia reperfusion model
In this study having developed a reproducible surgical technique to induce hepatic ischaemia
I investigated clamp duration and injury profile over time. As expected ALT was raised
throughout the reperfusion period. In this study I found an ALT peak at 6 hours (15893.3
IU/L ± 3059.6). Confidence intervals at all time points studied were wide although did
not overlap, an expected finding and one that has been shown previously [101]. Reasons
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for the wide confidence intervals in this type of model have been previously suggested
and include variations in age and weight. Whilst age was tightly controlled in this study
weight was variable between previously published ranges (20-30g), but may have led to the
variation seen. Whilst most studies don’t provide a time course of injury there is evidence
that in mouse models the peak ALT rise is at 12 hours [307]. As I did not look at a 12
hour time point it is possible that this is also the case for the model in this study. Due
to the logistical challenges and local policy it would have been difficult to undertake a
12 hour model in our institution as it would entail overnight working in order to collect
samples. As two distinct phases of injury occur in hepatic ischaemia reperfusion injury,
one in the first 6 hours and the other in the remaining 18 hours, this study almost certainly
represents the injury patterns occurring in each phase. Serum ALT levels were lower at
24 hours after an initial peak at 6 hours (2825.0 IU/L ± 873.3), however levels were still
100-200 fold higher than normal and nearly 100 times higher than sham surgical controls.
Histochemical analysis demonstrated an evolving injury pattern in the ischaemic lobes
over the time course studied with H and E staining demonstrating an initial extravasation
of red blood cells into the spaces between hepatocytes, followed by morphological changes
in the liver parenchyma. PAS staining confirmed glycogen depletion from the beginning
of the reperfusion period. This is to be expected as after 60 minutes of ischaemia the
glycogen stores will have been used up. The depletion showed a peak at 6 hours indicating
ongoing cell death as glycogen will be lost as cells die. Levels at 24 hours were marginally
lower indicating some recovery, although sham surgical controls showed considerably less
glycogen depletion (17.05% ± 0.90 vs 66.74% ± 11.86). Considering these findings along
with the reduction in ALT seen at 24 hours it is likely less cell death is occurring at
this point as the majority of cells have been injured earlier on in the time course of this
experiment.
Interestingly the non-ischaemic lobes also showed considerable injury throughout the
time period studied. With a 70% clamp blood supply should be maintained through the
remaining 30% without mechanical obstruction. H and E staining in the non-ischaemic
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lobes showed red cell extravasation and necrosis at 6 hours following clamp removal,
however by 24 hours these changes had resolved with no apparent necrotic areas visible.
PAS staining also showed glycogen depletion with a peak at 6 hours and a reduction at
24 hours, although levels were considerably lower than those seen in the ischaemic lobes
(33.60% ± 6.99 vs 66.74% ± 11.86 at 24 hours).
6.3.1.1 Liver immune cell populations in ischaemia reperfusion injury
The liver infiltrating immune cell profile seen in this study shows an interesting pattern of
immune cell infiltration in keeping with other published works, although very few studies
have used flow cytometric analysis of digested liver tissue so direct comparison is difficult.
A variety of descriptions exist in the published literature regarding reperfusion injury
and there is perhaps a lack of clarity as to the timings of when different immune cell
populations are present in an ischaemia organ, and what the significance of these cells
are. The ischaemic insult sustained in hepatic reperfusion injury has been shown to cause
a large number of pathways to activate, but two important processes which have been
extensively described are the generation of superoxide and reactive oxygen species [313],
and the activation of TLR4 [314]. The majority of publications describe the first six hours
of reperfusion as the ’acute phase’ of reperfusion injury and characterise this as a time
when lymphocyte numbers increase [73], followed by the ’sub-acute phase’ over the next
18 hours which is characterised by a rapid rise in neutrophil number [315]. In this study
the number of CD45+ cells rose following reperfusion in the ischaemic lobes and continued
to rise during the 24 hour study period, whereas the CD45+ cells in the non-ischaemic
lobe remained relatively constant.
Unlike other studies which describe a rise in the lymphocyte populations in the first 6
hours, I showed a decrease in both CD4+ and CD8+ cells. However in the non-ischaemic
lobes CD4+ and CD8+ cell numbers increased in the first 6 hours, with a reduction again
by 24 hours. The difference between my findings and those in the published literature
could be related to technique. There are very few studies in murine hepatic ischaemia
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reperfusion injury which use flow cytometry to assess immune cell numbers, and studies
that have use low n numbers and only looked at the first 4 hours of reperfusion [316].
Most studies use immunohistochemistry which may not give an accurate representation of
the cell numbers seen. It is biologically plausible that immune cell populations fall in the
first few hours due to two factors. Ischaemia reperfusion injury has been shown to lead to
microvascular occlusion and platelet activation in the hepatic sinusoids [317], and in large
animal models of warm ischaemia microvascular occlusion coupled with cell oedema has
been shown to lead to an arterial shunt [318]. In my study there was a large increase in
platelet numbers in both the ischaemic and non-ischaemic lobes during the first 2 hours
after reperfusion. All other immune cell numbers remain static or decrease during this
time period. With such large platelet numbers it is likely that microvascular occlusion is
present and as such access to the liver by immune cell populations is likely to be restricted.
Platelet numbers rapidly decrease following a peak at 2 hours and this is accompanied
by an increase in almost all cell types measured between 2 and 6 hours after reperfusion.
Further study would be needed to confirm this finding in small animal models as whilst
functional studies which block platelet adhesion to the endothelium have been shown to
reduce liver injury, it is unclear what effect this has on immune cell infiltration as there
was no effect seen on inflammatory cytokine levels [317]. It is worth noting that CD4+
T cell depletion has been shown to reduce hepatic ischaemia reperfusion injury in mouse
models, implying that CD4+ cell function is important in hepatic ischaemia reperfusion
injury [319], as such the function of the immune cell populations is almost certainly more
important than the absolute numbers present.
In keeping with other studies I showed a large increase in neutrophil numbers in
the ischaemic lobes of mice undergoing hepatic ischaemia reperfusion injury at 24 hours
following reperfusion. No increase in neutrophil recruitment was seen in the non-ischaemic
lobes. It is worth noting that this finding is important as most of the papers published have
used either myeloperoxidase as a surrogate for neutrophil numbers or immunohistochemistry
[320]. By using flow cytometry with a neutrophil specific staining and gating strategy
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[321], I have been able to confirm this finding in a more accurate way than previously
described. This finding also suggests that neutrophil recruitment is not dependent on
CD4+ numbers alone.
In this study natural killer cell numbers remained fairly constant in the ischaemic
lobe, however there was a large increase in the non-ischaemic lobe at reperfusion with
levels gradually declining over the 24 hours study period. It has been suggested that
natural killer cells play an important role in hepatic ischaemia reperfusion injury with a
protective effect seen when using a CD39 depletion technique [322], however contradictory
evidence also suggests that it is natural killer T-cells that are responsible [323]. It is
interesting then that in this study levels appear to increase in the non-ischaemic lobe. An
explanation for this could be that local leakage of inflammatory mediators during the
ischaemic phase coupled with a lack of access to the ischaemic lobe due to the portal
clamp led to an increase in natural killer cells in the non-ischaemic lobe which persisted
during the reperfusion period.
6.3.2 The effects of clamp duration on ischaemic injury in the
hepatic ischaemia reperfusion injury model
Due to the wide range of ischaemic time studied in the literature I opted to assess a shorter
clamp time of 30 minutes to ascertain if a suitable injury pattern for testing PαS MSC
could be elicited, further reducing the overall surgical burden and therefore reducing the
confounding factors associated with a longer operating time.
A clamp duration of 30 minutes greatly reduced the injury seen compared to 60 minutes
when assessing serum ALT with peak levels again occurring at 6 hours (1170.0 IU/L ±
665.1 vs 15893.3 IU/L ± 3059.6). At 24 hours of reperfusion levels had fallen to 185.0 IU/L
± 155.0, with some mice having normal levels of ALT. Histochemical analysis showed little
structural change on H & E staining, but PAS staining gave similar levels of glycogen
depletion to those found in mice undergoing 60 minutes of ischaemia. This suggests that
ischaemia has occurred in the same number of hepatocytes, but has not progressed to
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necrosis and highlights the limitations of using PAS staining alone as a surrogate for
necrosis. Flow cytometric analysis showed a reduction in total CD45+ cells as well as
CD4+, CD8+ and NK1.1+ cells in both the ischaemic and non-ischaemic lobes with a
similar pattern seen in platelets. Neutrophil numbers did increase at 24 hours in the
ischaemic lobe but the degree of rise was considerably less than mice undergoing 60 minutes
of ischaemia. Taken together these findings indicate that the 30 minute clamp time was
not sufficient to cause lasting damage and would make testing the efficacy of PαS MSC
difficult in this model. As such I decided to use a 60 minute clamp time for the MSC
experiments.
6.3.3 The effects of PαS MSC therapy on hepatic ischaemia reper-
fusion injury
In this chapter I have demonstrated that the model of ischaemia reperfusion injury
employed leads to a rise in neutrophils by 24 hours of reperfusion, but a reduction in
lymphocyte numbers in the first 6 hours of reperfusion. MSC have been shown to reduce
neutrophil recruitment to ischaemic gut [324], inhibit neutrophil extracellular trap and
reactive oxygen species formation [325], and reduce lymphocyte activation and proliferation
[246], indeed in earlier chapters I have confirmed that PαS MSC can have similar effects in
CD8+ lymphocytes in vitro. This makes MSC a potentially beneficial therapy in hepatic
ischaemia reperfusion injury. However treatment of mice undergoing hepatic ischaemic
reperfusion injury with PαS MSC did not lead to a significant change in ALT or glycogen
depletion. There were also no significant changes in immune cell populations in either the
liver or the whole blood when assessed by flow cytometry. There are a number of possible
reasons for these findings. It is possible the PαS MSC are unable to reduce the injury
in hepatic ischaemia reperfusion injury. Whilst I have shown the ability of PαS MSC to
reduce lymphocyte proliferation in vitro, as well as their ability to reduce liver injury in
the MDR2-/- model, the mechanisms responsible for hepatic reperfusion injury are more
complex and not fully understood. The inflammatory micro-environment to which MSC
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are exposed is critical in determining the effects that they exert on the immune system
[249], and the inflammatory environment seen in ischaemia reperfusion injury is different
to those in other models due to high levels of reactive oxygen species and relative hypoxia.
Whilst MSC have been shown to support antioxidant systems in colitis [326], they have
also been shown to undergo senescence and their functions can be impaired by reactive
oxygen species [327]. As PαS MSC were given prior to induction of ischaemia then it is
conceivable that they were already localised in the liver and underwent a period of hypoxia.
Whilst there have been studies into the effects of hypoxia on MSC survival [328], further
work needs to be done in order to ascertain if MSC retain their immunosuppressive actions
or indeed if their immunosuppressive phenotype is significantly altered by exposure to
extreme hypoxia. It is also conceivable that the dose given was inappropriate in this study.
A higher dose was used compared with previous work [237] in order to give the best chance
of efficacy as this model was logistically more challenging so numbers had to be limited as
best possible. MSC have been shown to have no greater effects once a threshold dose is
reached, and in ARDS this dose has been shown to be 2x106 cells/kg. Whilst threshold
doses are likely to be different between MSC types and disease processes the dose used in
this study equated to 3-5x107 cells/kg which is likely to be above the threshold level. The
route of administration used in this study was different to that used in the MDR2-/- in
order to facilitate administration of a higher dose of PαS MSC which may also explain
why the cells did not have the desired effects. The intra-peritoneal route has been shown
to increase MSC engraftment in gut injury models [309], and has also been shown to be
efficacious in mouse models of liver injury using PαS MSC [237], although further work
would need to be done to confirm viability of PαS MSC in this model and also to assess
their location and trafficking. Finally it is possible that this study was not powered to
detect a beneficial effect of PαS MSC therapy. Whilst the primary outcome measure in
this study was ALT, levels of immune cells or their function may undergo more subtle
changes and whilst I did see some interesting trends in immune cell numbers these did not
reach statistical significance. Whilst it is possible to undertake more repetitions to confirm
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this hypothesis and undertake cytokine analysis this model is costly and time consuming
and so further work would need to be targetted at specific outcomes which would be most
likely to show a significant difference with PαS MSC therapy.
6.3.4 Chapter summary
In this chapter I have developed a repeatable mouse model of hepatic ischaemia reper-
fusion injury which enables portal vessel clamping with minimal surgical insult. I have
demonstrated that this model shows a significant injury as assessed by a large ALT rise
over the 24 hour time course with some resolution at 24 hours. I have also demonstrated
that by assessing immune cell populations using flow cytometry that whilst neutrophil
cell numbers follow a similar pattern to those described by other techniques, lymphocyte
numbers appear to remain similar to those at induction of injury. One explanation for this
could be microvascular occlusion by platelets which I have shown to be raised in the first
few hours following ischaemia. Following treatment with PαS MSC there was no significant
difference in primary outcome measure (ALT) at 24 hours between treatment and control
animals. There was also no significant difference found in immune cell populations in either
the liver or whole blood of mice undergoing ischaemia reperfusion injury. This makes it
likely that PαS MSC do not reduce the injury seen in hepatic ischaemia reperfusion injury




7.1 Summary of the main findings
End stage liver disease is a clinical condition with a high level of morbidity and mortality
and its incidence is still increasing in the developed world [6]. Whilst liver transplantation
offers a viable therapy it is a major surgical undertaking and the paucity of donor organs
has led to the use of more marginal organs with an increased complication rate [42]. There
is an urgent need to increase the available pool of donor organs and improving the outcomes
from the transplantation of marginal donors is one way to achieve this [329]. One possible
strategy to improve the outcomes from [32, 330] organ donation is to reduce the amount
of ischaemia and reperfusion injury sustained by these organs. A number of promising
therapies have been demonstrated in pre-clinical models of reperfusion injury however few
have made the translation into clinical practice in part due to the complexity of the injury
sustained during ischaemia and reperfusion [189]. As reperfusion injury is a combination
of oxidative stress and immune mediated damage involving both the innate and adaptive
immune systems, a broad acting and adaptable therapy is likely to yield the greatest effect.
Medium term complications from marginal donation show a different pattern to those
from organs having undergone less ischaemia with a greater incidence of non-anastomotic
biliary complications [331, 43]. There have so far been no therapies proposed to enable
the treatment of non-anastomotic biliary complications with more focus being placed on
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reducing ischaemic time and donor and recipient selection in order to improve outcomes
[31, 332].
MSC represent a potential therapy for both early and medium term complications
in marginal organ liver transplantation due to their ability to modulate a number of
different pathways and cell types in the innate and adaptive immune system. Whilst a
number of clinical trials have been performed in liver disease there are as yet no definitive
positive results that have led to clinical translation [1]. Whilst some pre-clinical trials
have demonstrated a reduction in liver injury and increased regeneration following liver
ischaemia with partial hepatectomy there have been limited mechanistic insights and
these studies have used human cells into mouse models [301]. The use of MSC in liver
transplantation appears to be viewed as an acceptable and potentially useful therapy with
ongoing early phase trials currently being undertaken [333]. The use of prospectively
isolated murine MSC has the potential to yield a beneficial therapy in post transplantation
liver injury and allow for mechanistic studies of MSC. In order to meet these needs this
thesis focusses on the use of prospectively isolated murine PαS MSC in models of liver
ischaemia reperfusion injury and biliary injury.
7.1.1 Phenotype and immunosuppressive action of PαS MSC in
vitro
The original paper describing the isolation of PαS MSC was published in 2009 [150],
however since this paper little further work has been carried out using these cells outside
of our laboratory. Whilst previous work has characterised PαS MSC extensively and
demonstrated that they meet the ISCT criteria for MSC [237, 236], limited in vitro and
in vivo studies have been carried out to demonstrate their immunomodulatory abilities.
Reasons for this are unclear but are likely due to the difficulty of replicating the isolation
technique described in the original paper. Difficulty has also been found as using PαS
MSC isolated from C57BL/6 mice in in vitro assays with purified immune cells did not
show any effect of the PαS MSC. In this study I was able to successfully isolate PαS
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MSC from murine bone marrow and grow them in culture. I also developed an in vitro
immunosuppression assay which allowed for the testing of PαS MSC isolated from C57BL/6
mice. I was able to demonstrate suppression of CD8+ T cell proliferation by PαS MSC
and following stimulation with inflammatory cytokines PαS MSC were able to secrete
anti-inflammatory cytokines, in particular Il-10. This is an important finding as a number
of studies have suggested that MSC do not directly secrete Il-10 but instead stimulate
other intermediary cells to do so [334]. In this study I have demonstrated that a purified
population of prospectively isolated murine MSC are able to secrete significantly higher
amounts of Il-10 following an inflammatory stimulus, an important finding given the
functions of Il-10 as an immune regulator. It is not clear however whether this is indeed
the mechanism by which PαS MSC exert their effects in vivo, or whether priming of PαS
MSC is required to guarantee their effects.
7.1.2 The in vivo effects of PαS MSC in hepatic ischaemia reper-
fusion injury
In order to examine the effects of PαS MSC on ischaemia reperfusion injury in the liver
I developed a surgical model of hepatic ischaemia. Whilst not a new model by limiting
the surgical insult I was able to show a large increase in markers of liver injury with
little confounding injury due to surgical technique. By utilising flow cytometry I have
been able to demonstrate the profile of infiltrating immune cells in the liver in a different
way to those commonly published [335], and whilst infiltrating neutrophils followed a
similar pattern to that seen in the majority of the hepatic ischaemia reperfusion literature,
infiltrating CD4+ and CD8+ lymphocytes appeared to show a different pattern. I also
analysed the lobes not undergoing ischaemia, something not commonly published. This
also yielded some interesting findings showing high levels of a number of immune cells
including platelets and natural killer cells. This finding is important as natural killer cells
have been implicated in both liver injury and neutrophil recruitment following ischaemia
and transplantation [336]. Remote immune mediated damage to the kidney and liver
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following ischaemic injury to other areas has been described in the literature and is likely
due to the systemic transport of reactive oxygen species to well perfused organs [337, 338].
Understanding the implications of this and the effects of more local immune mediated
damage in liver ischaemia requires further study but is important to help develop therapies
that can improve patient outcomes from liver transplantation.
In this study PαS MSC did not show a significant reduction in liver injury following
ischaemia and reperfusion. Due to the complexity of the injury seen following hepatic
ischaemia it is difficult to make definite conclusions based on this study alone. Indeed
systemically administered MSC are able to engraft in the liver and may differentiate
into hepatocytes although this finding has been disputed [186]. Mice undergoing hepatic
ischaemia reperfusion injury and hepatectomy seemed to benefit from the administration
of MSC with a reduction in ALT [301] and mice with acute liver failure injected with MSC
via the portal vein seemed to show an increased benefit compared with other routes of
administration [339]. Whilst these studies show a different outcome to this study there are
important differences. In particular the use of human MSCs in these studies may account
for the difference in response seen. A large proportion of the MSC literature use human
MSC into mouse or rat models of disease as arguably this represents the ultimate therapy
to be delivered to patients. Whilst true this ignores the issue of xenotransplantation and
whilst MSC are thought to be relatively immunoprivileged due to their low expression of
MHC class II [340], there remain concerns about use between species and whilst most work
has been carried out assessing the potential use of non-human MSC in human patients
[341, 342] it stands to reason that the use of human MSC in animal models may lead to
results which cannot be translated into clinical practice. In a recent paper using human
MSC in a model of graft versus host disease Galleu demonstrated that the infused MSC
are attacked by the host immune system and shortly after transfer cytotoxic cells render
MSC apoptotic. Following phagocytosis IDO is released and exerts an immunosuppressive
effect [167].
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7.1.3 The in vivo effects of PαS MSC in biliary injury
Non-anastomotic biliary complications represent a significant problem following marginal
organ transplantation and a major cause of retransplantation [42]. As yet there are no
models of non-anastomotic biliary injury, however in this study I used the MDR2-/- mouse
model as the injury pattern and mechanism of toxic bile injury seen in this model is
similar that seen in patients with non-anastomotic biliary injury [343]. Treatment with
systemically administered PαS MSC led to a reduction in markers of liver injury in the
MDR2-/- model. Despite this reduction the total number of infiltrating immune cells
appeared to remain unchanged. PαS MSC therapy led to a change in the balance of
macrophage types with an increase in the number of restorative macrophages. Macrophage
biology in the liver is complex with a number of different populations of cells present.
Broadly speaking there are resident hepatic macrophages and infiltrating macrophages from
the systemic circulation. Whilst resident macrophages seem to be important in sensing
injury and initiating the inflammatory process, circulating monocytes seem to be involved
in chronic inflammation and fibrosis [344]. Restorative macrophages have been shown
to resolve fibrosis in pre-clinical models of fibrosis [345], and monocyte differentiation
into restorative macrophages is driven in part by the production of Il-10 [346]. Given the
findings in this study that PαS MSC secrete Il-10 in response to an inflammatory stimulus
it is indeed conceivable that this mechanism is responsible for the improvement seen in
the MDR2-/- model. It would also explain why the improvement in ALT persisted at 2
weeks following therapy despite very few cells remaining in the liver in the first few days
following injection of PαS MSC as restorative macrophages are able to secrete Il-10 and
maintain the stimulus for a restorative phenotype after MSC have been cleared. Further
work will be needed to confirm this hypothesis.
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7.1.4 PαS MSC trafficking and remote effects in biliary injury
The understanding of how MSC are able to exert their immunosuppressive effects is
still incomplete with debate over whether direct cell contact is required or whether
effects can be exerted from remote locations. MSC encapsulated in alginate have been
shown to reduce inflammation in models of graft versus host disease [155], and MSC
administered subcutaneously are able to reduce injury in a cardiac ischaemia model [347].
Following systemic administration PαS MSC appeared to be trapped in the lungs, however
a proportion of the cells administered were present in the liver. This proportion seemed to
increase after 24 hours indicating either slower clearance from the liver or redistribution
from the lungs. It was not possible in this study do quantify the exact location of MSC
within the liver, and further investigation to demonstrate the location of MSC and whether
they are present at the site of injury or immune cell recruitment following administration
will be required. In cardiac injury MSC trapped in the lungs appear to be able to exert an
immunomodulatory effect [288] via a remote action. It is possible that the same process
is occurring in this study although remote action was not confirmed in the experiments
using other routes of administration.
In this study subcutaneously administered PαS MSC did not reduce liver injury unlike
experiments using systemic administration. Whilst this is contrary to some of the published
literature there are key differences between this study and others. Models which have
shown a beneficial effect from encapsulated MSC use systemic models such as graft versus
host disease rather than organ specific models. Also the encapsulation process may confer
beneficial effects on MSC such as prolonged survival. Whilst subcutaneously administered
MSC were beneficial in a cardiac ischaemia model, these were human MSC and it is
possible that either a different secretome is found in these cells or a local reaction to
xenotransplantation leads to the effects rather than the MSC themselves as no human
cellular controls were used in these studies. Further work would be needed to explore this.
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7.2 Future work
The results of this study have demonstrated some interesting findings and a number of
questions which may benefit from future work in order to answer them. The main areas of
potential further study are summarised below.
7.2.1 What is the mechanism of PαS MSC mediated immunosup-
pression in the MDR2-/- model?
In this study I showed a beneficial effect of systemic but not subcutaneously administered
PαS MSC in the MDR2-/- with an increase in restorative macrophages. Due to their ability
to secrete Il-10 demonstrated in vitro it is possible that this represents the mechanism
of action, however further study is required. Firstly the significance of macrophages
in the MDR2-/- should be elicited and one way of achieving this would be to knockout
macrophages. This can be achieved by using clodronate liposomes [348] or diphtheria toxin
mediated depletion [349]. Treating macrophage deplete MDR2-/- with PαS MSC would
give further mechanistic insight. Further experiments using PαS MSC isolated from Il-10
deficient mice would enable the investigation of the effects of Il-10 secreted by PαS MSC.
7.2.2 Can PαS MSC be primed to respond depending on the
inflammatory microenvironment?
PαS MSC secrete a variety of cytokines following stimulation with TNFα and IFN-γ. The
importance of an inflammatory stimulus to lead to MSC taking on an immunosuppressive
phenotype has been studied previously [350]. Whilst the majority of the MSC literature
use naive MSC it is possible that cytokine priming may improve the efficacy of MSC
therapy by reprogramming them to exert an anti-inflammatory effect. Further work
examining the effects of other pro-inflammatory cytokines on cultured PαS MSC may yield
a different secretome and aid in predicting how cells will respond to different inflammatory
microenvironments in vivo. Using cytokines in culture media throughout culture likely
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leads to a change in phenotype of PαS MSC [237]. There may be additional benefit in this
approach as one advantage of cell therapy is the ability to modulate the immune system
rather than completely suppress it allowing the host the ability to fight opportunistic
infection [351] and may even improve immune function in viral infection [352], an advantage
not seen by conventional immunosuppressant therapies.
7.2.3 Can PαS MSC reduce injury in ischaemia reperfusion in-
jury?
In this study PαS MSC did not reduce injury in a model of hepatic ischaemia reperfusion
injury. However some studies have shown a potential benefit of MSC therapy in hepatic
ischaemia reperfusion injury [193, 186, 301, 353]. One study has demonstrated an effect of
rat MSC given into a rat model of hepatic ischaemia reperfusion injury, however these cells
were isolated using plastic adherence and culture expansion and not prospective isolation
meaning that the population of cells was certainly more heterogeneous than PαS MSC
[353]. In order to confirm the effects of PαS MSC in hepatic ischaemia reperfusion injury
further work is certainly needed using different routes of administration. As previously
discussed the inflammatory microenvironment may determine the way in which MSC act
and so in vitro testing of PαS MSC and their secretome following exposure to reactive
oxygen species may yield further information to guide future experiments.
7.2.4 Is MSC therapy a double edged sword?
The description of MSC as a double edged sword was coined by Li et al [354] to describe
the dual effects of MSC to both suppress and promote inflammation. In this study I have
demonstrated the potential for pro-inflammatory effects with a significant worsening of
markers of liver injury following subcutaneous administration of PαS MSC in the MDR2-/-
model and an increase in CCL19 secretion following an inflammatory stimulus. Other
studies have demonstrated pro-inflammatory effects, in graft versus host disease MSC
242
have both increased and decreased disease severity [165]. Before further clinical trials
are undertaken a better understanding of why and how MSC exert pro-inflammatory
effects, and what the clinical significance of this is need to be undertaken. One approach
with PαS MSC could be to expose cultured cells to different pro and anti-inflammatory
cytokines and assess their response including phenotype and secretome. Genomics may
be able to help and sequencing the MSC transcriptome following exposure to different
microenvironments may yield further information to help understand the dual effects seen
in vivo.
7.2.5 What are the effects of xenotransplantation and are murine
cells a better model for further study?
As discussed earlier a potential problem with the current approach in the MSC literature is
the use of human MSC in mouse small animal models of injury. Whilst this is seemingly a
sensible approach in order to reduce the number of steps to translation there are potential
problems related to the use of xenotransplanted cells. Recent work has shown the human
MSC can still exert an anti-inflammatory effect when killed prior to injection [355] and
tracking of systemically administered MSC has shown that cells migrating to the liver
are often dead cells [356]. These findings suggest that either surface marker expression
on MSC is all that is required to modulate immune responses as secretion of cytokines
does not occur in dead cells, or there is an immune response generated by the injection of
xenotransplanted cells. This work needs to be repeated with PαS MSC to confirm if the
effect is due to xenotransplantation and further work eliciting the response of rodents to
the injection of human cells needs to be carried out.
7.3 Final conclusions
In summary I have isolated and expanded in cell culture a purified population of murine
bone marrow MSC based on the markers PDGFRα and Sca-1. These cells were used in
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a series of in vitro and in vivo experiments to demonstrated their ability to modulate
the immune system and their potential as a therapy for post transplant liver injury. I
have demonstrated that PαS MSC are able to suppress lymphocyte proliferation and that
following stimulation with pro-inflammatory cytokines they are able to secrete a number
of lymphocyte chemoattractants as well as the immunomodulatory cytokine Il-10.
In the MDR2-/- model of biliary injury systemically administered PαS MSC were able
to reduce the injury seen by increasing the population of restorative macrophages whilst
subcutaneous administration did not yield the same results. Tracking experiments showed
that PαS MSC were mainly trapped in the lungs but persisted in the liver for up to 7 days
following systemic administration. In a model of hepatic ischaemia reperfusion injury PαS
MSC were unable to reduce the injury seen.
Taken together these findings indicate a potential role for MSC therapy in post
transplantation liver injury however further work is required in order to confirm the
mechanism of action before clinical translation is undertaken.
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